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ABSTRACT OF THE DISSERTATION
Elucidating the Roles of Astrocyte-derived Factors in Recovery and Regeneration Following
Spinal Cord Injury
By Russell Edward Thompson

Doctor of Philosophy in Biomedical Engineering
Washington University in St Louis, 2019
Professor Dennis Barbour, Chair
Professor Shelly Sakiyama-Elbert, Co-Chair

Central nervous system (CNS) injury often causes some level of long-term functional
deficit, due to the limited regenerative potential of the CNS, that results in a decreased quality of
life for patients. CNS regeneration is inhibited partly by the development of a glial scar
following insult that is inhibitory to axonal growth. The major cell population responsible for the
formation this glial scar are astrocytes, which has led to the belief that astrocytes are primarily
inhibitory following injury. Recent work has challenged this conclusion, finding that astrocyte
reactivity is heterogeneous and that some astrocytes are pro-regenerative following injury.
Astrocyte transplantation studies following spinal cord injury (SCI) have also found that
outcomes depend on astrocyte phenotype. Specifically, transplantation of astrocytes with the
hallmarks of protoplasmic (grey matter) populations improve behavioral and histological
outcomes; whereas, transplantation of astrocytes exhibiting fibrous (white matter) hallmarks
worsen outcomes following transplantation. These studies suggest that it could be possible to
develop an astrocyte-based CNS injury therapeutic by harnessing regenerative astrocyte
populations.

xii

In this work, the ability of mouse embryonic stem cell (mESC)-derived astrocyte
populations to provide substrates that improve neuronal growth is explored. In addition, the
effect of implantation of mESC-derived astrocyte extracellular matrix (ECM) on SCI outcomes
is tested. Methods were developed to derive populations containing predominantly fibrous or
protoplasmic astrocytes from mESCs. Since these mESC-derived astrocyte populations contain
other cell types as well, CRISPR-Cas9 technology was used to generate a mESC line that
expresses puromycin resistance under the control of an astrocyte-specific gene, aquaporin-4.
This cell line shows promise as a source of live astrocytes for transplantation in the future;
although further experiments will be required to validate it. Growth of mESC-derived
motoneurons and V2a interneurons on substrates generated by unselected astrocytes was tested
and it was found that both neuronal populations extended significantly longer neurites on
protoplasmic substrates than fibrous substrates. Of particular interest, protoplasmic ECM alone
was able to support neuronal growth, while fibrous ECM was not. Since ECMs have been
successfully used to promote recover in other tissues with poor regeneration, astrocyte ECMs
were further characterized with proteomics. Proteomics data revealed that protoplasmic ECMs
contained significantly more axon growth permissive proteins, while fibrous ECM contained
significantly more axon growth inhibitory proteins. These findings suggest that the mESCderived protoplasmic astrocyte populations may be able to provide therapeutic value following
SCI.
To explore whether astrocyte ECMs provided any recovery benefit after SCI, mESCderived astrocyte ECMs were mixed with hyaluronic acid (HA) hydrogels. The resulting
HA:ECM gels were then injected following SCI and the effects of ECM presence on histological
markers of recovery was assessed. These studies found that protoplasmic ECM presence within
xiii

the SCI lesion decreased immune cell infiltration, decreased astrocyte reactivity, and increased
axonal penetration into the SCI lesion. These benefits were not observed when fibrous ECM was
implanted and, in fact, the presence of fibrous ECM caused an increase in the presence of
inhibitory molecules within the glial scar compared to HA alone implantation. This suggests that
protoplasmic astrocyte ECM has an immunomodulatory effect and alters the phenotype of native
astrocytes. Finally, the ability of HA and HA + protoplasmic ECM gels to support cell
transplantation was explored by incorporating V2a interneurons into the hydrogels prior to
transplantation. HA with and without ECM was found to support the transplantation of the V2a
interneurons and the transplanted interneurons were found to migrate into and extend processes
within the host spinal cord. Taken together these in vivo experiments demonstrate that HA:ECM
hydrogels have potential as a SCI treatment and, due to the use of mESCs, this material can be
more easily scaled for large-scale material production than would be possible with a primary cell
approach.

xiv

Chapter 1: Introduction
1.1 Spinal Cord Injury
Spinal cord Injury (SCI) is characterized as either traumatic or nontraumatic. Traumatic
injuries are defined as sudden damage to spinal cord due to either concussive force or penetration
trauma, and nontraumatic injury are defined as vascular damage, cord stenosis, or resulting from
cancer.(Hatch et al. 2017) Both of these types of insults lead to incomplete or complete lesion of
the spinal cord itself, which severs the connection between the brain and the rest of the body,
often resulting in some level of paralysis. SCI has an annual incidence of 17,000 new cases a
year in the United States with an estimated 243,000 to 347,000 Americans living with chronic
SCI.(Of 2013) About 80% of new SCI occurs in men, most commonly due to automobile
accidents followed by falls. Both of these types of injury tend to cause severe neck motion,
which leads to a cervical cord contusion injury. SCI patients who recover from the initial
traumatic event tend to have shortened life expectancies compared to uninjured peers and have
decreased mental well-being.(Boakye, Leigh, and Skelly 2012) In addition, within the SCI
patient population, life expectancy is shorter when the injury is more rostral.(Of 2013) A big part
of the poor long-term prognosis of patients who suffer from SCI is that human spinal cord has
limited ability to regenerate following injury. This means that SCI patients are not likely to have
significant changes in their level of paralysis following the initial recovery period; therefore, SCI
is a chronic condition that requires lifelong care. Due to the chronic nature of these injuries, there
is a clear clinical need to find ways to improve the long-term prognosis for these patients.
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1.1.1 Spinal Cord Injury Biology
A large contributor to the limited regenerative capacity of the human spinal cord is the
stereotyped scar environment that forms following injury called the glial scar. In particular, there
are two well defined phases of SCI lesion development with the primary injury caused by the
original trauma followed by a secondary injury that is caused by the immune and inflammatory
response to the injury. The secondary injury causes an increase in the size of the injury area and,
in humans, often leads to the formation of a cystic injury cavity. This lesion cavity is filled with
inflammatory cells and fibroblasts that have invaded from the periphery, and is surrounded by a
fibrotic scar environment that is formed primarily by astrocytes, the main support cell found in
the central nervous system (CNS)(Cregg et al. 2014). This scar environment is relatively
inhibitory to the growth on new axons due primarily to the presence of both inhibitory
chondroitin sulfate proteoglycans (CSPGs) and myelin associated inhibitors (MAIs)(Simonen et
al. 2003; Ohtake and Li 2014), and so it is difficult for new neurite growth to occur within the
lesion area and so few, if any, new connections to be formed across the scar. This injury
progression overall results in a long-term loss of communication between the brain and the rest
of the body, which causes paralysis and sensory deficits distal to the injury site.
Both parts of the glial scar, the lesion core and the surrounding scar, limit the ability of axon
to extend through the injury. The cavity lacks the normal spinal extracellular environment and
contains a high concentration of MAIs(Caroni and Schwab 1988), which accumulate due to the
degradation of the myelin sheaths. Myelin sheaths normally surround axons to improve signal
transmission, but they degrade into MAIs when the associated axons are damaged or destroyed
by the injury. Targeting of MAIs and/or their signaling pathway has been used previous to
improve growth of neurons in vitro(Caroni and Schwab 1988) and increase neuronal
2

regeneration following SCI.(Simonen et al. 2003; Wilems and Sakiyama-Elbert 2015) The
astrocytic scar that surround the lesion cavity also contains factors that are inhibitory to axon
growth. These factors include proteins that are produced by the scar astrocytes such as inhibitory
CSPGs(Bradbury et al. 2002), tenascin R(Apostolova, Irintchev, and Schachner 2006), and
keratin sulfate proteoglycans.(Chu et al. 2014) Together these proteins represent a significant
inhibitory signal to new neurite extension. In addition to this chemical barrier, astrocytes around
the lesion expand and undergo significant process hypertrophy. These hypertrophic processes
overlap and form a woven physical barrier that prevents access to the lesion area.(Sun et al.
2010) Numerous studies have been performed using different techniques to degrade or block the
action of these astrocyte-derived inhibitory molecules in order to improve axon regeneration
following SCI.(Bradbury et al. 2002; Wilems et al. 2015; Shinozaki et al. 2016) Due to the
production of this large number of inhibitory factors, the prevailing theory in the field has been
that astrocytes were predominantly an inhibitory barrier that needed to be removed to allow for
improved recovery.
In order to test the idea that astrocytes are inhibitory following SCI, SCI recovery was
studied in mice who had been genetically modified to allow for the ablation of the reactive
astrocyte population. Astrocyte reactivity was knocked-out in mice prior to SCI with either
vimentin and glial fibrillary acidic protein (GFAP) double knock out or conditional knockout of
STAT3 (a required factor for astrocyte reactivity) in astrocytes. The result was an increase to the
size of the injury area due to worsened secondary injury (increased immune cell infiltration) and
further lack of recovery.(Pekny et al. 1999; J. R. Faulkner et al. 2004; Herrmann et al. 2008)
These findings indicated that the physical barrier formed by the astrocytes was important to limit
the damage caused by inflammation of the injury area.
3

This still left open the possibility that astrocytes were helpful in the acute phase of injury, but
detrimental in chronic SCI cases. To test this hypothesis, delayed astrocyte ablation was
performed using a GFAP-driven thymidine kinase and ganciclovir injections. These strategies
allow for the astrocytes around the SCI lesion to be ablated 2 weeks after injury. This delayed
ablation allows the SCI lesion to stabilize in size and the secondary injury to resolve before the
astrocytes are removed. However, even in the case of delayed ablation, the lack of astrocytes led
to decreased functional recovery and a loss of improvement with transplanted
hydrogels.(Anderson et al. 2016; J. R. Faulkner et al. 2004) Together these knockout studies
suggest that astrocytes both play a role in the formation of the inhibitory scar, and a role in the
creation of an environment that is permissive to axon regeneration. This demonstrates that
astrocytes are necessary for recovery following SCI.(Lukovic et al. 2014) Another observation
supporting the hypothesis that astrocytes can create axon permissive environment is that axons
within an SCI lesion colocalize with “GFAP+ bridge” in both mice(Zukor et al. 2013) and
zebrafish.(Yona Goldshmit et al. 2012) Overall these recent studies suggest that astrocytes are an
overlooked cell population in terms of their ability to promote recovery following SCI.
To overcome the complexity of the glial scar environment, a multi-faceted treatment
approach will be required that addresses the inhibitory aspects of both parts of the glial scar,
while also providing a substrate that encourages or, at least, is permissive to the growth of new
axons and the formation of new connections within and beyond the scar environment.
Furthermore, a treatment scaffold will need to contain the correct growth signals to encourage
neurites to extend into the lesion.

4

1.1.2 Spinal Cord Injury Models
There are many different potential animal models used for SCI research, but rats are the most
commonly used species since rats, like humans, form a lesion within the spinal cord following
injury. There is a large body of work performed in mice as well due to ready availability of
genetically modified mouse strains; however, mice in general do not form a large lesion cavity
making mouse SCI less similar to the human pathology.(Byrnes, Fricke, and Faden 2010)
Another area of variation in SCI models is the modality of injury used. The most common
modalities are contusion, transection/hemisection, and compression. Contusion and compression
are the best models for simulating the most common injury modalities in patients and thus are
better mimics the neuropathology of human injury. Transection or hemisection, on the other
hand, is the superior model to for assessing regeneration since the axons are certain to have been
severed when the injury occurred rather than compressed thus ensuring that any growth into the
injury region is in fact new growth.(Sharif-Alhoseini et al. 2017)

1.2 Material Transplant in Spinal Cord Injury
One clear option to achieve the goals of generating an improved axon growth environment is
to transplant a new material into the lesion cavity. It is important that these materials be
biocompatible and minimally immunogenic, a problem for some scaffold systems as breakdown
products from the implanted material can cause an immune reaction. To achieve this goal,
materials are often composed of natural or synthetic biomaterials. These transplanted
biomaterials provide a new substrate within the lesion cavity where the normal extracellular
matrix (ECM) substrate has been destroyed. Biomaterials can also be modified to include or
release factors that counteract inhibitory signals and/or promote axon growth into the

5

transplanted substrate. Here SCI treatment materials are divided into two classes: injectable and
non-injectable.

1.2.3 Non-injectable Scaffolds
These materials tend to have a relatively defined volume and shape so the scar environment
must often be somewhat dissected to create a space that is same size as the scaffold in the case of
a subacute implantation. This addition dissection often results in additional damage to the spinal
cord at the time of implantation. There are also many studies that perform the implantation
acutely and so cut a large enough defect in the spinal cord for the scaffold. A large number of
different materials have been used for this including: fibrin, collagen, agarose, chitosan.(M. Kim,
Park, and Choi 2014) It is worth noting that both fibrin and collagen can be injectable, in certain
formulations, but the formulations discussed here are not injectable. The most commonly used
natural materials are fibrin and collagen which are discussed briefly here. An advantage of using
these non-injectable scaffolds is that it is easier to control the precise conditions during scaffold
formation and so have more precise control of scaffold pore-size and a much wider range of
conditions that can be utilized. Furthermore, these scaffolds can be modified prior to
implantation to contain fixed growth factor gradients and other specific topographical features
that are impossible to form in an injectable scaffold.

1.2.1.1

Fibrin

Fibrin has been used extensively in SCI animal models to promote regeneration due to its
flexibility and biocompatibility. There are many drug and cell delivery systems that have been
used in fibrin transplantation.(Wilems et al. 2015; D. A. McCreedy et al. 2014; Wilems and
Sakiyama-Elbert 2015; Johnson, Parker, and Sakiyama-Elbert 2009; Vadivelu et al. 2015) Fibrin
scaffolds are relatively easily produced by mimicking the same enzymatic cross-linking process
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that is used during normal clot formation. Unfortunately, fibrin cannot be injected once
polymerized which limits the use of these scaffolds in a contusion SCI, since in this type of
injury the lesion cannot be accessed without some additional tissue dissection and so injury to
the spinal cord. One way to address this issue is to allow the fibrin-thrombin reaction to occur in
situ and so form a scaffold that fills the lesion and so the polymerization solution can be injected.
A drawback to a two-phase approach such as this is that polymerization can difficult to achieve if
there is any flow of cerebrospinal fluid (CSF) over the injury site.(Sharp et al. 2012)
A major advantage to fibrin scaffold systems, in addition to its degradability and
biocompatibility, is the simple incorporation of growth factors through the use of a heparin
binding system.(Sakiyama, Schense, and Hubbell 1999) The heparin system has been use to
deliver neurotrophic 3 (NT-3) which has been found to improve SCI outcomes.(Taylor et al.
2006) In addition, fibrin scaffolds have also been used to deliver neural progenitors leading to
improved functional outcomes(Johnson et al. 2010), as well as progenitor motoneurons.(D. A.
McCreedy et al. 2014) Toward the goal of creating a multi-faceted treatment system, fibrin
scaffolds were loaded with NEP1-40 (inhibits MAI signaling) and chondroitinase ABC
(degrades CSPGs). This combination treatment was found to decrease CSPG deposition in the
scar and increase the axon growth into the SCI lesion(Wilems and Sakiyama-Elbert 2015);
however, these benefits were largely lost when progenitor motoneurons were transplant as
well.(Wilems et al. 2015)
Fibrin itself has also been functionalized with synthetic peptide ligands that bind to the
α6β1 integrin receptor. This modification was found to improve neurite extension from rat dorsal
root ganglion in vitro and to increase axonal growth cone formation following a complete
transection SCI in vivo.(J. Silva et al. 2017) There has also been study of different animal fibrins
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as potential scaffolds for SCI injury treatment. Human fibrin alone has been found to improve
open-field locomotion following subtotal T9 lateral hemisection.(Petter-Puchner et al. 2007)
Recently, salmon fibrin scaffolds have been shown to improve locomotor and bladder function
recovery following implantation after a T9 dorsal hemisection.(Sharp et al. 2012) Fibrin has also
been mixed with other peptides to provide further neuronal growth benefits. In particular, fibrin
scaffolds modified with laminin and N-cadherin have been found to enhance axonal regeneration
in vivo.(Schense et al. 2000) Overall, fibrin has been heavily studied as a scaffold for improving
CNS regeneration and has been found to have numerous beneficial effects.

1.2.1.2

Collagen

Collagen is the most abundant extracellular protein in the body and is highly conserved
between species. It has a fibrous structure, is inexpensive, easily accessible, and biocompatible.
This makes it an appealing biomaterial due to ease of acquisition and low immunogenicity.(M.
Kim, Park, and Choi 2014) Collagen has the added advantage of being highly bioactive
containing many cell-binding and signaling domains which allows collagen itself to provide cellsignaling. Collagen is also easily modified in the fabrication process to create different fiber
diameters with and without alignment. Finally, there are many different crosslinking methods
that can be used to modify the mechanical and degradation properties of collagen
scaffolds.(Hapach et al. 2015) Due to these factors, collagen-based biomaterials have been
widely used in tissue engineering applications and in SCI treatment.(Haggerty, Marlow, and
Oudega 2017) Here some more recently documented uses of collagen are mentioned.
Crosslinked, aligned collagen scaffolds placed acutely into a complete spinal cord
transections have been found to improve axon regeneration showing the utility of collagen-based
materials and alignment on axon growth.(Suzuki et al. 2015) Aligned collagen nano-fibrous
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nerve conduits have also been transplanted for SCI treatment and have been found to facilitate
cellular infiltrates with limited ED-1 (macrophage) staining visible.(T. Liu et al. 2012) It has also
been demonstrated that aligned collagen scaffolds can improve forepaw reaching after a lateral
cervical resection injury.(Altinova et al. 2014) Collagen sponges have also been transplanted into
complete transections along with synthetic hydrogels to limit pore size with improved axon
penetration.(Kaneko, Matsushita, and Sankai 2015) Collagen scaffold with micropatterned
porosity have been found to slightly improve locomotion after complete transection.(Snider et al.
2017) A major drawback to the use of collagen as a scaffold material is that the most abundant
collagen, collagen I, has been associated with an increase in astrocyte expression of inhibitory
genes associated with the glial scar and collagen is not normally a major component of spinal
cord ECM.(Hara et al. 2017)

1.2.2 Injectable Scaffolds
Injectable biomaterial scaffolds tend to be hydrogels that can be formed either prior to
transplant or in situ. These materials will fill the entire lesion area, without requiring any lesion
dissection. This avoids one of the major issues with the non-injectable scaffolds, namely the
need to match scaffold size to the size of the lesion area. These scaffolding systems tend to be
hydrogels which improves their biocompatibility. Unfortunately, the reaction conditions for
crosslinking these materials is much more limited due to the requirement that they be shearthinning or have fast enough reaction kinetics to form in situ prior to being overly diluted by
CSF flow.

1.2.2.1

Hyaluronic Acid-based Injectable Scaffolding

Hyaluronic acid (HA) is already widely used for clinical applications and the
predominant component of the native CNS ECM, making it a popular choice for CNS
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injectables.(Pakulska, Ballios, and Shoichet 2012) Unfortunately, HA alone does not form a
sufficiently stable gel in vivo, so the HA must be mixed with other molecules such as
methylcellulose to form an HAMC hydrogel(Gupta, Tator, and Shoichet 2006) or chemically
modified to allow a crosslinking reaction to occur. Many chemical modifications have been used
to functionalize HA macromolecules so that they will react with a crosslinking molecule and
form a stable hydrogel for treatment of SCI. Functionalization of the HA is often achieved by
reacting the carboxylic acid group on HA with part of the crosslinking system to be used.
Examples of functionalization strategies include: thiol-modified (disulfide bond linkage)(Shu et
al. 2002), aldehyde (Diels-Alder linkage)(Nimmo, Owen, and Shoichet 2011), and
tetrabutylammonium (TBA) (esterification).(Gaffey et al. 2015)
These systems either can then be injected as a 2-phase system with fast gelation kinetics
that will gel in situ (disulfide) or will shear-thin following gelation which allows for
prefabrication of the gels. Disulfide bond crosslinked HA has been injected as a two phase
system acutely following SCI and has been found to be neuroprotective to secondary injury, but
did not improve regeneration(Kushchayev et al. 2016; Horn et al. 2007). A major requirement
for these multiple phase systems is that they have fast enough gelation kinetics (on the order of
seconds to minutes) for the gels to form before the components become too diluted. A way for
gels with slower kinetics to still be useable is for the gels to be shear-thinning. This means that
the gels can be pre-formed within the barrel of a syringe and then injected into the injury site.
Shear thinning HAMC gels have been used intrathecally to improve dural regeneration(Gupta,
Tator, and Shoichet 2006) and as a vehicle for cell delivery.(Ballios et al. 2015) HA-aldehyde
crosslinked with malemide-PEG-malemide also forms a hydrogel that has been successfully used
intrathecal as drug-depo.(Führmann et al. 2015) A major advantage to this crosslinking method
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compared to others is that the Diels-Alder reaction used to create the crosslink between HA
molecules does not require the use of a catalyst and the reactants are not toxic. This means that
no clean-up needs to take place after the crosslinking reaction has been completed which greatly
simplifies the use of this system as a treatment.(Nimmo, Owen, and Shoichet 2011) In addition,
Diels-Alder chemistry is stereospecific and highly specific to dienes and dienophiles so other
materials can be incorporated without risking nonspecific reactions. Overall the literature shows
that HA-based materials are very flexible, tolerated biologically making these materials
potentially useful for future treatment modalities. In addition, long HA macromolecules
themselves have been found to improve SCI outcomes.(Khaing et al. 2011)

1.2.2.2

Other Injectable Scaffolds for CNS injury

While HA is the most commonly used injectable scaffold used for both acellular and
cellular transplantation in CNS injury, there have been other injectable scaffolds published. One
such scaffold is a hydrogel formed by combining oligomeric gelatin with copper-capillary
alginate. These scaffolds have been shown to support the growth of primary radial glia both in
vitro and in vivo when transplanted into a hypoxic stroke cavity; however, alginate gels are more
commonly used in other organ systems as a stem cell encapsulation and drug delivery
material(Willenberg et al. 2011). There has also been work exploring in situ gelling collagen
hydrogels as a delivery vehicle for GDNF overexpressing mesenchymal stem cells in vivo
following stroke and that the collagen hydrogel delivery decreased the reaction of host astrocytes
and immune cells to the transplant.(Hoban et al. 2013) Another injectable hydrogel system that
has been explored is a diblock copolypeptide hydrogel composed on hydrophobic and
hydrophilic segments. This is a synthetic gel system that has tunable material properties and has
been used to successfully support the survival of neural stem cells and to release of hydrophobic
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and hydrophilic effector molecules.(Zhang et al. 2014; Zhang et al. 2015) While these injectable
systems show promise, the presence of high levels on HA within the CNS makes HA a appealing
base material for the generation of an astrocyte-derived biomaterial.

1.2.3 Drug Delivery
Many of the materials discussed above have been transplanted without any drugs or other
bioactive molecules being incorporated. Unfortunately, the materials discussed thus far tend to
not have the maximum regenerative benefits without the incorporation of bioactive molecules. In
the case of SCI, the most commonly included molecules are growth factors that are known to
improve neurite extension from host neurons or enzymes that nullify the effects of the inhibitory
molecules present within the glial scar. One approach to load growth factors in fibrin matrices
was to anchor heparin to the fibrin and then rely on the binding affinity between growth factor
and heparin to allow for controlled growth factor delivery.(Sakiyama-Elbert and Hubbell 2000)
Unfortunately, not all bioactive compounds are readily water soluble and/or require enzymatic
activity to be effective which makes this type of delivery strategy more challenging. In the case
of HAMC gels, the incorporation of methylcellulose allows for more direct incorporation of
poorly water-soluble drugs. Altering the methylcellulose concentration can in turn tune the
release of these molecules.(Y. Wang et al. 2009)
Other scaffolds tend to require the incorporation of lipid microtubules, polymer spheres
(such as PLGA microspheres),(Wilems and Sakiyama-Elbert 2015) or have enzymatically
degradable linkages within the scaffold.(Pakulska, Ballios, and Shoichet 2012) A drawback of
having these delivery systems present is that they can generate breakdown products that
negatively impact the regenerative environment. In the case of PLGA microspheres, the
acidification caused by the breakdown of PLGA can cause an increase in the inflammatory
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response within the spinal cord.(Wilems et al. 2015) This can mean that combination therapies
with many different drug delivery systems can cause unanticipated interactions which can
attenuate the positive effects observed when each delivery system was used on its own. Thus, it
is appealing to attempt to capture signaling complexity without having to include multiple drug
delivery platforms. One method that has been used in other fields to achieve signaling
complexity without having to include a large number of different growth factors is to use
decellularized extracellular matrix (ECM) materials.

1.2.3.1

Decellularized Extracellular Matrix

The ECM is composed of proteins that are produced by the cells that occupy a given
region within the body. The most common ECM proteins are often used as base material for
transplantable biomaterials, such the collagen, fibrin, and HA materials discussed above. The
ECM also contains several other proteins that are present at lower levels and attach to the base
proteins. These proteins all come together to form a complex environment that can bind growth
factors, especially since most ECM proteins are quite large and contain multiple functional
domains including cell binding and growth binding regions. For example, fibronectin has been
found to have a highly promiscuous growth factor binding domain.(Martino and Hubbell 2010)
The multifactorial nature of decellularized ECMs makes them an appealing way to deliver a
multitude of bioactive molecules at once.
The use of decellularized whole tissue is already used clinically for treatment of peripheral
nerve injuries where is defect is longer than a few millimeters. In the case of these injuries, a
decellularized nerve graft can be used to enhance regeneration of the damaged nerve(Isaacs
2013). Another approach being used is to pulverize whole tissue and then form a gel out of the
resulting powder. This approach has been used in the treatment of myocardial infarctions(Seif13

Naraghi et al. 2013; Singelyn et al. 2012), and for orthopedic tissue engineering.(Benders et al.
2013) In the context of CNS injury, ECM gels made using decellularized brain ECM
demonstrated that ECM from the CNS does provide a more growth permissive substrate for
neuronal cultures than ECM harvested from other parts of the body in vitro.(Crapo et al. 2012)
Further work has shown that spinal cord ECM increased neuronal differentiation efficiency of
NPCs while brain ECM lead to longer neurite extensions.(Medberry et al. 2013)
The benefit of CNS ECM over other ECMs has largely not extended to in vivo treatments.
For example, hydrogels made from spinal cord ECM and urinary bladder ECM were found to
have no significant differences when transplant acutely following a dorsal hemisection SCI.
However, both types of ECM were found to increase neurite growth into the lesion and
neovascularization.(Tukmachev et al. 2016) Similar to the case with treatment SCI , urinary
bladder ECM implantation into stroke cavities has been shown to increase host cell infiltration
into the lesion core and promote the infiltrating macrophages to adopt a more pro-regenerative
phenotype(Ghuman et al. 2016a). Taken together, these studies suggest that an ECM-based
material could provide significant therapeutic benefits to patients that suffer from a CNS injury.
In additional to their growth benefits, the highly conserved nature of ECMs means that
decellularized ECM materials can be xenografted without requiring immune
suppression.(Mirmalek-Sani et al. 2013; Hudson et al.) This is especially important since the
immune system plays an important role in tissue regeneration as demonstrated by the discovery
of M1 and M2 subtypes of macrophages present during the normal repair pathway.(Novak and
Koh 2013) In the context on CNS regeneration, microglial have also been found to play an
important long term role in the generation of an axon growth promoting environment by clearing
cellular debris and secreting factors such as matrix metalloprotease-13 that degrade the fibrotic
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scar.(X. Jin and Yamashita 2016) Furthermore, infiltration of T-cells and macrophages from the
periphery has been demonstrate to be required for repair following SCI.(Raposo et al. 2014)
These observations show that the immune system plays an important role in tissue repair and that
it would be desirable to avoid therapy that requires immune suppression, since it could
negatively impact recovery in unforeseen ways.

1.3 Cell Transplantation in Spinal Cord Injury
A major issue for acellular spinal implants is the lack of good cell infiltration into the injury
site either due to the lack of migration of the native cell populations or a lack of the appropriate
migratory signals within the implant. One way to ensure that transplants have cells present
within them is to transplant the cells directly into the injury site. Cell transplants have been
performed with stem/progenitor cells, neuron populations, peripheral cells and glial cell
populations.(Tetzlaff et al. 2011) An issue with cell transplantation is survival of the transplanted
cells since they are often being placed into an environment that is full of inflammatory
signals.(Medalha et al. 2014) One way that this issue has been addressed is transplantation of the
cells in a scaffold that provides them with support to help improve their survival within the
spinal cord lesion

1.3.1 Neuronal Population Transplantation
Neurons are the primary cell type responsible for transmitting signals from the brain to the
rest of the body via the spinal cord. It is the severing of the axons in an SCI that causes paralysis
of the body below the level of the injury. For recovery from SCI to be possible, these
connections must be restored. One appealing way to achieve this connectivity is to transplant
neurons into the injury area so that they can form a relay circuit or, much more unlikely due to
the distances involved, directly reestablish connection. This type of integration has been
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successfully achieved in transplants of embryonic medial ganglionic eminence cells. These cells
are GABAergic interneurons from the brain that were able to integrate into the host’s spinal
circuitry and can prevent the development of mechanical hypersensitivity when transplanted
prior to peripheral nerve injury.(Etlin et al. 2016) Unfortunately, primary neurons are difficult to
isolate and primary cells in general are difficult to translate into the clinic, this makes deriving
neurons from tissue culture sources appealing.
One way to acquire neurons in a tissue culture setting is to use an immortalized cell line. A
immortalized neuronal cell line, NT2, has been successfully manipulated to allow for
transplantation following SCI with the result of reducing allodynia via neurotransmitter
production.(Eaton et al. 2007) Another way to acquire neurons is to derive them from embryonic
stem cells (ESCs) or another pluripotent population. The major issue with stem cell-derived
neurons is that the pluripotent cells remaining within the transplant can form teratomas within
the spinal cord.(Johnson et al. 2010) A way to avoid the remaining ESC problem is to create a
method by which residual ESCs can be removed. This can be achieved with puromycin
selection(D. a. McCreedy et al. 2012) or fluorescence activated cell sorting. Once the ESCs have
been removed, the cells can be transplanted without risk of teratoma formation.(D. A. McCreedy
et al. 2014; Wilems et al. 2015) One ESC-derived neuronal population that has been used for SCI
treatment are progenitor motor neurons derived from human ESCs(Erceg et al. 2010), and mouse
ESCs.(Wilems et al. 2015) Although these cells demonstrated relatively mild benefits and this
progenitor population also forms astrocytes and oligodendrocytes.(Mccreedy et al. 2014)
Overall, there is much work to be done in neuronal transplantation since pure neuronal
populations after difficult to acquire from progenitor cells due to their relative fragility in culture.
As techniques for acquiring pure neuronal population cultures improve, it will be possible to
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explore the effects of different neuronal subpopulation transplants on SCI recovery.(Iyer,
Wilems, and Sakiyama-Elbert 2016)
One interesting neuronal population to explore are the spinal interneurons (INs). INs form
connections between all the neuronal populations with the spinal cord and have been shown to
play important regulatory roles in coordination, rhythmicity, and spinal reflex arcs. It has been
shown, in mice, that spontaneous recovery from spatially and temporally separated lateral
hemisection SCIs is dependent on neuronal populations present around the level of injury, not
sparing of the long tract axons projecting from the brain.(Courtine et al. 2008) This implies that
INs are required in order to facilitate the local rewiring that allows spontaneous recovery to
occur. Further work based on this study has shown that dl3 INs are necessary for motor function
recovery after SCI.(Bui et al. 2016) There has been only limited work demonstrating the effects
of transplantation of IN populations into CNS lesion making this an active area of exploration;
however, primary GABAergic brain IN precursors have been shown to functionally integrate and
limit hypersensitivity in mice following a lumbar spared peripheral nerve injury(Etlin et al.
2016). This study shows the promise of IN transplantation in terms of enabling functional
recovery following nerve injury.
A population of spinal INs that has been a particular focus in SCI treatment are V2a INs. V2a
INs are a largely glutamatergic, ipsilateral projecting IN population found throughout the spinal
cord, but predominantly in the lumber and cervical regions. In the lumbar region, V2a INs are
important for left-right alternation in the normal spinal cord, especially at high speeds of
locomotion.(Steven A. Crone et al. 2008; S. A. Crone et al. 2009) Further dissection of the roles
played by V2a INs in the lumbar spinal cord found that V2a INs tend not to synapse on other
V2a INs, but instead tend to project to central pattern generators and ipsilateral motor neuron
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pools. Some of V2a INs have also been found to have long ascending or descending branches.(K.
J. Dougherty and Kiehn 2010) This suggests that V2a INs play an important rely and
coordination role in the lumbar spinal cord, but not a significant role in pattern generation. In
contrast, V2a INs in the cervical cord have been linked to central respiratory rhythm based on the
loss of respiratory rhythm, and decreased respiratory rate, in V2a knockout mice.(S. A. Crone et
al. 2012) The concept of V2a INs as an important population for both relying signals and in the
respiratory circuitry is supported by the observation that V2a INs are recruited into phrenic
motor circuitry after a high cervical lateral hemisection SCI. This suggest that the V2a
population may aid in functional compensation/recovery from cervical SCI.(Zholudeva et al.
2017) Recently methodology to derive V2a INs from mouse ESCs has been developed(Brown et
al. 2014) as has a mouse ESC cell line that allows these ESC-derived V2a IN populations to be
purified.(Iyer et al. 2016) With the development of these ESC tools it is now possible to
transplant V2a INs following SCI. In this work, we perform a pilot study to determine if these
mESC-derived V2a INs are able to survive transplantation.

1.3.2 Progenitor Transplantation
Since transplantation of specific neuronal populations has proved difficult, transplantation of
proliferative progenitor cells that can differentiate into neurons has been widely attempted. The
cells most commonly used in SCI treatment are called neural progenitor cells (NPCs). These
cells can become neurons, oligodendrocytes, or astrocytes after further differentiation meaning
that, in theory, transplanting these cells can restore all the cell populations normally present
within the spinal cord. NPCs are found throughout the CNS in the region surrounding the
cerebral spinal fluid system and can be harvested from animals at any age. NPCs can also be
acquired by differentiation of induced pluripotent stem cells (iPSCs) or ESCs. Due to the
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teratoma formation observed with ESC transplants, any ESC-derived population must be further
defined into a specific cell fate prior to transplantation.(Johnson et al. 2010)
NPCs have been transplanted in chronic SCI lesions in rodents and histological improvement
has been observed, but it has proven difficult achieve good connectivity between the transplanted
cells and the host, limiting functional improvement.(Y Jin et al. 2016) Furthermore,
transplantation of primary adult NPCs has been shown to improve functional outcomes when
transplanted two weeks after a cervical crush injury.(Wilcox et al. 2014) Unfortunately, it has
proved difficult to control the differentiation of NPCs once they are transplanted with most of
them differentiating into glial cells (astrocytes or oligodendrocytes).(Pfeifer et al. 2004) This has
led to a focus on factors that can be included with the NPCs in order to help better promote
differentiation into neurons;(X. Li et al. 2013) however, differentiation of NPCs is also heavily
influenced by the local environment within the host.(Ying Jin, Sura, and Fischer 2012) Thus,
while there is significant promise to NPC transplantation, the lack of ability to specifically
control what these cells differentiate into has led investigators to pursue the use of predifferentiation prior to transplant to control cellular phenotype. This has proven to be much
easier for transplanting glial cell populations than neurons since glial cells are still capable of
dividing and so much easier to maintain in in vitro cell culture.

1.3.3 Glial Cell Transplantation
Glia are a large population of supporting cells that are found in nervous tissue that primarily
serve to support neuronal function. They achieve this by clearing debris following injury, toxic
metabolites, maintaining homeostasis, and facilitating signal transmission and propagation. Since
these cells are so important for appropriate neuronal function, they are a logical population to use
for transplantation following SCI. Comparison of Schwann cells (SCs) , peripheral glial cells,
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and olfactory ensheathing cells to fibroblastic populations have shown that these glial
populations are associated with decreased scar formation and improved axon growth into the
lesion demonstrating that glial cells are able to perform CNS specific functions that improve
regeneration.(Toft et al. 2013)

1.3.3.1

Schwann Cell Transplantation

SCs are the primary supportive cell in the peripheral nervous system. These cells have
been studied for an ability to support recovery from spinal cord injury because of the strong
regenerative potential of peripheral nervous system injuries with peripheral axons able to regrow
across small defects. Furthermore, SCs are myelinating so can, in theory, reform the myelin
sheaths that surround axons to allow for faster conduction. Meta-analysis of SC transplantation
studies showed that, regardless of source (primary or stem cell-derived), transplantation of
Schwann cells significantly improved locomotor function after SCI.(Yang et al. 2015) A specific
example of SC transplantation is the use of oligo[poly(ethylene glycol) fumarate] scaffolds as a
vehicle for transplantation. These scaffolds were found to decrease the size of the glial scar and
reduce the presence of inhibitory CSPGs; although, there were signs of increased inflammation
and immune cell infiltration due to the presence of the scaffold.(Hakim et al. 2015) Another use
for SCs is to modify them to overexpress growth factors thus allowing them to serve as both a
permissive cell population and a drug eluting depot. One example of SCs as growth factor
delivery vehicles is the transplantation of fibroblast growth factor-2 (FGF-2) overexpressing
Schwann cells. Transplantation of these SCs were able to improve the growth of motor axons in
the sciatic nerve following injury.(Allodi et al. 2014) Overall SC transplantation has shown great
promise and SCs are currently under investigation in clinical trials for use in humans. One caveat
to the utility of these transplants is that the ability of the Schwann cells to integrate into the host
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spinal cord is determined by the phenotype of the host astrocytes and often axons are unable to
leave to lesion area in SC transplanted animals.(Bunge 2016)

1.3.3.2

Oligodendrocyte Transplantation

Oligodendrocytes (OLs) are native to the CNS and are primarily responsible for the
formation of myelin sheaths. One significant difference between OLs and SCs is that an OL will
myelinate many different axons while Schwann cells myelinate only a single axon. Since they
are native to the CNS, OL transplantation has been attempted to facilitate myelination of
regenerating nerve fibers. Myelination is an important focus of potential regenerative treatments
since it is the final step of recovery in the PNS and is critical for appropriate transmission of
action potentials and protection of the axons. Native remyelination in the CNS is more difficult
to achieve than in the PNS because mature OLs lack the capacity to produce new myelin
sheaths.(Keirstead and Blakemore 1997) This means that central remyelination must be carried
out by dividing and differentiating oligodendrocyte precursor cells (OPCs), or infiltrating
SCs.(Gensert and Goldman 1997; Brook et al. 1998) There has been some work looking to how
to activate local remyelination pathways without requiring cell transplantation. One interesting
finding is that treatment of the spinal cord with a synthetic TLR4 agonist (E6020) accelerated
myelin debris clearance and remyelination following a demyelinating injury with lysolecithin.
This data shows that there is a clear role of macrophage activation in remyelination, it is also
worth noting that astrocytes express TLR4 so they may play a role as well.(Church et al. 2017)
Unfortunately there are not many native OPCs and their migration distance is
limited(Levine, Reynolds, and Fawcett 2001), so transplantation of OPCs and control of their
differentiation in vivo has been heavily explored. OPCs themselves do not produce myelin, so
they must be differentiated into mature, myelinating OLs. Unfortunately, OLs have proven more
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difficult to differentiate from stem cells or progenitors than either astrocytes or neurons partially
due to the dependence of OL differentiation on material properties. Materials that are compatible
with OL differentiation have been reviewed by Russell and Lampe.(Russell and Lampe 2016)
Primary OPCs have been transplanted following SCI, after having been cultured and
modified to express ciliary neurotrophic factor, and were found to improved functional recovery
and remyelinated the axons.(Cao et al. 2010) Similarly, it has been found that human induced
pluripotent stem cells can be pre-differentiated into OPCs and that those cells are able to promote
myelination following a thoracic contusion SCI.(Kawabata et al. 2016) Likewise, human
embryonic stem cells (hESCs) pre-differentiated into OPCs have been found to improve
remyelination and functional repair following contusion or complete transection SCI.(J. Faulkner
and Keirstead 2005; Erceg et al. 2010) Extensive study of these hESC-derived OPCs has
indicated that they are safe for clinical trial(Priest et al. 2015), which has led to an ongoing Phase
I/II clinical trial sponsored by Asterias Biotherapeutics that has reported promising initial
efficacy data.(Biotherapeutics 2017) Despite these early successes with this OPC population in
humans, it is worth noting that a review of all SCI treatment studies using rodent-derived
remyelinating populations found that there is significant inconsistencies in recovery findings,
showing that more work is needed on understanding and manipulating myelinating glia
populations.(Myers et al. 2016)

1.3.3.3

Olfactory Ensheathing Cells

Olfactory ensheathing cells (OECs) are a specialized cell found within the nasal mucosa
that facilitates repeated growth of axons from the peripheral nervous system (nasal mucosa) to
the CNS (olfactory bulb).(Tetzlaff et al. 2011) Due to this role, these cells have been heavily
studied as a means to achieve improved regeneration in both the CNS and peripheral nervous
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system. In SCI, transplantation of OECs has been shown to improve axon growth and limit
immune cell infiltration into the injury leading to overall improved recovery.(Khankan et al.
2016) There is also some evidence that OEC transplantation may improve recovery from
autonomic dysreflexia, which can be a fatal complication of SCI. Specifically, rats with a T4
complete transection SCI were found to have reduced automonic dysreflexia with OEC, but not
fibroblast, transplantation.(Cloutier et al. 2016) OECs are used as primary cells that can be
isolated directly from the patient due to easy access to the olfactory epithelium. Importantly, the
exact function of the OECs in transplantation is dependent on where they are isolated from in the
body and how they are treated in culture.(Mayeur et al. 2013) Autologous transplantation of
OECs has been attempted as a phase I clinical trial and appeared to be safe with 2 of 3 patients
showing improvements in their neurological function score with rehabilitation training.(Tabakow
et al. 2013) The difficulty with any autologous treatment is donor site morbidity, in the case of
OECs there is a risk of anosmia, and the inherent heterogeneity of primary cultures which makes
quality control more difficult. These complications have led to a recent decrease in the number of
papers published exploring OEC transplantation.

1.4 Astrocyte Roles in CNS Regeneration
Astrocytes are a large heterogeneous population of glia that serve many important
functions that support neuronal activity. These support functions include maintenance of the
blood-brain barrier, disposal of toxic metabolites by neurons, signal transduction through
tripartite synapses, and water homeostasis. Despite this large variety of roles, astrocytes have
been relatively poorly studied in terms of their ability to promote regeneration. A significant
contribution to lack of astrocyte study was the general belief in the SCI field that astrocytes are
largely responsible for creating an inhibitory environment that needs to be circumvented in for
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recovery to occur. This concept is supported by the fact that astrocytes create a physical barrier
of overlapping processes(Sun et al. 2010; Sun and Jakobs 2012), as well as produce molecules,
such as CSPGs, that are inhibitory to neuronal growth.(Oohira, Matsui, and Katoh-Semba 1991)

1.4.1 Variability in Astrocyte Reactivity
One explanation of the observed duality in astrocytic roles following SCI is that different
astrocyte subpopulations are involved in scar formation versus bridge formation. This hypothesis
is supported by the inherent heterogeneity of astrocytes(Cahoy et al. 2008) and the known
differences in the purpose and functions of different astrocyte subpopulations within certain
brain regions.(Oberheim, Goldman, and Nedergaard 2012) In support of the idea that there is
heterogeneity in astrocyte reactivity, it has been observed that astrocyte gene expression changes
depending on whether the CNS insult was ischemic or inflammatory. Ischemic injury has been
found to lead pro-regenerative reactive astrocytes, while inflammatory insults leads to more
inhibitory reactive astrocytes.(Zamanian et al. 2012) This injury type-dependent reactivity has
led to the concept that astrocytes may have two types of reactive polarization, similar to
macrophages and microglia, which have been termed A1 or A2 reactive astrocytes. A2 (proinflammatory) astrocytes have “harmful” functions, such as synapse destruction, while A1
reactive astrocytes have “helpful” (pro-regenerative) functions. The heterogeneity of astrocyte
reactivity is a newly appreciated concept and has been reviewed by Liddelow and
Barres.(Liddelow and Barres 2017)
In addition to the differences in astrocyte reactivity depending on insult, it has also been
found that different brain regions behave differently in response to injury. While there are many
astrocyte subtypes in the CNS, astrocytes can be broadly defined as either fibrous (found in
white matter) or protoplasmic (found in grey matter). Interestingly, studies looking at the
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reactivity of white matter and grey matter astrocytes following CNS injury have found
significant differences in how astrocyte morphology changes in response to injury. Optic nerve
crush and corpus callosum injury studies have shown that fibrous astrocytes initially retract their
processes following insult and then re-extend them leading to a significant increase in the area
covered by each astrocyte. This process re-extension and hypertrophy leads to significant process
overlap, which disrupts the normal lamellar structure of the white matter.(Sun et al. 2010) In
contrast to this, filling studies performed on resting and reactive protoplasmic astrocytes show
that reactive protoplasmic astrocytes exhibit some process hypertrophy, but they do not exhibit
the same increase in process overlap between adjacent astrocytes.(Wilhelmsson et al. 2006)
These observations together suggest that fibrous astrocytes are more involved in the creation of
the physical barrier found in the glial scar environment, and that potentially a subset of
protoplasmic astrocytes may be responsible for the formation of GFAP+ bridges across lesion
cavities.

1.4.2 Astrocyte Phenotype alters Transplant Outcomes
The inherent functional differences between fibrous and protoplasmic astrocytes has been
observed in SCI transplant studies as well. Glial restricted progenitors (GRPs) are a population
of primary cells that can be isolated from E13.5 embryos and can differentiate into either fibrous
or protoplasmic astrocytes as well as oligodendrocytes, but not neurons.(Rao, Noble, and MayerPröschel 1998) Pre-differentiation of these cells into astrocytes using basic fibroblast growth
factor (FGF-2), bone morphogenetic protein 4 (BMP-4) and N2 media supplement showed
improved recovery of when compared to the transplantation of undifferentiated GRPs.(J. E.
Davies et al. 2006) These BMP-4 differentiated astrocytes have a phenotype that is most similar
to protoplasmic astrocytes. Interestingly, when GRPs are pre-differentiated into fibrous-like
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astrocytes using ciliary neurotrophic factor (CNTF) they have a detrimental effect of recovery
leading to decreased axon penetration into the injury site and increasing allodenia.(J. E. Davies et
al. 2008; S. J. A. Davies et al. 2011) Similar to other studies using primary cells, there has been
heterogeneity of these findings, likely due to variations in the methods used, that affects study
outcomes. When the GRPs remain in a more immature state, transplantation of GRP-derived
astrocytes has been found to improve axon penetration into the injury site, regardless of
phenotype at the time of transplantation.(C. Haas et al. 2012) Further investigation of the CNTFexposed GRPs and BMP-4-exposed GRPs has demonstrated that one of the factors responsible
for the observed functional difference is periostin-1, which is produced by BMP-4 exposed
GRPs, but not CNTF-exposed astrocytes.(Shih et al. 2014) Further periostin-1 experiments found
that recombinant periostin-1 improved neurite extension in vitro and that periostin-1-deficient
BMP-4-exposed GRPs did not have the same beneficial effects as wild type BMP-4-exposed
GRPs.(Shih et al. 2014)
The major issue with GRP transplantation is that these cells need to isolated from an
embryo, making it difficult to acquire human cells for transplantation and study. One way to
address this issue is to develop methods to derive these astrocytes from ESCs thereby allowing
these astrocytes to be derived entirely in vitro. There have been methods developed that allow for
astrocytes to be derived from ESCs(Roybon et al. 2013; R. J. Benveniste, Keller, and Germano
2005), but only mixed populations of astrocytes have been produced rather than attempting to
specifically derive populations that exhibit more a fibrous-like or protoplasmic-like phenotype.
Overall there is significant promise to astrocyte-based therapies, but there is much left to be
elucidated in terms of the reactive states of different astrocyte subtypes and how different
astrocyte subtypes effect axon growth and regenerative potential.(Chu et al. 2014)
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1.4.3 Small Molecule Manipulation of Host Astrocyte Phenotype
Instead of transplanting astrocytes, there have also been studies investigating the use of
growth factors and/or small molecules to cause the native astrocytes to adopt a more proregenerative phenotype. Metallothionein is one factor that has been shown to induce astrocytes to
become more pro-regenerative through both intracellular and extracellular actions (Leung et al.
2009). Furthermore, delivery of metallothionein has been found to improve neuronal
regeneration following an optic nerve crush injury (Siddiq et al. 2015). Endogenous glial cells
can also be manipulated by FGF-2 exposure. Studies in both mice and zebrafish have shown that
FGF-2 signaling facilitates glial bridge formation following SCI.(Yona Goldshmit et al. 2012;
Yona Goldshmit et al. 2014) In addition, knockout of spry4, a FGF signaling inhibitor, has been
found to reduce inflammatory response and decrease gliosis following SCI.(Y. Goldshmit et al.
2015) FGF-2 within lipid microtubules has been incorporated into collagen-based hydrogels
leading to increased astrocyte infiltration into hydrogels in vitro.(Macaya et al. 2013)
There is also evidence that astrocytes exhibit plasticity of their reactive phenotype based
on the local, extracellular environment. Astrocytes transplanted acutely into an SCI lesion, but
not healthy spinal cord, have been shown to adopt an inhibitory phenotype. This phenotypic
switch has been shown to be dependent on integrin-binding to collagen I within the scar.
Inhibition of collagen I binding with an anti-β1 integrin antibody leads to increase axon
penetration into the SCI lesion and improved behavioral recovery following a spinal cord
contusion injury in mice.(Hara et al. 2017)
Consistent with the classification of reactive astrocytes using the same system as
macrophages, astrocytes express receptors and cytokines that are associated with the immune
system. In particular, astrocytes are known to express toll-like receptor 4 (TLR4), suggesting a
pathway for activation in response to lipopolysaccharide (LPS).(Bsibsi et al. 2002) Loss-of27

function and gain-of-function studies of TLR4 and triggering receptor expressed on myeloid
cells-2 (TERM-2), a negative regulator of TLR signaling, have shown that increased TLR4
activation with LPS increases pro-inflammatory gene expression by astrocytes. In contrast,
increased TERM-2 signaling has been found to modulate this response by decreasing NF-κB
activation, suggesting that NF-κB signaling could be an important regulator of pro-inflammatory
reactive astrocytes.(Rosciszewski et al. 2017)
Astrocytes are also known to upregulate interleukin receptors in response to injury and to
express some interleukins. Because of these expression profiles, it stands to reason that
interactions with immune cells and their secreted factors may alter astrocyte phenotype. Two
interleukins that have been extensively studied in astrocyte phenotype manipulation are IL-6 and
IL-10. IL-6 is a pro-inflammatory cytokine that modulates CNS inflammation. IL-6 is produced
by astrocytes after injury or infection(E. N. Benveniste et al. 1990), and the presence of IL-6 has
been associated with astrocyte proliferation and scar formation, as well as immune cell
infiltration in the acute phase following injury.(M. Nakamura et al. 2005) There is also evidence
that in the subacute phase of SCI injury, IL-6 expression has pro-regenerative effects, suggesting
a duality of roles for this molecule.(Codeluppi et al. 2014) In contrast, IL-10 is an antiinflammatory cytokine that is important for the resolution of the immune response throughout
the body. In the context on CNS injury, IL-10 has been delivered intrathecally and
intramuscularly to improve functional recovery.(Jackson et al. 2005) Furthermore, astrocytespecific production of IL-10 has been shown to increase immune cell infiltration, but also
increases motor neuron survival following a facial nerve axotomy.(Villacampa et al. 2015) There

28

has been some work using flavopiridol, a
cell-cycle inhibitor, as a way to alter the
interleukin expression from astrocytes. In
particular, flavopiridol delivery from
poly(lactic-co-glycolic acid) (PLGA)
nanoparticles was found to reduce astrocytic
synthesis of pro-inflammatory cytokines,
including IL-6, as well as increasing
astrocyte-based IL-10 expression.(Ren et al.
2014) These observations of the astrocytic
Figure 1.1: Schematic Summary of Factors Known to
Affect Astrocyte Reactivity

roles in immunomodulation suggest that

anti-inflammatory signaling cascades used to alter the immune response in other organ systems
may be able to alter reactive astrocyte phenotypes as well. The factors discussed here are
summarized in Figure 1.1. Overall the manipulation of astrocyte heterogeneity is still being
actively investigated and holds great potential as a means to harness astrocytes as a regenerative
population.

1.5 Biomaterial-based Manipulation of Glial Phenotypes
Given the complexities of glial cell response to trauma, with some glia providing a proregenerative support and others tending to inhibit regeneration, there is significant potential
benefit to use materials to manipulate the phenotypes of both transplanted and native glia. The
major approaches used for these manipulations are modifying the mechanical properties,
composition, growth factor delivery, and alignment of the materials. Here what is known about
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how these biomaterial factors affect the phenotype and differentiation of the major CNS glial
populations is discussed.

1.5.1 Material Properties affecting Cell Fate
Matrix stiffness is a powerful tool for the manipulation of cell phenotype and the
differentiation of neural progenitor cells (NPCs). NPCs have been shown to differentiate into
OLs and neurons on softer matrixes and generally differentiate into astrocytes on stiffer
matrices.(Seidlits et al. 2010; Russell and Lampe 2016) In addition to OL differentiation being
dependent on matrix stiffness, myelination by either SCs or OLs is affected by matrix elasticity
with low elasticity matrices allowing for increased myelin production by OLs. In contrast, high
matrix elasticity increases SC myelin production.(Urbanski et al. 2016) These elasticity
differences are the result of non-muscle myosin II which has been found to be a positive myelin
regulator in the PNS, but a negative myelin regulator in the CNS.(Urbanski et al. 2016; H. Wang
et al. 2008) These studies demonstrate that material properties are an important consideration
when designing scaffolds for either the CNS or PNS.
Consistent with the observation that material properties affect NPC differentiation, there is
also evidence that integrin signaling is important for astrocytic differentiation from neural
progenitor populations. In particular, the exposure of NPCs to IKVAV peptide amphiphile
(IKVAV-PA) has been shown to increase neuronal differentiation and decrease astrocyte
differentiation.(G. A. Silva et al. 2004) IKVAV is an important integrin binding region of
laminin, demonstrating the importance of ECM signals in NPC differentiation, and the
amphiphile structure used for delivery of the peptides allows for a significant increase in epitope
density. Delivery of IKVAV-PA has also been shown to decrease glial scar density, and increase
oligodendrocyte infiltration following a compressive SCI in mice.(Tysseling-Mattiace et al.
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2008) The observed effect of IKVAV-PA particles on differentiation has been partially attributed
to β1-integrin signaling with both ESCs and subventricular zone NPCs demonstrating increased
astrocyte differentiation in the presence of IKVAV when β1-integrin is knocked out. The
importance of β1-integrin signaling in functional recovery following SCI is further suggested by
observed behavioral improvements in mice treated with 2 other β1-integrin binding peptide
amphiphiles, RGD-PA or ADEGVFDNFVLK (Tenascin C)-PA.(Pan et al. 2014)

1.5.2 Materials that increase Myelination following CNS Trauma
Since myelination is a critical step in recovery from nervous system trauma, the ability of
implanted materials to increase the percent of myelinated fibers could have significant clinical
utility. Since remyelination occurs late following SCI and native OLs don’t have a high capacity
for remyelination, the ability of materials to promote local remyelination in vivo has not been
extensively studied. A comparative study of different substrates effect on myelination in vitro by
myelinating cultures composed of primary cells isolated from E15 rat spinal cords found that low
molecular weight ε-polycaprolactone (PCL) increased myelination compared to polycarbonate,
poly(methyl) methacrylate, polystyrene, poly-L-lactide, polydimethylsiloxane, and high
molecular weight PCL. These studies also showed a clear effect on astrocyte phenotype on
myelination with media conditioned by astrocytes cultured on PCL decreasing OL myelination,
while media conditioned by astrocytes cultured on glass increased OL myelination.(Donoghue et
al. 2013) This suggests that astrocyte phenotype should be considered when designing materials
to increase remyelination following CNS injury.
There have been some acellular in vivo implantation studies that have shown increased
myelin production. One strategy is to deliver sonic hedgehog (SHH) and neurotrophin-3 (NT-3).
These factors were delivered following a lateral hemisection SCI using lentivirus within a
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multiple channel bridge composed of PLGA. The inclusion of NT-3 was found to increase
myelination by infiltrating SCs, while SHH over-expression significantly increased OL
myelination.(Thomas et al. 2014) Another material found to increase myelination is a Chitosan
Fragmented Physical Hydrogel suspension (Chitosan-FPHS). This material was found to
increase myelination in rats at 4, 8 and 10 weeks after a dorsal over-hemisection SCI from both
SCs and OLs. Interestingly, the OL myelination observed in this study was restricted to regions
in which astrocytes were able to infiltrate the Chitosan-FPHS.(Chedly et al. 2017)

1.5.3 Materials that Alter Astrocyte Phenotypes
Astrocyte phenotype and penetration is an important consideration for CNS repair
materials since astrocytes are known to support neuronal growth and to be required for the
survival of certain neuronal populations. It has been found in many biomaterials that neuronal
growth into the material is correlated with astrocytes or their processes.(Pawar et al. 2015;
Taylor et al. 2006) This makes the astrocytic response to transplanted materials crucial to
consider and demonstrates the importance of determining how to push native astrocytes away
from a scar phenotype toward a more pro-regenerative state. One material that has been shown to
limit inhibitory astrocyte formation is high molecular weight (MW) hyaluronic acid (HA). Acute
transplant of high MW HA following dorsal hemisection SCI decreased immune cell infiltration
and CSPG deposition.(Khaing et al. 2011) The same is not true of small (40-400 kDa) HA
chains, which have been shown to activate NF-κB in astrocytes and so upregulate inhibitory
reactive astrocytes.(Pandey et al. 2013) Similar to this observation with HA, implantation of
fibrin scaffolds has also be found to slow the accumulation of reactive astrocytes around a SCI
lesion.(Johnson, Parker, and Sakiyama-Elbert 2010)
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Matrix alignment has been shown to be a powerful tool in glial manipulations with glia
cells, and neurons, aligning to a provided matrix. Unfortunately, alignment is extremely difficult
to achieve in vivo, so much of what is known about alignment effects is based on in vitro data.
Aligned cell morphology has been shown to result in increased neurite outgrowth in both 2 and 3
dimensions.(Corey et al. 2007; East et al. 2010) Furthermore, when aligned astrocytes enhance
neuronal growth in the direction of alignment.(Biran, Noble, and Tresco 2003) In addition,
randomly-aligned, electrospun polyamide nanofibers have been found to decrease astrocyte
process hypertrophy and GFAP expression in vitro compared to poly-L-lysine on either glass or
Aclar in response to an inflammatory stimulus (dibutyryladenosine cyclic
monophosphate).(Volkan Müjdat Tiryaki et al. 2015; Volkan Mujdat Tiryaki et al. 2012) This
suggests that astrocytes may adopt a more quiescent phenotype when on a fibrillar surface in
vitro, regardless of alignment. Here only the effect of electrospun materials on astrocytes is
reviewed, for a complete review of electrospun material in SCI regeneration see Schaub et
al.(Schaub et al. 2016)
Since electrospinning can be used to generate alignment, the benefit of fibrillar matrices
and alignment has been widely used material starting point for astrocyte manipulations in vitro.
Study of astrocytes cultured on aligned collagen fibers in vitro have found that astrocytes in an
aligned environment decrease expression of GFAP, a hallmark of astrocyte reactivity, and
elongated in the direction of alignment. This in turn led to more organized neurite outgrowth
from dorsal root ganglions (DRGs).(T. Liu et al. 2012) Furthermore, these structures could be
rolled into 3D conduits that maintain their alignment growth benefits.(T. Liu et al. 2012) Further
manipulation of collagen fibers with other matrix proteins can be used to improve astrocyte
alignment and decrease the expression of CSPGs. In particular, fibrinogen coating significantly
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increased alignment with the collagen fibers, while aggrecan, laminin, and fibrinogen, but not
fibronectin decreased CSPG expression of cultured astrocytes.(Hsiao, Tresco, and Hlady 2015)
Astrocytes cultured on aligned PLLA materials have also been found to elongated and
upregulate the two major glutamate transporters, glutamate transporter 1 (GLT-1) and glutamate
and aspartate transporter 1 (GLAST).(Zuidema et al. 2014) The presence of these transporters is
important to the support of excitatory, glutamatergic neurons which are unable to process the
glutamate they release leading to excitotoxicity. PLLA scaffolds have also been used to release
6-aminonicotinamide, which is an anti-metabolite, to reduce the metabolic rate of astrocytes
cultured on the drug-eluting fibers.(Schaub and Gilbert 2011) In addition to alignment effects,
fiber size also impacts astrocyte phenotypes with 400 nm silk fibers inducing longer astrocyte
process extension, increasing area per astrocyte, and improving neuronal maturation when
compared to 1200 nm fibers.(Qu et al. 2013) Increasing the stiffness of 400 nm cellulose acetate
nanofibers from a tensile modulus of around 24 MPa to around 80 MPa resulted in an increase in
astrocyte attachment, proliferation, and ECM deposition.(Min et al. 2015) It is important to note
that alignment is difficult to achieve in an implantation setting, and so the clinical utility of
alignment is currently limited. However, randomly aligned, coated electrospun fibers could have
significant potential as a strategy to manipulate glial populations. Electrospun, randomly aligned
PCL scaffolds have been seeded with human endometrial stem cells and transplanted following
dorsal hemisection in rats. The PCL scaffold implant was found to slightly increase neurite
growth into the SCI lesion, demonstrating the potential of electrospun scaffolds as a treatment
strategy.(Terraf et al. 2017)
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1.6 Summary
Recent work has shown promise for improved treatments for SCI, although there is much
work still to done to improve the prognosis for those who suffer from SCI. In this work, methods
are developed to derive protoplasmic and fibrous astrocytes from mouse ESCs and the
differences in the ability of these populations ability to support the growth of ESC-derived
neuronal populations is explored. To further future transplantation and functional studies, a new
mESC cell line is developed that could allow for pure ESC-derived astrocyte population
acquisition. Finally, the ability of a novel hydrogel, composed of HA and decellularized
astrocyte ECM, to improve the expression of histological recovery markers following a thoracic
dorsal hemisection SCI was explored as was the ability of these hydrogels to support V2a
interneuron transplantation. (R. Thompson and Sakiyama-Elbert 2018)
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Chapter 2: Different Mixed Astrocyte
Populations Derived from Embryonic Stem
Cells have Variable Neuronal Growth
Support Capacities
2.1 Abstract
Central nervous system (CNS) injury often leads to functional impairment due, in part, to
the formation of an inhibitory glial scar following injury that contributes to poor regeneration.
Astrocytes are the major cellular component of the glial scar, which has led to the belief that they
are primarily inhibitory following injury. Recent work has challenged this by demonstrating that
some astrocytes are required for spinal cord regeneration, and that astrocytic roles in recovery
depends on their phenotype. In this work, two mixed populations containing primarily either
fibrous or protoplasmic astrocytes were derived from mouse embryonic stem cells (ESCs).
Motoneuron and V2a interneuron growth on live cultures, freeze-lysed cultures, or decellularized
extracellular matrix (ECM) from astrocytes was assessed. Both neuronal populations were found
to extend significantly longer neurites on protoplasmic-derived substrates than fibrous-derived
substrates. Interestingly, neurons extended longer neurites on protoplasmic-derived ECM than
fibrous-derived ECM. ECM proteins were compared with in vivo astrocyte expression profiles,
and it was found that the ESC-derived ECMs were enriched for astrocyte-specific proteins.
Further characterization revealed that protoplasmic ECM had significantly higher levels of axon
growth promoting proteins, while fibrous ECM had significantly higher levels of proteins that
inhibit axon growth. Supporting this observation, knockdown of spondin-1 improved neurite
growth on fibrous ECM, while laminin α5 and ɣ1 knockdown decreased neurite growth on
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protoplasmic ECM. These methods allow for scalable production of specific astrocyte subtypecontaining populations with different neuronal growth support capacities, and can be used for
further studies of the functional importance of astrocyte heterogeneity.

2.2 Introduction
Central nervous system (CNS) trauma represents a significant healthcare burden in the
United States, in part due to its limited regenerative capacity. Spinal cord injury (SCI) is a good
modality for studying CNS regeneration because the cord can be relatively easily accessed, the
axonal tracts can be reliably severed by hemisection, and a stereotyped glial scar and lesion
cavity forms after injury(Cregg et al. 2014). The lack of regeneration following CNS trauma has
historically been partially attributed to the astrocytes present within the glial scar, which
represents a physical and chemical barrier to axon growth. This has led to a focus in the field on
removing astrocytes to facilitate CNS regeneration.
Astrocyte removal has been achieved in SCI models by using genetic tools to knockout genes
required for astrocytes reactivity. In vimentin and glial fibrillary acidic protein (GFAP) double
knockout mice, astrocytes do not become appropriately reactive after SCI leading to impaired
glial scar formation, and increased bleeding (Pekny et al. 1999). Similarly, conditional knockout
of floxed STAT3, an inducer of astrocyte reactivity, using GFAP-Cre has been found to disrupt
the formation of the glial scar, increase macrophage infiltration into the spinal cord, and lead to a
larger lesion cavity after SCI (Herrmann et al. 2008). Conditional ablation of reactive astrocytes
at the time of injury or 5 weeks after SCI using GFAP-thymidine kinase (TK) + ganciclovir has
also been shown to lead to worse functional outcomes due to death of dividing GFAP+ cells.
These studies demonstrate that astrocytes are required both acutely to control spread of
secondary injury and chronically to facilitate functional recovery (Anderson et al. 2016; J. R.
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Faulkner et al. 2004). Thus, there is a clear role for astrocytes in CNS regeneration and potential
for their contribution to regenerative therapies.
Recent work on astrocytes has shown that there are many more distinct astrocyte populations
than previously believed (Cahoy et al. 2008; Oberheim, Goldman, and Nedergaard 2012).
Furthermore, the type of insult, inflammatory or ischemic, to the CNS has been shown to affect
whether native astrocytes become more pro-regenerative or more inhibitory, supporting the idea
that some astrocytes have pro-regenerative roles (Zamanian et al. 2012). The physical barrier
represented by the glial scar is primarily due to the woven nature of astrocyte processes adjacent
to the lesion (Sun and Jakobs 2012). Structural studies of astrocytes suggest that not all astrocyte
populations form such barriers in response to trauma. In particular, fibrous (white matter)
astrocytes have been shown to exhibit process hypertrophy and a significant increase in process
overlap following injury in optic nerve (Sun et al. 2010); conversely, protoplasmic (grey matter)
astrocytes have been demonstrated to exhibit some process hypertrophy after injury, but little to
no increase in process overlap (Wilhelmsson et al. 2006). These studies show that fibrous
astrocytes adopt a phenotype more consistent with classic glial scar morphology in response to
injury, suggesting that these populations may be more involved in glial scar formation. With the
lower levels of overlap observed in reactive protoplasmic astrocytes, it is possible that a subset of
these astrocytes may be responsible for pro-regenerative effects of astrocytes following CNS
injury.
The concept that astrocyte subtypes have variable roles following injury has been explored
using primary glial restricted progenitors (GRPs), isolated from rat, mouse and human
embryonic spinal cords (Rao, Noble, and Mayer-Pröschel 1998). These cells have been
successfully transplanted into rats following a right-sided cervical dorsal column transection SCI
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leading to improved recovery (Y Jin et al. 2016; J. E. Davies et al. 2006). Furthermore, GRPs
have been pre-differentiated into astrocytes using either ciliary neurotrophic factor (CNTF) or
bone morphogenic protein 4 (BMP-4) to generate fibrous-like or protoplasmic-like astrocytes (J.
E. Davies et al. 2008). When transplanted following spinal cord injury, GRPs differentiated into
fibrous astrocytes were found to have a detrimental effect on axon growth into the lesion and
functional outcomes, while protoplasmic transplants improved axon growth and functional
outcomes (J. E. Davies et al. 2008; S. J. A. Davies et al. 2011). While isolation of GRPs from
humans has been achieved from a fetal brain and spinal cord, these methodologies are not
scalable for clinical use. The novel component of our work is the derivation of these astrocyte
populations from mouse embryonic stem cells (ESCs). This methodology could be applied to
human pluripotent cells, and thus represents a scalable cell source for future pro-regenerative
astrocyte-based therapy development. Furthermore, an ESC source of these astrocytes could
allow for further elucidation of the mechanisms utilized by pro-regenerative astrocytes that are
absent in astrocyte populations inhibitory to axon growth and vice versa.
Previous protocols to derive astrocytes from ESCs have not focused on deriving specific
astrocyte subtypes. In this work, glial cell populations containing primarily fibrous or
protoplasmic astrocytes are derived from mouse ESCs. These populations are then demonstrated
to have different abilities to support the growth of ESC-derived motoneurons and V2a
interneurons, with protoplasmic populations allowing neurons to extend significantly longer
neurites than observed on fibrous populations. Finally, these neuronal growth support differences
are found to be due, in part, to altered extracellular matrix (ECM) composition with fibrous
astrocyte populations depositing more axon growth-inhibitory proteins while protoplasmic
astrocyte populations deposit more axon growth-permissive proteins.
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2.3 Materials and Methods
2.3.1 mESC Culture
RW4 (ATCC, SCRC-1018) mESCs were maintained in complete media (10% Fetal Bovine
Serum (Invitrogen), 10% Newborn Calf Serum (Invitrogen), 132 µM beta mercaptoethanol
(BME) (Sigma, St Louis, MO), 10,000 units/mL mouse leukemia inhibitory factor (Life
Technologies, Carlsbad, CA) and passaged when at 60-80% confluency. Cells were passaged
using 0.25% trypsin-EDTA (Life Technologies) at 37°C for 5 min to dissociate the cells. The
trypsin reaction was quenched and cells were seeded into a new T25 flask coated with 0.1%
gelatin (Sigma).

2.3.2 Glial Population Differentiation
1x106 RW4 ESCs were cultured in suspension on agar-coated 10 cm dishes in 10 mL DFK5
(DMEM/F12 (Life Technologies) plus 5% Knockout Serum Replacement (Life Technologies),
50 µM nonessential amino acids (Life Technologies), 1x Insulin-Transferrin-Selenium (Life
Technologies), 100 µM beta-mercaptoethanol (Sigma), 5 μM thymidine, and 15 μM of the
following nucleosides: adenosine, cytosine, guanosine, and uridine (Life Technologies) for two
days to form embryoid bodies (EBs) followed by 4 days in 10 mL DFK5 plus 2 µM RA and
600nM Smoothened Agonist (SAG) to confer a spinal identity with a media change after 2 days
(Roybon et al. 2013). On day 6, the EBs were dissociated and 4x106 cells were seeded onto a
gelatin-coated low adherence 10 cm dish (ThermoFisher) in DFK5 media plus 20 ng/mL
epithelial growth factor (EGF) (Peprotech), 10 ng/mL fibroblast growth factor 1 (FGF-1)
(Peprotech) and 1 µg/mL laminin for 5 days as described in Benvensite et al. (R. J. Benveniste,
Keller, and Germano 2005). On day 11, the cultures were switched into lineage-specific media
for 4 additional days on the same plates. Fibrous media: DMEM/F12 plus 1x G5 supplement
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(Invitrogen), 10 µg/mL CNTF (Peprotech); Protoplasmic media: DFK5 plus 10 µg/mL FGF-1,
10 µg/mL BMP4 (Peprotech); Benveniste astrocyte media: DFK5 plus 10 µg/mL FGF-1, 10
µg/mL platelet derived growth factor AA (PDGF-AA) (Peprotech) (R. J. Benveniste, Keller, and
Germano 2005). At day 15 the cells were reseeded onto gelatin-coated plates at a density of
20,000 cells/cm2 and maintained in lineage specific media for 6 additional days prior to use
(Figure 2.1A).

2.3.3 Immunocytochemistry (ICC)
Cells were fixed in 4% paraformaldehyde (Sigma) for 20 mins and then permeabilized in 0.1%
Triton-X (Sigma) for 15 mins. Cells were then blocked with 5% of an appropriate serum (Goat
(Sigma) or Donkey (Sigma)) in phosphate buffered saline (PBS) for 1 hr. Primary antibodies
were used at the following dilutions: GFAP 1:100 (Immunostar), A2B5 1:25 (DSHB), aquaporin
4 (Aqp4) 1:100 (Santa Cruz Biotechnology), Olig2 1:1000 (Santa Cruz Biotech), CS56 1:250
(Sigma), Spondin-1 1:100 (Abcam), Collagen XIIα1 1:100 (Santa Cruz Biotechnology), Sox2
1:100 (Santa Cruz Biotechnology), HSPG2 1:100 (Fisher), O4 1:100 (Millipore), S100 1:100
(Dako, Santa Clara, CA), SSEA-1 1:25 (DSHB), Oct 3/4 1:200 (Santa Cruz Biotech), β-tubulin
1:1000 (Biolegend), Neurofilament 1:10 (DSHB), Nestin 1:10 (DSHB). Primary antibody
incubation was carried out overnight in 2% of appropriate serum in PBS. Secondary antibodies
(Life Technologies) were all used at a 1:1000 dilution and incubated in 2% of appropriate serum
in PBS for 1 hr at room temperature. 1:1000 Hoechst (Invitrogen) in PBS was incubated with the
cells for 15 min prior to imaging. Nuclear colocalization was determined using Cell Profiler
software (Broad Institute).
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2.3.4 Flow Cytometry
Fibrous and protoplasmic populations were removed from the plate surface with 0.25% trypsinEDTA and fixed using 1% paraformaldehyde for 15 min followed by blocking in 5% goat serum
in PBS for 20 min. Primary antibody incubation was performed for 45 min using the same
dilutions as ICC. Cells were washed once with PBS and secondary incubation was performed for
45 min prior to washing three times with PBS. Cells were then analyzed using a Guava EasyCyte
(Millipore), and the data was quantified using FlowJo. For analysis, a cell gate was drawn based
on forward scatter and side scatter. Staining graphs were restricted to events within this cell gate
and stain gates were drawn based on secondary only controls to exclude 99% of control events
from the gate to minimize the false positive rate. Quadrant gates for double stained samples were
drawn based on secondary controls as well as single stained populations.

2.3.5 Quantitative reverse transcriptase PCR (qRT-PCR)
Table 2.1: qPCR primers used to validate
astrocyte identity

Target

Primer ID (ThermoFischer)

β-actin

Mm02619580

GFAP

Mm01253033

GLT-1

Mm01275814

GLAST

Mm00600697

Day 21 glial populations were removed from the
culture plate via 0.25% trypsin treatment followed by
quenching with CM. The resulting cell suspension was
then spun down at 300 rcf at 4° C for 5 min, and the
RNA was extracted using a Qiagen RNA extraction kit
following manufacturer instructions. RNA
concentration was determined using an Implen

GDNF

Mm00599849
Nanophotomer and 500 ng of RNA from each sample

was converted to cDNA using a High-Capacity RNA to cDNA kit (Applied Biosystems).
Finally, the mRNA levels of the genes of interest was determined using specific Taqman assays
following manufacturer instructions (Life Tech, Table 2.1). β-actin was used as the
normalization control in all samples.
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2.3.6 Viral Knockdown
At day 15 of differentiation, cells were seeded at 10,000 cells/cm2 in appropriate media. Cells
were then infected with mission shRNA lentiviral particles (Sigma, Table 2.2) at a multiplicity of
infection of 2.5 on day 16. Infection was

Table 2.2: shRNA viruses used for ECM knockdown
studies

allowed to proceed for 1 day and media was

Target

TRC Number

Spondin-1

0000090520

Laminin ɣ1

0000055421

Laminin α5

0000252850

Perlecan

0000256980

were present, cultures were selected with 2

Collagen XIIα1 1

0000091115

µg/mL puromycin for either 1 day for the

Collagen XIIα1 2

0000091116

Collagen XIIα1 3

0000335258

Collagen XIIα1 4

0000335319

protoplasmic cultures. On day 21, all cells

Collagen XIIα1 5

0000335320

were removed from the plate using trypsin

Collagen VIα3 1

0000091854

Collagen VIα3 2

0000091855

Collagen VIα3 3

0000091856

plates. Cells were then cultured for 6 days

Collagen VIα3 4

0000091857

with media changes every other day to allow

Laminin β1 1

0000094314

Laminin β1 2

0000094315

Laminin β1 3

0000094316

cells were removed by decellularization as

Laminin β1 4

0000094317

described in substrate preparation or stained

Laminin β1 5

0000094318

then replaced and the cells cultured for an
additional day. To ensure only infected cells

fibrous cultures or 2 days for the

and reseeded onto gelatin-coated 48 well

for ECM deposition. After ECM deposition,

for ICC.

2.3.7 Substrate Preparation
Day 21 glial cells were seeded onto gelatin-coated 48-well plates at a density of 20,000 cells/cm2
and cultured for 6 days in appropriate media to allow for matrix deposition. Following the 6 day
culture period, cells were removed via decellularization (using a modified Hudson protocol
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(Hudson, Liu, and Schmidt 2004)), lysed via freezing, or left alive. For frozen cells, the plates
were sealed with Parafilm (Bemis, Neenah, WI) and placed in the freezer overnight. All plates
were washed once with DMEM containing 25mM HEPES (Life Technologies) prior to neuron
seeding.

2.3.8 Motoneuron Culture
Motoneurons were derived from Hb9-Puro CAG-TdTomato mESCs that constitutively express
TdTomato under the control of the synthetic CAG promoter, as previously described (D. A.
McCreedy et al. 2014). To obtain pure motoneuron cultures, EBs were selected with 4 µg/mL
puromycin from day 5 to 6 of differentiation prior to dissociation seeding onto the desired
substrate at a density of 20,000 cells/cm2. Motoneurons were cultured in half DFK5 and half
Neurobasal media (Life Tech) plus 1x B27. Cultures were then imaged at regular time points
over 2 days.

2.3.9 V2a Interneuron Culture
V2a interneurons were generated from Chx10-PAC bact-TdTomato mESCs as previously
described (Iyer et al. 2016). After induction, EBs were dissociated with 0.25% trypsin and
2.5x107 cells were seeded onto a poly-L-ornithine/laminin coated T25 flask. Chx10+ cells were
then selected in half neural basal-half DFK5 media with 1x GlutaMAX (Life Tech), 1x B27, 2
µg/mL puromycin and 10 ng/mL of the following growth factors for 24 hr: glial-derived
neurotrophic factor (GDNF) (Peprotech), neurotrophin-3 (NT-3) (Peprotech), and brain-derived
neurotrophic factor (BDNF) (Peprotech). After selection, neurons were lifted from the flasks
using Accutase® (Sigma) treatment for 30 min and then reseeded at 50,000 cells/cm2 onto the
desired substrate in half neuro basal-half DFK5 media plus 1x GlutaMAX, 1x B27, and 10
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ng/mL of the following growth factors: BDNF, GDNF, NT-3. Neurite extension for both
neuronal types was determined using Cell Profiler.

2.3.10 Conditioned Media
After day 15 of differentiation, each population was seeded in its appropriate media for 2 days to
condition the media. Conditioned media (CM) was subsequently harvested and spun down at
3000 rcf for 25 min. Motoneurons were seeded at 84,000 cells/cm2 onto poly-L-ornithine coated
6-well polystyrene dishes in one of three media conditions: 50% unconditioned protoplasmic
media and 50% unconditioned fibrous media, 50% protoplasmic CM and 50% unconditioned
fibrous media, or 50% unconditioned protoplasmic media and 50% fibrous CM. This 50:50
mixing strategy was used so CM effects could be directly compared without having the growth
factors in the astrocyte media affect neuronal growth outcomes. Following the addition of one of
the three media solutions to motoneuron cultures, five images of each condition were acquired in
a random spatial orientation every 24 hrs for 3 days, and the neurite area per nucleus was
quantified with Cell Profiler.

2.3.11 Proteomics and Western Blotting
Day 21 cells were seeded at 20,000 cells/cm2 onto gelatin-coated plates and allowed to grow for
6 days prior to decellularization. After decellularization, the residual proteins were scraped off
the plate into Milli-Q water and lyophilized overnight. The resulting powder was dissolved in
4% sodium dodecyl sulfate (SDS) (Sigma) 100mM Tris-HCl pH 7.6 (ThermoFisher). Protein
concentration of this solution was determined using a BCA Assay Kit (ThermoFisher) and then
dithiothreitol (DTT) (ThermoFisher) was added to the samples to a final concentration of
100mM. 15 µg of ECM protein was used for proteomics analysis. For western analysis, the
samples were run on 4-15% mini-PROTEAN TGX gradient gels (Bio-rad) at 130 V for 1.5 hr.
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Western tank transfer was performed at 30 V overnight using 10% methanol (Sigma), 25 mM
Tris Base (ThermoFisher) and 192 mM Glycine (Sigma) transfer buffer to a PVDF membrane
(Millipore). The membrane was then probed with the following antibody dilutions overnight:
Spondin-1 1:150, Collagen XIIα1 1:200, HSGP2 1:100. Licor goat anti-rabbit and goat anti-rat
secondary antibodies were used at a dilution of 1:15000 in PBS and were incubated for 20 min
prior to imaging.

2.3.12 Preparation of peptides for LC-MS
15 µg of ECM proteins solubilized in 30 µL SDT buffer (4%SDS, 100mM Tris-HCl pH 7.6,
100mM DTT) were diluted with 200 µL of 100 mM Tris-HCL buffer, pH 8.5 containing 8M
urea. Detergent was removed by buffer exchange in filter unit with a 30K MWCO (Millipore,
part# MRCF0R030). Iterative centrifugations were performed at 14,000 rcf for 15 min with the
addition of 200 µL of 100mM Tris-HCL buffer pH 8.5 containing 8M urea to the top filter unit.
The proteins were alkylated with 100 µL of 50mM iodoacetamide directly in the top of the filter,
mixing at 25 rcf and incubating at room temperature for 20 min in the dark. The filter was spun
at 14000 rcf for 10 min and the flow through discarded. Unreacted iodoacetamide was washed
through the filter with application of 2 x 200 µL of 100mM Tris-HCL buffer, pH 8.5 containing
8M urea with centrifugation for 10 min after each addition. The urea buffer was exchanged into
100 mM ammonium bicarbonate buffer, pH 8 with two additions of 200 µL each and spinning
after each addition. The filters were transferred to a new collection tube and 100 µL of 0.05
µg/µL trypsin, dissolved in 100mM ammonium bicarbonate buffer, was added to each filter. The
samples were digested overnight at 37°C in a humidity chamber. An additional aliquot of trypsin
(1 µg) was added and digestion was continued for 4 hr. The filter units were spun for 15 min and
the digest was collected in the lower unit. The filter was washed with 50 µL 0.5M sodium
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chloride, and the wash was collected with the peptides. Residual detergent was removed by ethyl
acetate transfer, followed by acidification to 5% formic acid final concentration in preparation
for desalting. The peptides were desalted using micro-tips (C4, BIOMEKNT3C04 and porous
graphite carbon, BIOMETNT3CAR) (Glygen) on a Beckman robot (Biomek NX) as previously
described (Chen et al. 2012) for analysis using LC-MS.

2.3.13 LC/MS Analysis
LC-ESI/MS/MS analysis was performed using a Q-Exactive™ Plus Hybrid QuadrupoleOrbitrap™ Plus mass spectrometer (ThermoFisher) coupled to an EASY-nanoLC 1000 system
(ThermoFisher). The samples were loaded (2 µL) onto a 75 m i.d. × 25 cm Acclaim PepMap
100 RP column (ThermoFisher). The peptides were eluted at a flow rate of 300 nL/min with an
acetonitrile gradient in aqueous formic acid (0.1%) as mobile phase A. Peptide elution occurred
in the following sequence: 0-4% B (buffer B) for 1 min, 4-12% B over 127 min, 12- 22% B over
112 min, 22-30% B over 40 min, 30-70% B over 6 min, hold at 70% B for 6 min, followed by
increase in B to 95% B over 1 min and an isocratic wash at 95% B for 6 min. Full-scan mass
spectra were acquired using the Orbitrap™ mass analyzer in the mass-to-charge ratio (m/z) of
375 to 1500 and with a mass resolving power set to 70,000. Ten data-dependent high-energy
collisional dissociations (HCD) were performed with a mass resolving power set to 35,000, a
fixed first m/z 100, an isolation width of 2.0 m/z, and the normalized collision energy (NCE)
setting of 27. The maximum injection time was 120 ms for parent-ion analysis and 120 ms for
product-ion analysis. Target ions already selected for MS/MS were dynamically excluded for 30
sec. An automatic gain control (AGC) target value of 3x106 ions was used for full MS scans and
5x105 ions for MS/MS scans. Peptide ions with charge states of one or greater than seven were
excluded from MS/MS acquisition. The tandem mass spectra were processed using Matrix
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Science Distiller version 2.5 without charge state deconvolution and deisotoping. The processed
files were used for protein database searches using Mascot (Matrix Science, London, UK;
version 2.5.1). The UniProt Mouse Reference database (downloaded May 3, 2014, 69021
entries) was used. A parent ion tolerance and MS2 fragment tolerance were set to 10 ppm and
0.05 Da, respectively. Carbamidomethyl of cysteine was specified as a fixed modification and
oxidation of methionine was set as a variable modification. Protein identifications were
performed using Scaffold, version 4.4.8 (Proteome Software Inc., Portland, OR) implementing
the Protein and Peptide Prophet algorithms (Keller et al. 2002; Nesvizhskii et al. 2003). Peptide
identifications were accepted with > 90.0% probability. Protein identifications were accepted if
they could be established at greater than 95.0% probability and contained at least 2 peptides with
unique sequences. Protein probabilities were assigned using the Protein Prophet algorithm.
Proteins that contained similar peptides, but could not be differentiated based on identification of
unique peptide sequences, were grouped to satisfy the principles of parsimony.

2.3.14 TRAP-Seq analysis
TRAP libraries were sequenced on an Illumina HiSeq 2500, and reads were analyzed as
previously described (Reddy et al. 2016). Differential expression analysis of cortex TRAP vs.
PreIP was performed using the edgeR package. Raw and analyzed RNA-sequencing data are
available at GEO: GSE74456. For the present study, only cortex PreIP and TRAP samples were
used (GSM1920988-1920993). Candidate ECM components were mapped to Ensembl gene IDs
using the biomaRt package, based on gene symbol. Out of the 638 ECM components with ≥99%
protein identification probability, 559 were robustly expressed in the TRAP-seq samples and
thus were used for comparative analysis.
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2.3.15 Statistics
Statistical analysis was performed using Minitab software for neurite length measurements (oneway ANOVA with Bonferroni correction). Excel was used for qRT-PCR (pairwise t-test) and
colocalization data (Student’s t-test). Proteomics data was analyzed using Scaffold4, significance
determined with Fisher exact test using the Benjamini-Hochberg false positive correction
method.

2.4 Results
2.4.1 Generation of Fibrous Astrocyte or Protoplasmic Astrocyte containing
Glial Populations from mESCs
To determine the effect of fibrous and protoplasmic populations on neuron growth,
methods were developed to obtain these astrocyte subtypes from mESCs. In particular, this
protocol was based on prior ESC-derived astrocyte protocols described in Benveniste et al. (R. J.
Benveniste, Keller, and Germano 2005) and Roybon et al. (Roybon et al. 2013), and the GRPderived astrocyte protocol described in Davies et al. (J. E. Davies et al. 2006). This protocol was
designed to generate spinal populations by first caudalizing mESCs with RA treatment
(Wichterle et al. 2002) followed by BMP-4 treatment to obtain cultures containing protoplasmic
astrocytes, and CNTF treatment to obtain cultures containing fibrous astrocytes (Figure 2.1A, (R.
E. Thompson et al. 2017)). To allow for direct comparison of protein expression between the
fibrous and protoplasmic populations, a second population containing protoplasmic-like
astrocytes was generated using the protocol described in Benvensite et al. (R. J. Benveniste,
Keller, and Germano 2005). This protocol was not used for future studies because the continued
use of PDGF-AA led to significant oligodendrocyte presence within the cultures. To determine
the dominant phenotype of the astrocytes within these cultures, the expression of known
protoplasmic or fibrous markers was assessed using ICC and qRT-PCR. In particular, A2B5
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Figure 2.1: mESCs can be
selectively differentiated
into mixed populations
containing either
protoplasmic or fibrous
astrocytes. A) Schematic
representation of the
astrocyte differentiation
protocols used in this work.
All astrocytes are subjected
to the same initial 11 days
after which media factors
are changed so that fibrous,
protoplasmic or the BA
(Benveniste protocol (R. J.
Benveniste, Keller, and
Germano 2005)) population
develops. RA: retinoic acid,
SAG: smoothened agonist,
EGF: epithelial growth
factor, FGF-1: fibroblast
growth factor 1, CNTF:
ciliary neurotrophic factor,
BMP-4: bone
morphogenetic protein 4,
PDGF-AA: platelet-derived
growth factor AA. B-C)
GFAP (red) and A2B5
(green) staining in
protoplasmic (B) or fibrous
(C) cultures at the end of
differentiation. D-E) Olig2
(red) and CSPG (green)
staining in protoplasmic (D)
or fibrous cultures (E) at end
of differentiation. Nuclei
stained with Hoechst (blue).
Scale bar: 100 µm. F)
Quantification showing the
percent of nuclei that
colocalized with Olig2
staining in different cultures.
Error
bars: std
error, n=9-12.
G) Log2 expression difference in mRNA levels for fibrous and protoplasmic astrocyte
markers
compared
to BA
control population. Error bars represent standard error, n=6. **: p<0.01, ***: p<0.001

(Holland 2001) and nuclear Olig2 (J. E. Davies et al. 2008) are expected be elevated in fibrous
astrocytes and oligodendrocyte precursors (OPCs). ICC demonstrated that cells exposed to
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CNTF and G5 containing media expressed both A2B5 and nuclear Olig2, as expected for fibrous
astrocytes (Figure 2.1B-E). Quantification of Olig2+ nuclei in both fibrous and protoplasmic
cultures revealed that a significantly higher percentage of nuclei were Olig2+ in fibrous cultures
than protoplasmic cultures (Figure 2.1F).
To further confirm the presence of either fibrous or protoplasmic astrocytes within these
mixed cultures, qPCR was used to determine mRNA levels of genes known to be differentially
expressed between these astrocyte populations, specifically GFAP (general reactive astrocyte
marker), glutamate transporter 1 (GLT-1), glutamate and aspartate transporter 1 (GLAST), and
glial cell line-derived neurotrophic factor (GDNF). Based on primary cell characterizations and
analysis of GRPs in culture, GLT-1 is slightly elevated in fibrous astrocytes (Goursaud et al.
2009), GLAST is significantly elevated in fibrous astrocytes (Goursaud et al. 2009; Vanhoutte et
al. 2004), and GDNF is elevated in protoplasmic astrocytes (S. J. A. Davies et al. 2011).
Consistent with these observations, the ESC-derived populations showed significant upregulation
of GLAST and slight upregulation of GLT-1 in the fibrous population, and significant
upregulation of GDNF in the protoplasmic population suggesting that astrocytes within these
populations are either protoplasmic or fibrous depending on media exposure (Figure 2.1G).
To determine the percentage of cells in these cultures expressing mature astrocyte
markers, flow cytometry was performed for aquaporin-4 (Aqp-4) and A2B5 expression (Cahoy
et al. 2008) (Figure 2.2B). Aqp-4 is known to be specifically expressed on the cell membranes of
both mature fibrous and mature protoplasmic astrocytes, but not radial glia radial glia in vivo
(Nagelhus et al. 1998). This makes it an appealing marker to determine the percentage of mature
astrocytes in these cultures by flow cytometry. A notable drawback to the use of Aqp-4 is that
Aqp-4 is known to have variable expression levels both in cultured astrocytes and in vivo. Thus,
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Figure 2.2: Quantification of astrocytes present in mESC cultures. A) Representative images showing
A2B5, Aqp-4 and merged staining in protoplasmic and fibrous cultures 6 days after differentiation. Blue
represents Hoechst nuclear stain. Scale bar: 100 µm. B) Representation flow cytometry graphs of secondary
controls and samples stained for Aqp-4 and A2B5 for both fibrous and protoplasmic cultures. Each graph
represents 10,000 cells based on a forward scatter (FSC) and side scatter (SSC) gate. Quadrant gates drawn
based on single stained samples and secondary controls. Numbers represent the percent of cell events within
each quadrant C) Average percentage of cells staining for A2B5, Aqp-4, and both markers in Fibrous and
Protoplasmic cultures. n=5, error bars: std error, **: p<0.01. D-E) Average percent of total cells staining βtubulin+ (neurons) (D) or S100+ (E). N=4, error bars: 95% confidence interval. **: p<0.01
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Aqp-4 quantification may result in an underestimation of the percent of astrocytes present in the
culture (Figure 2.2A) (Kleiderman et al. 2016). Quantification of flow cytometry data
demonstrated 48.8±0.8% of cells staining Aqp-4+ in protoplasmic cultures and 39.7±0.5% of
cells staining Aqp-4+ in fibrous cultures with 34.0±0.4% of cells in fibrous cultures staining both
Aqp-4+ and A2B5+ (Figure 2.2B,C). Overall, fibrous cultures had a significantly higher
percentage of A2B5+ cells than protoplasmic cultures and a significantly higher percentage of
cells both Aqp-4+ and A2B5+, consistent with the expected fibrous astrocyte phenotype (Figure
2.2).
Since flow cytometry quantification indicated that other cells types may be present, ICC
staining was used to determine what non-astrocyte populations were present and to cast a larger
net for astrocytes. Cultures were stained for S100, which has been shown to be upregulated in
astrocytes as they mature (Raponi et al. 2007), β-tubulin (neurons), O4 (oligodendrocytes),
SSEA-1 (mESCs), and Oct 3/4 (mESCs). It is important to note that S100 is also present in some
radial glial populations and early oligodendrocyte lineages based on lineage tracing experiments
(Hachem et al. 2005), although it is generally used as an astrocyte marker. We found that fibrous
populations contained 8.6 ± 4.9% neurons based on β-tubulin staining and that 82.8 ± 2.2% of
the cells were S100+. Protoplasmic populations were found to have 5.6 ± 1.9% β-tubulin+ cells
and 91.5 ± 2.3% S100+ cells (Figure 2.2D, E). There was no observable staining of nuclear S100
in either culture, which has been linked to oligodendrocyte differentiation (Deloulme et al.
2004), indicating that, combined with a few to no cells staining O4+, both cultures do not contain
significant oligodendrocyte presence (Brunne et al. 2010). There were also few to no cells
staining SSEA-1+ or Oct 3/4+, demonstrating limited presence of undifferentiated stem cells.
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Taken together, this data suggests that these glial cultures are primarily composed of cells within
the astrocyte lineage with some presence of gliogenic radial glia and neurons.

2.4.2 Astrocyte-derived substrates modify neuronal growth
Next, the ability of these two populations to serve as supportive substrates for neuronal
growth was assessed and it was observed that live astrocyte substrates exhibiting either
phenotype were able support motoneuron neurite outgrowth (Figure 2.3A, D). To determine
what aspects of these substrates contributed to neurite outgrowth, modified substrates were

Figure 2.3: Protoplasmic astrocyte-derived substrates are permissive to motoneuron growth and neurite
extension. A-G) Representative images of motoneurons on different astrocyte-derived substrates after 48 hours
in culture. A-C) Fibrous substrates, D-F) Protoplasmic substrates. A, D) Live astrocyte substrate, B, E) FreezeLysed astrocyte substrate, C, F) Decellularized astrocyte substrate. G) Gelatin control shows no clear neurites.
Scale bar: 100 µm H) Quantification of neurite extension from motoneurons cultured for 48 hours on different
astrocyte substrates. Error bars: std error, n: 19-52. * p<0.05, ** p<0.01, *** p<0.001. Dark bars = protoplasmic
substrate, light bars = fibrous substrate.

54

produced using decellularization or freeze lysis. Decellularization leaves only ECM on the plates
while freeze lysis leaves behind ECM and cell membranes. The neurite outgrowth area per
nucleus from motoneurons was measured on live, decellularized, and frozen substrates to
determine the relative contribution of ECM, membrane, and secreted factors. Motoneurons could
extend neurites on both live (Figure 2.3A, D) and frozen (Figure 2.3B, E) substrates; however,
the motoneurons exhibited only limited neurite extension on decellularized fibrous ECM (Figure
2.3C), while showing robust growth on protoplasmic ECM (Figure 2.3F). Neurite area was also
found to be significantly greater on live protoplasmic substrates than decellularized protoplasmic
ECM or any fibrous substrate after 2 days of culture (Figure 2.3H). Furthermore, decellularized
protoplasmic ECM exhibited significantly greater growth than either unmodified gelatin or
decellularized fibrous ECM (Figure 2.3H).
The effect of fibrous and protoplasmic conditioned media (CM) on neurite extension
from motoneurons was also tested to determine if there were any growth benefits of the factors
secreted by the astrocyte populations. To allow for direct comparison between fibrous and
protoplasmic CMs, and control for the effect of the astrocyte growth factors on the neurons,
motoneurons were grown in ½
fibrous media and ½
protoplasmic media. These
studies found that protoplasmic
CM slightly, but significantly,
improved neurite extension
Figure 2.4: Protoplasmic CM significantly improves motoneuron
growth. Neurite area per nucleus of motoneurons grown in fibrous and
protoplasmic astrocyte CM over 72 hours. Error bars: Std Error, n=1421, ** p<0.01
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from motoneurons compared

to unconditioned media after 72 hours (Figure 2.4).
To confirm that these growth differences were not specific to motoneurons, the effect of
frozen and decellularized astrocyte substrates on mESC-derived V2a interneuron neurite
extension was tested. V2a interneurons were derived from mESCs using a Chx10-PAC cell line
with constitutively active TdTomato expression (Iyer et al. 2016). It was found that the
interneurons, similar to motoneurons, exhibited significantly longer neurite outgrowth on
protoplasmic (Figure 2.5 C-D) versus fibrous substrates (Figure 2.5 A-B); in addition, the
magnitude of the ECM effect was found to be greater on the interneuron cultures than the
motoneuron cultures (Figure 2.5F).

Figure 2.5: Protoplasmic astrocyte-derived substrates are more permissive to V2a interneuron growth
than fibrous astrocyte-derived substrates. A-E) Representative images of V2a interneurons after 72 hours in
culture on different astrocyte-derived substrates. A,B) Fibrous substrates, D,E) Protoplasmic substrates, A,D)
Freeze-Lysed astrocyte substrate, B,E) Decellularized astrocytes substrate. C) Unmodified Gelatin Control.
Scale bar: 100 µm F) Quantification of neurite extension from V2a interneurons cultured for 3 days on different
astrocyte substrates. Error bars: Std. Error, n=40-56, *** p<0.001. Dark bars = protoplasmic substrate, light bars
= fibrous substrate.

2.4.3 Fibrous and protoplasmic astrocytes deposit distinct ECMs
Since the ECM deposited by these predominantly glial cultures was sufficient to support
neuron growth, label-free LC/MS proteomics was performed to determine what proteins are
present in ECMs harvested from both protoplasmic and fibrous populations. Identification of
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these proteins will allow for better understanding of the reasons for the observed neuronal
growth differences and potentially allow for customized substrate design. ECMs harvested from
mESC-derived populations were found to be largely similar with 530 of the 638 proteins
identified not being expressed at different levels; however, there were significant expression
differences of several key axon growth-related proteins (Figure 2.6A, Table 2.3, Table 2.4).
Fibronectin-1 was found to be most abundant protein in both ECMs with significantly more
spectral counts detected in the protoplasmic samples (Figure 2.6A). Fibronectin has been
described as being expressed by primary astrocytes in culture (Liesi, Kirkwood, and Vaheri

Figure 2.6: Protoplasmic and Fibrous
astrocytes have distinct ECM composition. A)
Graphical representation of proteomics results.
Each point represents the average spectral count
of the identified protein from 2 independent runs.
Lines denote 1, 2, or 3 standard deviations away
from equal spectral count of the specific protein
detected. Proteins found to be significantly
different between protoplasmic and fibrous ECMs
are denoted by green squares, Fisher exact test
with Benjamini-Hochberg correction, p < 0.001,
n=2. Orange squares denote proteins that did not
differ significantly between astrocyte ECMs. A’)
Blow up of indicated area in A. Red circles mark
proteins of interest: 1: spondin-1, 2: collagen
XIIα1, 3: perlecan, 4: neurocan, 5: versican, 6:
laminin α5. B) Confirmation of proteomics
findings for spondin-1, collagen XIIα1, and
perlecan with IHC (target protein in green and
nuclei in blue) showing an expression pattern
consistent with the proteomics data. Scale bar =
100 µm. C) Western blots of ECMs harvested
from decellularized plates also shows the expected
pattern spondin-1, collagen XIIα1, and perlecan.
F: Fibrous ECM, P: Protoplasmic ECM,
Arrowhead denotes protein band.
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1986), is transiently expressed away from the blood vessels during CNS development (Stewart
and Pearlman 1987), and has been linked to improved neuron growth in adult white matter (Tom
et al. 2004). The proteins with the greatest differential expression between the protoplasmic and
fibrous populations, were spondin-1 (spon1), Collagen XIIα1 (col12a1), and perlecan (hspg2).
Spondin-1, also known as F-spondin, was expressed at significantly greater levels in fibrous
ECM and is known to be involved in axonal pathfinding and turning during development
(Burstyn-Cohen et al. 1999) (Figure 2.6A’ #1). Col12a1 and perlecan were both found at
significantly greater levels in protoplasmic ECM (Figure 2.6A’ #2, #3). Perlecan-coated plates
have been demonstrated to promote neurite extension in vitro (R. Nakamura, Nakamura, and
Fukunaga 2015). Also of note is that the chondroitin sulfate proteoglycans (CSPGs) (neurocan
and versican), which are known inhibitory molecules(Oohira, Matsui, and Katoh-Semba 1991),
were found to be significantly more prevalent in fibrous ECM (Figure 2.6A’ #4, #5), while
laminins, known to be axon growth promoting, were more prevalent within protoplasmic ECM
(Figure 2.6A’ #6). To confirm the validity of our proteomics results, ICC was performed on both
protoplasmic and fibrous cultures for collagen XIIα1, perlecan, and spondin-1 (Figure 2.6B). To
further validate the proteomics, western blotting was performed on ECMs harvested from
decellularized astrocyte plates (Figure 2.6C). The expression pattern of these proteins matched
the profiles found in the LC/MS data demonstrating the validity of the proteomic results (Figure
2.6B-C).

2.4.4 ECM produced by ESC-derived cultures is consistent with in vivo
astrocyte protein expression
The cultures used for this work are not purely astrocytic as there is a clear presence of
both neurons and glial progenitors. Thus, it was important to determine if the harvested ECMs
were consistent with in vivo astrocyte expression profiles to demonstrate if the harvested ECMs
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are similar to native astrocyte ECM production. This was achieved by comparing the proteins
found in astrocyte ECMs to a set of genes identified as expressed in astrocytes in vivo. In vivo
astrocyte expression profiles were determined using a previously described translating ribosome
affinity purification (TRAP) mouse line that targets all in vivo astrocyte populations using
ALDH1L1 (Doyle et al. 2008), coupled with RNAseq. This BAC-TRAP methodology compares
the prevalence of mRNA transcripts in the total brain isolate to the prevalence of the same
mRNA transcripts when only the mRNAs attached to astrocyte ribosomes are present. This
approach allows for any transcript that is enriched in the astrocyte (TRAP) fraction to be
considered astrocyte-specific, or at least more highly expressed by astrocytes than other CNS
populations. Genes that are relatively depleted in the TRAP fraction (enriched in the pre-IP
fraction) can be considered more highly expressed by a different population within the CNS or
not expressed by astrocytes. The distinction between enrichment and population-specific
expression was made based on the fold change in expression level of the particular gene between
the TRAP and pre-IP fractions.
The validity of the TRAP-Seq method was confirmed by locating all genes previously
identified as astrocyte- or neuron-specific within the data set (Tien et al. 2012). It was found that
84% of genes previously identified as astrocyte-specific were enriched in the astrocyte fraction,
and 81% of those previously identified as neuron-specific were depleted in the astrocyte fraction,
confirming a successful TRAP (Figure 2.7A). Based on the mean fold change of the neuronal
markers between the astrocyte fraction and whole brain isolate, a threshold was calculated to
allow for genes to be considered astrocyte-specific with 95% confidence. With a threshold
established, the mRNAs that encode for proteins found within the mESC-derived ECMs were
located within the BAC-TRAP RNA-seq samples. Based on this methodology, 183 (33%) of the
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ECM proteins identified can be considered to be astrocyte-specific (J. D. Dougherty et al. 2010),
and 159 of these were at least 2-fold enriched in the TRAP fraction (Figure 2.7B). The majority
of these astrocyte-specific ECM proteins were found in both protoplasmic and fibrous ECMs. In
addition to containing astrocyte-specific proteins, ECM components were also found to be more
highly expressed in the TRAP than in the PreIP fraction (Figure 2.7C, paired t-test, p < 0.0001).

Figure 2.7: ECM components generated by ESC-derived astrocytes are found in cortical astrocytes based
on BAC-TRAP. A) Astrocyte-specific genes (red) are enriched in the TRAP fraction while neuronal-specific
genes (green) are enriched in the PreIP samples. n=3. B) ECM candidate genes are enriched within the TRAP
fraction compared to PreIP sample. Lines are 95% and 68% confidence of astrocyte-specific expression. Grey
points are all genes detected in the BAC-TRAP data, red points denote genes that code for proteins detected in
ECM proteomics data. C) ECM proteins are significantly enriched in TRAP fraction as compared to the PreIP
fraction. Paired t-test, p = 5.66x10-9. D) Comparison of identified proteins with the proteomics and BAC-TRAP
data. Proteins were considered astrocyte-expressed if there was 95% confidence that the mRNA was enriched
within the TRAP fraction compared to the PreIP fraction. The ECM proteins identified in proteomics were
enriched for proteins expression in astrocytes based on BAC-TRAP at a significantly higher level than expected
by chance. Fisher exact test, p = 2.x10-7.
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Among those genes detectable in RNA-seq samples, ECM components were more likely than
chance to be identified as expressed by astrocytes in the BAC-TRAP data (Figure 2.7B,D,
Fisher’s exact test, p < 0.001). Furthermore, ECM components were more likely than chance to
be identified as having 2-fold higher expression in astrocytes in vivo (Fisher’s exact test, p <
0.05). This data shows that the proteins found within the ESC-derived ECMs are consistent with
in vivo astrocyte expression profiles and suggests that the mESC-derived ECMs from both
fibrous and protoplasmic populations are consistent with in vivo astrocyte ECM.

2.4.5 Motoneuron
growth depends on the
presence and absence of
specific ECM proteins
To test which proteins
within the mESC-derived
ECMs are important for
motoneuron growth, proteins
with known roles in neurite
growth found to be highly
expressed in one ECM, but
not the other were targeted
with shRNA knockdown.
Targets were preferentially
chosen from protoplasmic
ECM in order to determine
growth promoting factors for

Figure 2.8: Viral knockdown modifies motoneuron growth on
astrocyte ECMs. A-E) Aqp-4 (red) and A2B5 (green) staining of
infected astrocytes. A-C) Protoplasmic astrocytes infected with
nontargeting (A), laminin α5 targeting (B), or laminin ɣ1 targeting (C)
virus. D-E) Fibrous astrocytes infected with nontargeting (D), or spondin1 targeting (E) virus. Scale bar: 100 µm. F) Spondin-1 knockdown in
fibrous ECM leads to a significant increase in motoneuron growth. n=3958 G) Laminin α5 or laminin ɣ1 knockdown decreases motoneuron
growth on protoplasmic ECM. n=44-104. Error bars: std error; *: p<0.05;
**: p<0.01; ***: p<0.001.
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potential future work using a small number of specific proteins. In particular, collagen XIIα1,
collagen VIα3, laminin β1, perlecan, laminin α5, and laminin ɣ1 were targeted in protoplasmic
ECM, while spondin-1 was targeted in fibrous ECM. Since matrix deposition takes multiple
days, shRNAs were stably expressed using lentiviral transduction. Staining of astrocytes
following infection showed that both fibrous and protoplasmic astrocyte maintained the expected
morphology and phenotype, although cell density was significantly lower than previously
observed (Figure 2.8A-E).

Figure 2.9: Knockdown of collagen VIα3, laminin β1, collagen
XIIα1, or Perlecan does not significantly alter motoneuron
growth on protoplasmic astrocyte ECM. A) Effect of collagen
VIα3 (colVIα3) knockdown on motoneuron neurite length on
resulting protoplasmic ECM. N=15-67. 4 separate shRNA
constructs were used. B) Effect of laminin β1 (lam β1) knockdown
on motoneuron neurite length. N=19-67. 5 separate shRNA
constructs were used. C) Effect of collagen XIIα1 (colXIIα1) and
perlecan knockdown on motoneuron neurite length on resulting
protoplasmic ECM. N=13-30. 5 separate shRNA constructs were
used for collagen XIIα1, 1 previously validated construct was used
for perlecan.

Quantification of motoneuron growth on knockdown ECMs found that knockdown of
spondin-1 in fibrous cultures increased neurite extension (Figure 2.8F), while laminin α5 or
laminin ɣ1 knockdown in protoplasmic astrocytes decreased neurite extension (Figure 2.8G).
There were no significant effects observed for any of the shRNA constructs targeting collagen
XIIα1, collagen VIα3, laminin β1, or perlecan; however, knockdown was not verified in these
cultures due to the lack of effect (Figure 2.9). Using western blotting and qPCR, spon1 shRNA
treatment was found to decrease expression of spondin-1 to 53% of the uninfected control and
decreased mRNA levels to 44% of the non-targeted control (Figure 2.10). The laminin α5 and ɣ1
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shRNAs used have been
previously validated by
Sigma to reduce expression
of the target protein by 67%
and 95%, respectively, so no
Figure 2.10: Spondin-1 shRNA decreases both mRNA and protein
expression. A) mRNA levels decrease in fibrous astrocyte cultures
treated with spon1 shRNA when compared to astrocytes infected with
nontargeting shRNA. B) Western blot quantification using densitometry
shows decreased spondin-1 in cultures treated with spon1 shRNA. n=2,
Error bars: 95% Confidence Interval.

further validation was
performed on these
constructs. Interestingly, the
decreases observed in the

knockdown ECMs does not fully account for the growth differences observed between
protoplasmic and fibrous ECMs suggesting that the neuronal growth effects are multifactorial
and due to many different proteins within the ECMs.

2.5 Discussion
CNS injury leads to a significant economic and psychological burden for patients due, in
part, to the lack of spontaneous regeneration within the CNS (Boakye, Leigh, and Skelly 2012).
Classically, this lack of recovery has been thought to be partially caused by the formation of a
glial scar that contains woven astrocyte processes and a large number of proteins that inhibit
axon growth (Cregg et al. 2014). Recently, it has been observed that astrocytes are also involved
in spontaneous recovery in mice and zebrafish (Yona Goldshmit et al. 2014; Zukor et al. 2013;
C. Haas et al. 2012), and that astrocyte transplants can improve recovery following SCI, if they
have a pro-regenerative phenotype (J. E. Davies et al. 2008; Chu et al. 2014). Since astrocytes
have been successfully used for SCI treatment, a scalable methodology for the derivation of proregenerative astrocytes could have a significant clinical impact. This work demonstrates a
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scalable method to produce either fibrous or protoplasmic astrocytes from mouse ESCs (Figure
2.1, 2.2), with around 40% astrocytes in fibrous cultures and 49% astrocytes in protoplasmic
cultures based on Aqp-4 staining (Figure 2.2). This is likely a conservative estimate, as Aqp-4
staining is known to vary across astrocyte cultures, which is clear in our staining as well (Figure
2.2). Quantification of S100 staining suggests that fibrous cultures contain around 83%
astrocytic-lineage cells and protoplasmic cultures contain around 92% astrocytic-lineage cells,
even if not all the astrocytes express sufficient Aqp-4 for detection with flow cytometry (Figure
2.2). The significant differences in GLAST, GDNF, and A2B5 expression, coupled with the cell
morphology differences, indicate that these methods generate astrocytes that are consistent with
in vivo fibrous and protoplasmic astrocyte phenotypes, and that fibrous populations contain
mostly white matter astrocytes while protoplasmic populations contain mostly grey matter
astrocytes (Figure 2.1, 2.2). Astrocyte presence within these cultures was further confirmed with
BAC-TRAP demonstrating that ECMs derived from fibrous and protoplasmic cultures were
consistent with in vivo astrocyte expression profiles during development (Figure 2.7).
Functionally these predominantly astrocytic cultures were found to have differing
abilities to support neuronal growth with protoplasmic–derived substrates tending to be more
supportive of neuron growth than fibrous substrates. This was especially apparent in the case of
decellularized ECMs (Figure 2.3, 2.5). It is important to note that transplanted immature, but not
mature, astrocytes have been found to improve outcomes following SCI, while demonstrating
further migration from the transplant area and reduction of the glial scar (G. M. Smith and Silver
1988; G. M. Smith and Miller 1991). Due to these observations, and the relatively immature
nature of these cultures, it is possible that the functional differences observed in the mESC
cultures are applicable to embryonic, but not adult, astrocyte populations. However, this protocol
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does provide a readily scalable method to produce populations that can be used to support
neuronal growth.
It would be potentially interesting to explore the effects of inflammatory stimulus on the
observed neuronal growth support properties of these astrocytes. Recent work has demonstrated
that astrocytes exhibit a continuum of reactive phenotypes following injury, with some
exhibiting pro-regenerative phenotypes and others exhibiting inhibitory phenotypes (Liddelow
and Barres 2017). It has been observed that pro-inflammatory and anti-inflammatory stimuli
push reactive astrocyte phenotypes one way or the other on this continuum. In particular,
inflammatory injury caused by lipopolysaccharide (LPS) causes a astrocytes to adopt a more
inhibitory phenotype (Zamanian et al. 2012). In addition, interleukin-6 (IL-6), a proinflammatory cytokine, leads to an increase in astrocyte proliferation and scar formation in vivo
(M. Nakamura et al. 2005); while, IL-10, an anti-inflammatory cytokine, has been to shown
improve functional recovery following CNS injury when delivered intrathecally or
intramuscularly (Jackson et al. 2005). Future experiments could explore the effects of these
inflammatory and anti-inflammatory stimuli on the neuronal growth support capacities of these
mESC-derived fibrous and protoplasmic populations.
Recent work by Anderson et al. showed that astrocytes are required for recovery
following SCI in mice (Anderson et al. 2016). As part of this work, they compared axon growth
permissive and inhibitory proteins produced by astrocytes and non-astrocytes following injury.
The proteomics data set collected in this study was searched for these proteins, and it was found
that, if present within the ECMs, permissive proteins tended to be significantly upregulated in
protoplasmic.
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ECM while inhibitory proteins were

Table 2.3: Known axon growth modulatory
proteins identified in astrocyte ECM
proteomics data.
Protein

Neurocan
Versican
Netrin-1
Semaphorin3A
Tenascin C
Laminin α1
Laminin α5
Laminin β1
Laminin ɣ1
Collagen 4α1
Fibronectin
Perlecan
Matrillin-2

Significantly
upregulated
in
Fibrous
Fibrous
Fibrous
Fibrous

Axon
Growth
Role
Inhibitory
Inhibitory
Inhibitory
Inhibitory

Fibrous
Protoplasmic
Protoplasmic
Protoplasmic
Protoplasmic
Protoplasmic
Protoplasmic
Protoplasmic
N.S.

Permissive
Permissive
Permissive
Permissive
Permissive
Permissive
Permissive
Permissive
Permissive

upregulated in fibrous ECM (Table 2.3). This
suggests that the neuron growth differences
observed on the ECMs derived in this study
are likely due to both the more inhibitory
nature of the fibrous ECM and the more
permissive nature of the protoplasmic ECM.
This concept is supported by the observed
decrease in motoneuron growth on
protoplasmic ECM following knockdown of
laminin α5 and laminin ɣ1 and the increase in

motoneuron growth on fibrous ECM following spondin-1 knockdown (Figure 2.8). Future work
on which proteins are the most important for neuron growth in these ECMs could allow for a
small subset of ECM components to be mass produced and delivered to improve recovery
following CNS injury. (R. E. Thompson et al. 2017)
Table 2.4: Proteins found to have significantly different expression in mESCderived astrocyte ECMs. Proteins are listed in decreasing number of average
spectra detected. n=2.
Significantly enriched in
Fibrous ECM

Average
Percent of
Total
Spectra

Significantly enriched in
Protoplasmic ECM

Average
Percent of
Total
Spectra

Cytoplasmic dynein 1
heavy chain 1
Vimentin

0.37
0.31

2.25
1.27

Spondin-1
Tubulin beta-2B chain

0.30
0.15

Fibronectin
Myosin-9
Basement membranespecific heparan sulfate
proteoglycan core protein
Myosin-10
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0.74
0.66

Latent-transforming
growth factor beta-binding
protein 1
Combined Horseradish
Peroxidase
Tenascin
Neurocan core protein
Versican core protein
Glia-derived nexin
Protein Fndc1
Heat shock protein HSP
90-beta
Keratin, type I cytoskeletal
14
Keratin, type II
cytoskeletal 5
Tissue-type plasminogen
activator
Desmoplakin
Peroxidasin homolog
A disintegrin and
metalloproteinase with
thrombospondin motifs 4
Creatine kinase B-type
Multiple epidermal growth
factor-like domains protein
6
Semaphorin-3A
T-complex protein 1
subunit delta
Fatty acid synthase
Keratin, type II
cytoskeletal 2 epidermal
Unconventional myosin-Va
D-3-phosphoglycerate
dehydrogenase
SPARC-related modular
calcium-binding protein 1
Keratin, type I cytoskeletal
10
Splicing factor, prolineand glutamine-rich
Transcription activator
BRG1

0.13

Collagen alpha-1(XII)
chain

0.59

0.11
0.11
0.11
0.10
0.10
0.10

Protein Ahnak
Protein Col6a3
Laminin subunit alpha-5
Plectin
Filamin-A
Laminin subunit gamma-1

0.37
0.32
0.29
0.21
0.21
0.2

0.07

Fibrillin-1

0.17

0.07

Laminin subunit beta-2

0.17

0.07

Agrin

0.15

0.06

0.13

0.05
0.05

Laminin subunit beta-1
Protein-glutamine gammaglutamyltransferase 2
EMILIN-1

0.05
0.05

Fibrillin-2
Collagen alpha-1(VI) chain

0.09
0.09

0.04
0.04

Nidogen-1
Nidogen-2

0.09
0.09

0.04
0.04

Myosin-11
Laminin subunit alpha-1

0.08
0.07

0.04
0.04

Collagen alpha-2(VI) chain
Unconventional myosin-Ic

0.07
0.06

0.04

Periostin
Inter-alpha-trypsin
inhibitor heavy chain H5

0.06

Collagen alpha-2(IV) chain
Collagen alpha-1(XVIII)
chain

0.05

0.04
0.03
0.03
0.03

Collagen alpha-1(IV) chain
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0.12
0.10

0.06

0.05
0.05

Ubiquitin-like modifieractivating enzyme 1
Alpha-enolase
Phosphoglycerate kinase 1

Myosin phosphatase Rhointeracting protein
Annexin A1
Collagen alpha-1(V) chain
Tubulointerstitial nephritis
antigen-like
Cytochrome P450 1B1

0.03
0.03
0.03

Protein Gm20425
Lamin-B1
Dedicator of cytokinesis
protein 1
Junction plakoglobin

0.03
0.03

Netrin-1

0.03

Myoferlin
Protein Atp2b4
Sorbin and SH3 domaincontaining protein 2

Mitogen-activated protein
kinase kinase kinase kinase
4
Nuclear pore membrane
glycoprotein 210

0.02

E3 ubiquitin-protein ligase
RNF213

Low-density lipoprotein
receptor-related protein 2
Nascent polypeptideassociated complex subunit
alpha
WSC domain-containing
protein 1
Fructose-biphosphate
aldolase C
Plakophilin-1
14-3-3 protein theta
(Fragment)
Interleukin enhancerbinding factor 3
Bone morphogenetic
protein 1
Extracellular sulfatase
Sulf-2
Nephronectin
Heat shock protein HSP
90-alpha
Transforming growth
factor beta-2
Microtubule-associated
protein 2

0.03
0.03

0.02

0.02

0.02

0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
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0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.03

0.02

Collagen alpha-2(V) chain
Transforming growth
factor-beta-induced protein
ig-h3

0.02

Dysferlin
Thrombospondin type-1
domain-containing protein
4
Collagen alpha-1(XIV)
chain

0.02

0.02

0.02
0.01

Phosphoserine
aminotransferase
Keratin, type I cytoskeletal
16
Pleiotrophin
Apolipoprotein E
Dynactin subunit 1
Multifunctional protein
ADE2
Fatty acid-binding protein,
brain
T-complex protein 1
subunit theta

0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01

69

Chapter 3: Generation of Enriched Astrocyte
Cultures from a Selectable Mouse Embryonic
Stem Cell Line
3.1 Abstract
Central nervous system (CNS) trauma often leads to long term sequalae for patients due to the
limited regenerative capacity of the CNS. Part of the reason for the limited recovery following
CNS injury is that the native astrocytes form a barrier, called the glial scar, around the injury site
that prevents the growth of new axons. The role astrocyte play in the formation of the scar led to
the belief that astrocytes were primarily inhibitory following injury; however, recent work on
astrocyte knockout mice has found that astrocytes are also necessary for recovery from CNS
trauma. Furthermore, primary astrocyte transplantation into spinal cord injuries has been found
to lead to improved functional outcomes when protoplasmic (grey matter) astrocytes were
transplanted. Since it is difficult to translate primary cells transplantation into the clinic, methods
were developed to generate protoplasmic and fibrous (white matter) astrocytes from mouse
embryonic stem cell (mESCs). Unfortunately, mESC-derived cell populations need to be purified
prior to transplantation to remove the risk of teratoma formation. In this work, a cell line that
allows for selection of mESC-derived astrocyte culture is generated by using the Aqp4 locus to
drive the expression of a puromycin resistance gene. Selection of protoplasmic astrocytes
derived from this cell line was found to increase the percent of cells positive for Aqp4 and
GFAP. These selected astrocyte cultures have the potential to be used for both further in vitro
characterization of astrocyte functions and in vivo transplantation.
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3.2 Introduction
Astrocytes have historically been viewed as primarily inhibitory to recovery following
CNS trauma. This viewpoint arose because astrocytes are the main cellular component of the
glial scar, which represents both a physical and biochemical barrier to axon growth (Cregg et al.
2014). Thus, it seemed logical that mice lacking astrocyte reactivity because of a vimentin and
glial fibrillary acidic protein (GFAP) double knockout would have improved recovery from
spinal cord injury (SCI). Surprisingly, these double knockout mice were found to have
significantly increased bleeding, inflammation, and spread of secondary injury compared to
wild-type mice following SCI or stroke (Pekny et al. 1999; Z. Liu et al. 2014). Recent work has
also explored the effect of delayed astrocyte knockout using GFAP-thymidine kinase (TK) mice.
In these mice, ganciclovir administration causes targeted ablation of dividing GFAP+ cells (Bush
et al. 1998). Using this model, acute astrocyte ablation was still found to worsen secondary
injury following SCI, and to result in a decrease in axonal growth into the lesion area (Anderson
et al. 2016; J. R. Faulkner et al. 2004). Delayed astrocyte ablation was also performed 5 weeks
after SCI, which resulted in worse functional outcomes than mice with intact astrocytes
(Anderson et al. 2016). These genetic strategies demonstrate that astrocytes play some proregenerative roles in both the acute and chronic phases of CNS trauma, even though these roles
are not as well defined as the known inhibitory effects of scar astrocytes.
The concept of astrocytes as a pro-regenerative population is supported by the observed
tendency for the majority of axons within the SCI lesion to be associated with GFAP+ astrocyte
processes in rats (Taylor et al. 2006), mice(Zukor et al. 2013), and zebrafish(Yona Goldshmit et
al. 2012). This association between astrocytes and neurons within the lesion led to investigation
of the role of transplanted astrocytes in providing a permissive environment for axons in the
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lesion. Glial restricted progenitors (GRPs) can be isolated from mouse or human embryos and
differentiated into both white matter (fibrous) and grey matter (protoplasmic) astrocytes, as well
as oligodendrocytes, but not neurons (Rao, Noble, and Mayer-Pröschel 1998; S. J. A. Davies et
al. 2011). GRPs pre-differentiated into protoplasmic astrocytes have been shown to improve
recovery following right-sided cervical dorsal column transection SCI (J. E. Davies et al. 2006).
Interestingly pre-differentiation of GRPs into fibrous astrocytes did not confer these same
benefits and instead had a detrimental effect on recovery (S. J. A. Davies et al. 2011; J. E. Davies
et al. 2008). Importantly, similar to many primary cell transplantation therapies, there has been
some considerable variability in these findings, with another study showing that GRPs predifferentiated into astrocytes conferred a recovery benefit regardless of the astrocyte phenotype
(C. Haas et al. 2012).
Due to the inconsistencies in primary cell cultures, and the difficulty in obtaining
sufficient primary cells for transplantation, a pluripotent cell source of astrocytes could be
extremely useful. Astrocytes have been derived from human induced pluripotent stem cells
(iPSCs) and transplanted following a cervical contusion SCI. These iPSC-derived astrocytes
were found to not have significant effects on recovery; however, when modified to expression
high levels of glutamate transporter 1 (GLT1), iPSC-derived astrocyte transplantation reduced
lesion size and improved diaphragm function (K. Li et al. 2015). These transplantation studies
demonstrate that there is potential for astrocyte transplantation following SCI; however,
significantly more work it required to determine the best astrocyte populations for transplantation
and improve astrocyte-derivation methodology.
A highly purified, renewable source of astrocytes could be extremely valuable for
studying astrocyte function in vitro and improving in vivo outcomes of astrocyte transplantation.
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Methods have already been developed to specifically derive protoplasmic or fibrous astrocytes
from mESCs (R. E. Thompson et al. 2017); however, ESC-derived cell populations must be
purified in some way to remove undifferentiated stem cells. Without removal of the remaining
stem cells, there is significantly risk of teratoma formation following transplantation, which can
results in worse outcomes that the SCI itself (Führmann et al. 2016; Johnson et al. 2010). One
strategy that has been successfully used to remove residual undifferentiated ESCs from cultures
is to generate transgenic ESC lines that express puromycin N-acetyltransferase (PAC), which
confers resistance to puromycin, under the control of a cell-lineage specific promoter (Mccreedy
et al. 2014; Iyer et al. 2016; Xu et al. 2015). In this work, mESCs were modified using
CRISPR/Cas9 technology to express PAC under the control of the aquaporin-4 (Aqp-4)
promoter. Aqp-4 was chosen for this work because it is expressed specially in astrocytes, and all
mature astrocyte populations express some level of Aqp-4 (Nagelhus et al. 1998), which should
allow this cell line to generate cultures containing predominantly mature astrocytes.

3.3 Materials and Methods
3.3.1 mESC Culture
RW4 (ATCC, SCRC-1018) and Aqp4-PAC mESCs were maintained in complete media
(CM) (10% Fetal Bovine Serum (Invitrogen), 10% Newborn Calf Serum (Invitrogen), 132 µM
beta mercaptoethanol (BME) (Sigma, St Louis, MO), 10,000 units/mL mouse leukemia
inhibitory factor (Life Technologies, Carlsbad, CA) and passaged when at 60-80% confluency.
Cells were passaged using 0.25% trypsin-EDTA (Life Technologies) at 37 °C for 5 min to
dissociate the cells. The trypsin reaction was quenched with CM and cells were seeded into a
new T25 flask coated with 0.1% gelatin (Sigma).
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3.3.2 Aqp4-PAC Selection Vector
All cloning steps were carried out in DH5α E. coli.
The targeting cassette was constructed in a Gatewaycompatible plasmid (pStart-K; Addgene #20346,
Cambridge, MA) using a 718 bp SalI-AscI fragment of the
3’ end of the 2nd intron of the Aqp4 gene and a piece the 5’
untranslated region of the 3rd exon of Aqp4 (5’ arm) and a
618 bp AscI-NotI fragment containing the genomic
sequence of the 3’ end of the 3rd exon of aqp4 (3’ arm).

Figure 3.2: Plasmid map of the aqp4PAC targeting cassette in a pStartK
backbone.

This site was chosen of PAC insertion so that homologous
recombination would result in the Aqp-4 start codon being removed and replaced with the PAC
sequence. Between these 2 homology arms a PAC/Pgk-neo dual resistance gene was inserted.
This dual resistance cassette contains, from 5′ to 3′: an Asc1 site, Kozak sequence, the coding
region of PAC with bGH polyA signal (PKO-Select Puro; Agilent Genomics, Santa Clara, CA),
floxed phosphoglycerate kinase I (Pgk) promoter driving the neomycin phosphotransferase gene
(Neo) with bGH polyA signal, and another AscI site. Gateway recombination with the LR
Clonase II Kit (Life Technologies #11791) was used to insert the entire region between the attL1
and attL2 sites into a pWS-TK3 vector, which contains the thymidine kinase gene to allow for
negative selection of the electroporated ESCs (Wu et al. 2008) (Figure 3.1).

3.3.3 RW4 Electroporation and Clonal Analysis
Electroporation and clonal analysis was performed as previously described (Iyer et al.
2016). To facilitate a higher efficiency of homologous recombination in electroporated ESCs, a
CRISPR/Cas9 system was used. Guide RNAs (gRNAs), inserted into a derivative of Addgene
plasmid #43860, and Cas9 expression vectors (Addgene plasmid #43945) were generated by the
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Genome Engineering Core at Washington University in St Louis. For both gRNAs, there were no
common polymorphisms within the gRNA sequence and there was at least a 3 bp mismatch with
the 20 nucleotide targeting sequence and any other sites in the mouse genome (Table 3.1). By
Table 3.2: Guide RNA (gRNA) and Junction PCR (jPCR) Primer
Sequences

meeting these two criteria,

Name

Sequence

Aqp4 gRNA 1

GTGACAGAGCTGCGGCAAG

Aqp4 gRNA 2

ACAGAGCTGCGGCAAGGCGG

decreased (Veres et al.

jPCR Forward

ACCCCGATGCCAAGTGGCTG

2014). 1 x 107 RW4 ESCs

jPCR Reverse

GCGCCAGGAGGCCTTCCATCTGTTGCT

the probability of an offtarget cuts is greatly

were suspended in

electroporation buffer (20 mM HEPES pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4,
and 6 mM dextrose) with 8 µg Aqp4-PAC vector, 1 µg Cas9 expression vector and 1 µg of one
of the 2 gRNA vectors. Electroporation was performed in a 0.4 cm cuvette (Bio-Rad, Hercules,
CA) at 0.23 kV and 960 µF. Following electroporation cells were seeded in CM on a gelatin
coated 10 cm dish overnight to recover followed by 10 days of CM with 150 nM fialuridine
(FIAU, Moravek #M251, Brea, CA) and 40 μg/mL geneticin (G418, Life Technologies #10131),
replaced every 2 days.
After selection, 48 colonies were picked from each gRNA plate and the clones screened
by junction PCR (jPCR) with the primers in Table 1. jPCR positive clones were expanded until
they could be frozen in liquid nitrogen and analyzed for PAC and Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) copy number with quantitative real-time PCR (qPCR) using a
customized TaqMan Copy Number Assay according to manufacturer instructions. For these copy
number assays, mouse telomerase reverse transcriptase (Tert) was used as the endogenous
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control, RW4s were used as the negative control, and a previously validated PAC line, Hb9PAC, was used as the positive control (Mccreedy et al. 2014).

3.3.4 Derivation and Selection of Astrocyte Populations
Astrocyte were derived from Aqp4-PAC positive clones as previously described (R. E.
Thompson et al. 2017). Briefly: 1x106 ESCs were cultured in suspension on agar-coated 10 cm
dishes in 10 mL DFK5 (DMEM/F12 (Life Technologies) plus 5% Knockout Serum Replacement
(Life Technologies), 50 µM nonessential amino acids (Life Technologies), 1x InsulinTransferrin-Selenium (Life Technologies), 100 µM beta-mercaptoethanol (Sigma), 5 μM
thymidine, and 15 μM of the following nucleosides: adenosine, cytosine, guanosine, and uridine
(Life Technologies) for two days to form embryoid bodies (EBs) followed by 4 days in 10 mL
DFK5 plus 2 µM retinoic acid and 600nM Smoothened Agonist (SAG). On day 6, the EBs were
dissociated and 4x106 cells were seeded onto a gelatin-coated tissue culture treated 10 cm dish
(ThermoFisher) in DFK5 media plus 20 ng/mL epithelial growth factor (EGF) (Peprotech), 10
ng/mL fibroblast growth factor 1 (FGF-1) (Peprotech) and 1 µg/mL laminin for 5 days. On day
11, the cultures were switched into lineage-specific media for 4 additional days on the same
plates. Fibrous media: DMEM/F12 plus 1x G5 supplement (Invitrogen), 10 µg/mL ciliary
neurotrophic factor (CNTF) (Peprotech); Protoplasmic media: DFK5 plus 10 µg/mL FGF-1, 10
µg/mL bone morphogenic protein 4 (BMP4) (Peprotech). On day 15, the cells were reseeded
onto gelatin-coated plates at a density of 20,000 or 100,000 cells/cm2 and maintained in lineage
specific media for 2 additional days prior to selection in appropriate lineage specific media from
D17 to D18 at different concentrations of 0, 2, 4, or 8 µg/mL puromycin (Sigma).
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3.3.5 qPCR
RNA was harvested at various time points throughout the astrocyte differentiation protocol by
removing the cells from the culture plate with 0.25% trypsin treatment. Cells were then spun
down at 300 rcf for 5 minutes and the RNA extracted using a Qiagen RNeasy extraction kit
according to manufacturer instructions. For qPCR, 500 ng of RNA from each sample was
converted into cDNA using a High-Capacity RNA to cDNA kit (Applied Biosystems). Finally,
the mRNA levels of the genes of interest was determined using specific Taqman assays
following manufacturer instructions. β-actin was used as the normalization control in all samples.

3.3.6 Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (Sigma) for 20 mins and then permeabilized in 0.1%
Triton-X (Sigma) for 15 mins. Cells were then blocked with 5% of an appropriate serum (Goat
or Donkey (both from Sigma)) in phosphate buffered saline (PBS) for 1 hr. Primary antibodies
were used at the following dilutions: GFAP 1:100 (Immunostar), Aqp4 1:100 (Santa Cruz
Biotechnology), β-tubulin 1:1000 (Biolegend). Primary antibody incubation was carried out
overnight in 2% of appropriate serum in PBS. Secondary antibodies were all used at a 1:1000
dilution and incubated in 2% of appropriate serum in PBS for 1 hr. 1:1000 Hoechst (Invitrogen)
in PBS was incubated with the cells for 15 min prior to imaging. Percent of cells positive for
each marker in the cultures was determined by counting the number of nuclei visible per image,
and then the number of cells staining positive for the given marker. For each well, a minimum of
3 images taken at different locations were counted, and the average of those percentages used as
the percent positive for the given biological replicate.
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3.3.7 Statistics
Percent positive cells at different concentrations of puromycin were compared using a paired ttest in Excel at a 95% confidence interval. When appropriate, a Bonferroni correction was used
to account for multiple comparisons.

3.4 Results and Discussion
3.4.1 Aqp4-PAC ESC-derived Protoplasmic, but not Fibrous, Astrocytes
Express PAC mRNA
Clustered regularly interspaced short palindromic repeats combined with Cas9
endonuclease (CRISPR-Cas9) technology allows for high-efficiency, specific double strand
break creation based on the sequence 20 nucleotide guide RNA (gRNA) (Cong et al. 2013).
Double strand breaks are generally repaired by non-homologous end joining, but rarely, in the
presence of a donor DNA strand, homologous recombination repair occurs. The specificity of the
CRISPR-Cas9 double strand break allows for significantly shorter homology arms to be used in
the donor strand than previous required and the efficiency of the double strand break at the
targeted location enhances the need for repair. Here CRISPR-Cas9 was used to insert a PAC
gene into one of the two aqp4 alleles in the RW4 mESCs genome through a homology-directed
repair mechanism. PAC insertion designed to occur at the location of the normal aqp4 start
codon in the third exon of the gene (Figure 3.2A). After electroporation, mESC colonies were
selected with both neomycin (positive selection) and ganciclovir (negative selection). Surviving
colonies were then screened using junction PCR (jPCR) to confirm that PAC was inserted into a
aqp4 locus. jPCR revealed that 2 of the 48 picked clones for one of the gRNAs contained PAC in
the desired location (Figure 3.2B). Since insertion of PAC into both aqp4 loci and/or randomly
into the genome is theoretically possible, qPCR was used to determine the total number of copies
of PAC gene within the genome of the jPCR positive clones. Both jPCR positive clones were
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Figure 3.2: PAC was successfully inserted into 1 copy of the aqp4 gene and is expressed in protoplasmic
astrocyte cultures. A) Schematic representation of the CRISPR-Cas9 mediated strategy used to insert a copy of the
PAC gene into one of the two aqp4 alleles. B) Junction PCR demonstrating successful PAC insertion into the
targeted aqp4 locus (arrowhead). C) Copy number assay comparing GAPDH and PAC copies detected in
unmodified RW4 ESCs, previous described and validated selectable ESC line (Hb9-PAC), and 2 Aqp4-PAC clones
(D7 and B11). N=4, error bars: std err. D) qPCR data showing mRNA levels of aqp4 and PAC in astrocytes
cultures derived from D7 aqp4-PAC ESCs at different time points of either fibrous (left) or protoplasmic (right)
astrocyte differentiation. N=3-5; Error bars: std err; dashed lines: 2-fold change (either up or down regulated),
compared to undifferentiated ESCs E) qPCR data showing mRNA levels of aqp4 and PAC in astrocytes cultures
derived from D7 aqp4-PAC ESCs at different time points of either fibrous (left) or protoplasmic (right) astrocyte
differentiation. N=2-5; Error bars: std err; dashed lines: 2-fold change, either increase or decrease, compared to
undifferentiated ESCs.

found to have a single copy of PAC, based on comparison to a previously validated PAC
containing cell line, Hb9-PAC (Mccreedy et al. 2014) (Figure 3.2C).
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With both clones validated to contain only a single PAC at the expected location in the
genome, expression of both Aqp-4 and PAC throughout either fibrous or protoplasmic astrocyte
differentiation was determined with qPCR. qPCR revealed that neither B11 or D7 derived
fibrous astrocyte cultures exhibited a significant increase of PAC mRNA levels compared to
mESCs over the tested time course (Figure 3.2D, E, left panels). This lack of PAC upregulation
indicates that these Aqp4-PAC cell lines are not useable for selection of fibrous astrocyte
cultures. One potential option for future studies to pursue to obtain a selected fibrous astrocyte
culture would be to use a previously developed Olig2-PAC cell line (D. a. McCreedy et al.
2012). This cell line has been used to acquire progenitor motor neurons, which can form
astrocytes, oligodendrocytes and neurons, and has been transplanted following dorsal
hemisection SCI (D. A. McCreedy et al. 2014; Wilems et al. 2015). Fibrous astrocytes are known
to maintain Olig2 expression, while protoplasmic astrocytes translocate Olig2 to the cytoplasmic
and then stop expression (Cassiani-Ingoni et al. 2006; J. E. Davies et al. 2008). This effect has
been observed to occur at around D15-17 in the mESC-derived astrocyte cultures, and so this
Olig2-PAC mESC line could be used to select for specifically fibrous astrocytes at a later time
point in the differentiation protocol. Delayed selection should also remove any motoneurons,
which express olig2 early in their differentiation, from the cultures as well.
In contrast to the observations in fibrous differentiation, both B11 and D7 demonstrated a
clear upregulation of PAC mRNA levels compared to mESCs during protoplasmic astrocyte
differentiation. This peak was found to occur at around D17 of the protoplasmic astrocyte
differentiation protocol and coincides with the peak of Aqp-4 expression in both clones. Also, it
appears that PAC mRNA levels in general track with Aqp-4 mRNA levels, an indication that
PAC and Aqp-4 are driven by similar regulator mechanisms (Figure 3.2D, E, right panels). Since
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the D7 clone exhibited slightly higher levels of PAC mRNA than B11, puromycin selection
experiments were carried out using this cell line.
Previous experiments have shown that neurons extend longer neurites on protoplasmic
than fibrous substrates (R. E. Thompson et al. 2017), and that protoplasmic astrocytes improve in
vivo outcome when transplanted (S. J. A. Davies et al. 2011; J. E. Davies et al. 2008). These
observations suggest that a selected protoplasmic population is worth pursuing, even if the same
cell line cannot be used to generate selected fibrous populations. A potential explanation of the
lack of significant upregulation in PAC in the fibrous cultures is that fibrous differentiation does
not drive a large enough change in Aqp-4 levels over the mESCs to surpass the low levels of
expression of the PAC in ESCs. This is somewhat supported by the lower level of the Aqp-4
mRNA peak in the fibrous cultures than the protoplasmic cultures (Figure 3.2D, E). A potential
reason for the apparent low levels of aqp4-PAC expression is that the PAC-containing transcript
is not as well controlled by the posttranscriptional mechanisms that are known to be important
for normal Aqp-4 gene regulation (Moe et al. 2008).

3.4.2 Puromycin Selection of Aqp4-PAC Protoplasmic Astrocytes Increases
the Percent of Aqp4+ Cells
Since PAC mRNA was found to be upregulated in protoplasmic astrocytes at D17 of
differentiation, selection of astrocyte cultures derived from clone D7 Aqp4-PAC ESCs was
performed to determine if the PAC was functional, and if post-selection cultures were enriched
for astrocytes. Cells were selected for 24 hours at 2 different seeding densities (20,000 cells/cm2
and 100,000 cells/cm2) and exposed to 3 different concentrations of puromycin (0 µg/mL, 2
µg/mL, and 4 µg/mL). Post-selection cells were stained of Aqp-4 and GFAP to determine the
astrocyte percentage within the cultures (Figure 3.3A). Quantification of the percent of cells
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expressing these markers revealed that selection with 4 µg/mL puromycin significantly increased
the percent of aqp4 positive cells from 38 ± 5% to 62 ± 14% in plates seeded with 100,000
cells/cm2 (Figure 3.3B). There was also a significant increase from 44 ± 8% to 80 ± 12% GFAP+
cells on plates seeded with 20,000 cells/cm2 following selection with 4 µg/mL puromycin
(Figure 3.3C).

Figure 3.3: Puromycin selection increases astrocyte percentage is aqp4-PAC ESC-derived
protoplasmic astrocyte cultures. A) Representative images of selected and unselected protoplasmic
astrocyte cultures derived from Aqp4-PAC ESCs stained for Aqp-4 (red) and Tuj-1 (green). Scale bar:
100 µm, blue: nuclei. B) Quantification of the percent of cells expressing aqp-4 at different
concentration of puromycin and cell densities. Error bars: Std. err. n=3-4. C) Quantification of the
percent of cells expressing GFAP at different concentrations of puromycin and cell densities. Error
bars: Std. err. n=2-3. D) Quantification of the percent of cells expressing β -tubulin III at different
concentrations of puromycin and cell densities. Error bars: Std. err. n=2-3. *:p<0.05.

These plates were also stained for β-tubulin III (Tuj-1) since neurons have previously
been shown to be the primary non-astrocytic population in these ESC-derived cultures (R. E.
Thompson et al. 2017). β-tubulin III staining demonstrated a clear presence of neurons in
unstained plates, and an apparent loss of these cells in plates that had been exposed to puromycin
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(Figure 3.3A). Quantification of β-tubulin III staining revealed a significant decrease in neurons
following selection of both 100,000 and 20,000 cells/cm2 cultures. In 100,000 cells/cm2 cultures
the percentage β-tubulin III+ decreased from 20 ± 7% to 3 ± 1% (Figure 3.3D). These
preliminary findings indicate that selection of the Aqp4-PAC cultures increases the percentage of
astrocytes present with the culture and removes most of the main contaminating cell type,
neurons. Further experiments are required to validate these findings, explore potential alterations
to selection to improve purity, determine if any ESCs are remaining within the cultures, and
establish if there is functional maturation of these astrocytes.
It would be potentially interesting to perform calcium imaging on these post-selection
astrocyte cultures to determine the level of functional maturation. Calcium signaling in
astrocytes has recently been shown to be a major component of normal glial and neuronal
interactions, so any ESC-derived astrocyte population should exhibit appropriate calcium
signaling. In particular, astrocytes have been shown to propagate calcium waves in response to
neurotransmitters, adenosine triphosphate (ATP), and mechanical stimulus through 2 distinct
mechanisms: gap junctions and extracellular ATP release and subsequent signaling via P2Y
purinoceptors (Oberheim, Goldman, and Nedergaard 2012). It has been found that fibrous
astrocytes rely on the purinoceptors, P2Y1 and P2X7, to propagate calcium waves (Hamilton et
al. 2008). In contrast, protoplasmic astrocytes are reliant on gap junctions between neighboring
cells for calcium wave propagation. Although protoplasmic astrocytes do expressing P2Y1, and
so are responsive to exogenous ATP signaling (Fam, Gallagher, and Salter 2000; B. Haas et al.
2005). Together these observations of in vivo astrocytic calcium wave dynamics offer an
appealing approach to functionally confirm the fibrous or protoplasmic identity of the ESCderived astrocyte cultures following selection. This can be achieved by observing calcium wave
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propagation in these cultures in the presence of purinoceptor or gap junction antagonist in
response to ATP addition or a mechanical stimulus.
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Chapter 4: Effect of Hyaluronic Acid
Hydrogels Containing Astrocyte-Derived
Extracellular Matrix and/or V2a
Interneurons on Spinal Cord Injury
Recovery
4.1 Abstract
Spinal cord injury (SCI) represents a substantial financial and psychological burden for patients,
due to the limited capacity of the central nervous system (CNS) for spontaneous recovery. One
reason for the lack of regeneration, and poor clinical outcomes, is the formation of an astrocytederived glial scar that inhibits new axon growth. Astrocytes have also been shown to be
important for spontaneous SCI recovery in rodents, suggesting some astrocyte populations are
pro-regenerative, while others are inhibitory following injury. In this work, the effect of
implanting hyaluronic acid (HA) hydrogels containing extracellular matrix (ECM) harvested
from mouse embryonic stem cell (mESC)-derived astrocytes on SCI recovery in rats was
explored. In addition, the ability of HA hydrogels with and without ECM to support the
transplantation of mESC-derived V2a interneurons was tested. The incorporation of ECM
harvested from protoplasmic (grey matter) astrocytes, but not ECM harvested from fibrous
(white matter) astrocytes, into hydrogels was found to reduce the size of the glial scar, increase
axon penetration into the lesion, and reduce macrophage/microglia staining two weeks after
implantation. HA hydrogels were also found to support transplantation of V2a interneurons and
the presence of these cells caused an increase in neuronal processes both within the lesion and in
the 500 µm surrounding the lesion. Overall, protoplasmic mESC-derived astrocyte ECM showed
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potential for future development to treat CNS injury. In addition, ECM:HA hydrogels represent a
novel scaffold with potentially beneficial effects on SCI recovery both with and without cells.

4.2 Introduction
Every year 17,000 Americans experience a spinal cord injury (SCI) and, due to the
chronic nature of SCI, there are an estimated 243,000 to 347,000 Americans living with some
level of disability due to SCI (Of 2013). The high number of chronic SCI patients is due to the
lack of native regenerative capacity of the spinal cord, which means that SCI patients often
experience some degree of lifelong paralysis. This paralysis results in a decrease in both life
expectancy and quality of life for people living with SCI (Boakye, Leigh, and Skelly 2012). Due
to the high healthcare burden for SCI patients, there is significant interest in developing materials
and treatments that can be used to improve SCI outcomes. To facilitate treatment development, it
is important to understand the native repair pathways and the factors that inhibit these pathways.
One of the major inhibitors of spinal cord regeneration is the glial scar that develops
around the spinal cord lesion (Cregg et al. 2014). This scar has a stereotyped morphology with
astrocytes forming a scar penumbra that represents both a physical barrier, due the woven
morphology of astrocyte processes, and a biochemical barrier to new axon growth. One major
class of axon growth inhibitors present within the glial scar is chondroitin sulfate proteoglycan
(CSPG) (Oohira, Matsui, and Katoh-Semba 1991). Degradation of CSPGs with the enzyme
chondroitinase ABC has been show to improve SCI outcomes in rodents, indicating the
importance of CSPGs in axon growth inhibition (Bradbury et al. 2002; Wilems and SakiyamaElbert 2015). These observations, coupled with the role astrocytes play in the formation of a
physical barrier in the glial scar, led to the belief that astrocytes are primarily inhibitory
following SCI.
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Recent studies have challenged the conclusion that astrocytes are solely inhibitory
following SCI, with astrocyte knockout studies demonstrating that astrocytes are required for
recovery following SCI as well. In particular, glial fibrillary acid protein (GFAP)-thymidine
kinase (TK) mice, which allows ganciclovir administration to be used to ablate all dividing
GFAP+ cells, have been used to study the conditional ablation of astrocytes either at the time of
injury or 5 weeks after injury. These studies have found that the lack of astrocytes around the
SCI lesion acutely results in larger lesion area and decreased axonal growth into the lesion (J. R.
Faulkner et al. 2004; Anderson et al. 2016). Delivery of ganciclovir 5 weeks after injury caused
delayed scar ablation, but did not result in increased axonal growth. Furthermore, it was found
that hydrogel-based delivery of neurotrophin-3 (NT-3) and brain-derived neurotrophic factor
(BDNF) improved axon penetration into the lesion only when the glial scar was intact (Anderson
et al. 2016). These data suggest that some astrocytes can be pro-regenerative following SCI, and
that they are required for recovery.
These knockout observations are supported by recent astrocyte reactivity studies, which
found that reactive astrocytes exist on a phenotypic spectrum from pro-regenerative to inhibitory
for axon growth. (Liddelow and Barres 2017). One illustration of this reactivity spectrum is the
changes in astrocyte phenotype depending on insult. In particular, an inflammatory insult from
lipopolysaccharide has been found to lead to inhibitory reactive astrocytes, while an ischemic
insult leads to pro-regenerative reactive astrocytes (Zamanian et al. 2012). In addition, cytokines
have also been found to manipulate reactive astrocyte phenotype as well, with acute IL-6
exposure promoting inhibitory, scar astrocytes (E. N. Benveniste et al. 1990; Codeluppi et al.
2014) and IL-10 promoting pro-regenerative astrocytes (Jackson et al. 2005). These
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observations suggest that there is a role of the immune response in regulating the regenerative
potential of astrocytes.
Astrocyte populations from different regions of the central nervous system (CNS) have
also been found to have different responses to injury. Injury to fibrous (white matter) astrocytes
has been found to cause process hypertrophy and overlap reminiscent of the glial scar (Sun et al.
2010), while protoplasmic (grey matter) astrocytes exhibit minimal process overlap following
injury (Wilhelmsson et al. 2006). Functional differences between protoplasmic and fibrous
astrocyte populations have also been observed in transplantation following right-side cervical
dorsal column transection SCI. In particular, transplantation of human or mouse glial restricted
progenitor-derived astrocytes exhibiting a protoplasmic phenotype led to improved outcomes,
both histologically and behaviorally, compared to transplantation of astrocytes exhibiting a
fibrous phenotype (J. E. Davies et al. 2008; S. J. A. Davies et al. 2011). Recently, methods were
developed to specifically derive these astrocyte populations from mouse embryonic stem cells
(mESCs). Studies of in vitro neuron growth on substrates derived from these astrocytes revealed
that neurons extended significantly longer neurites on protoplasmic-derived substrates than
fibrous-derived substrates, particularly when only decellularized extracellular matrix (ECM)
from each type of astrocyte was tested (R. E. Thompson et al. 2017).
The ability of astrocyte-derived ECM alone to support neurite extension is particularly
appealing because ECMs often contain many bioactive molecules that can promote regeneration
(Badylak, Freytes, and Gilbert 2009). The capacity for ECM to promote regeneration has been
harnessed to improve recovery from bone and cartilage injury (Benders et al. 2013), peripheral
nerve injury (Moore et al. 2011) and myocardial infarction (Singelyn et al. 2012). Importantly
for implantation into patients, ECM xenografts have been successfully used without any
88

indication of immune rejection from the host (Seif-Naraghi et al. 2013; Mirmalek-Sani et al.
2013; Hudson et al.). Given both their bioactivity and low immunogenicity, compared to cell
transplantation, ECM-based materials have significant appeal for promoting tissue regeneration;
however, many ECM-derived materials require animal sacrifice for tissue harvest. One way to
avoid the animal harvest requirement is to derive ECMs from in vitro sources, such as ESCderived or induced pluripotent stem cells (iPSCs)-derived cell populations. One drawback to in
vitro harvested ECM is that they do not form a hydrogel without additional crosslinking. This
means that the in vitro ECM needs to be incorporated into a gelation system or crosslinked to be
useable as a scaffold.
Hyaluronic acid (HA) plays the major structural role in the native CNS ECM and
naturally binds to other CNS ECM components making HA a logical choice as a base scaffold
for SCI treatment (Bignami, Hosley, and Dahl 1993). HA needs to be crosslinked to have
sufficient stability for implantation, and a gentle, specific crosslinking reaction is required to
avoid modifying incorporated ECM proteins (Pakulska, Ballios, and Shoichet 2012). A
previously developed HA gelation system uses a Diels-Alder reaction between HA-furan and
polyethylene glycol (PEG)-dimaleimide that meets these requirements and forms an injectable,
biocompatible HA hydrogel (Nimmo, Owen, and Shoichet 2011; Führmann et al. 2015).
Injectability of the hydrogel is a desirable trait since it allows the entire, irregular lesion cavity to
be filled without requiring significant dissection of the glial scar to create space (Matthews et al.
2016).
Interneurons (INs) are the main neuronal population that facilitates local connectivity
between spinal cord neurons. This role makes INs key for coordination, left-right alteration,
reflex circuits, and central pattern generation. Interestingly, rodents have been found to
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demonstrate recovery from spatially and temporally separated left and right lateral transections,
but not just spatially separated left and right lateral transections. This suggests that local
rewiring, which is likely due to local IN populations, is important for spontaneous recovery from
SCI (Courtine et al. 2008). One IN population that has known involvement in spontaneous SCI
recovery is V2a INs. These cells have been implicated as required for normal left-right
alternation in the lumbar spinal cord, especially at high speeds of locomotion, as well as
respiratory recovery following cervical SCI (Steven A. Crone et al. 2008; S. A. Crone et al.
2009; Zholudeva et al. 2017). Recently, a mESC line has been developed that allows for highly
enriched populations of V2a INs to be derived in vitro, making transplantation of this specific IN
population possible (Iyer et al. 2016; Brown et al. 2014).
This work examines the effect of HA hydrogels containing ECM derived from different
mESC-derived astrocyte populations on motoneuron growth in vitro and the effects of these
astrocyte ECMs on recovery of rats from a thoracic dorsal hemisection SCI. The ability of HA
hydrogels with and without ECM to support transplantation of mESC-derived V2a INs into a
SCI lesion is also explored. This work represents the first implantation of a mESC-derived ECM
for the treatment of SCI, and, to the authors’ knowledge, is the first implantation study using an
in vitro derived ECM. The utility of the implanted ECM was found to depend on the phenotype
of the astrocyte-containing population that produced it. Fibrous ECM (F-ECM) was found to
confer no benefit and in some cases detrimental effects histological outcomes, while
protoplasmic ECM (P-ECM) was found to decrease the size of the glial scar, decrease
macrophage/microglia infiltration, and increase axonal ingrowth. mESC-derived V2a INs were
found to survive in HA hydrogels both with and without incorporation of P-ECM, and the
presence of V2a INs was found to increase the presence of neuronal processes within and around
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the SCI lesion. These data demonstrate a novel material platform that shows significant promise
as a material for development of future CNS injury treatments.

4.3 Materials and Methods
4.3.1 mESC Culture
RW4 (ATCC, SCRC-1018), Hb9-PAC CAG-TdTomato and Chx10-PAC bact-TdTomato
mESCs were maintained in complete media (CM) (10% Fetal Bovine Serum (Invitrogen,
Carlsbad, CA), 10% Newborn Calf Serum (Invitrogen), 132 µM beta mercaptoethanol (BME)
(Sigma, St Louis, MO), 10,000 units/mL mouse leukemia inhibitory factor (Life Technologies,
Carlsbad, CA) and passaged every 2 to 3 days (60-80% confluency). 0.25% Trypsin-EDTA (Life
Technologies) incubation at 37°C for 5 min was used to dissociate mESCs from the culture flask.
This reaction was then quenched with fresh CM and cells were seeded into a new T25 flask
coated with 0.1% gelatin (Sigma).

4.3.2 Astrocyte ECM production
Fibrous and protoplasmic populations were derived from RW4 ESCs as previously
described (Figure 4. 1A) (R. E. Thompson et al. 2017). Briefly, 1x106 RW4 ESCs were cultured
in suspension on agar-coated 10 cm dishes in 10 mL DFK5 (DMEM/F12 (Life Technologies)
plus 5% Knockout Serum Replacement (Life Technologies), 50 µM nonessential amino acids
(Life Technologies), 1x Insulin-Transferrin-Selenium (Life Technologies), 100 µM betamercaptoethanol (Sigma), 5 μM thymidine, and 15 μM of the following nucleosides: adenosine,
cytosine, guanosine, and uridine (Life Technologies) for two days to form embryoid bodies
(EBs) followed by 4 days in 10 mL DFK5 plus 2 µM RA and 600nM Smoothened Agonist
(SAG) (Roybon et al. 2013). On day 6, EBs were dissociated and 4x106 cells were seeded onto a
gelatin-coated low adherence 10 cm dish (ThermoFisher) in DFK5 media plus 20 ng/mL
91

Figure 4.1: Schematic representation of astrocyte ECM production and V2a derivation. A) Protoplasmiclike and fibrous-like astrocytes were derived from mouse embryonic stem cells (mESCs) using a 15-day
protocol. Following the 15 days of induction, astrocytes were allowed to mature in appropriate media for 6 days
(D15-D21) prior to being seeded for matrix deposition (D21-27). After deposition, plates were decellularized,
and the ECM scraped off the plates and lyophilized in 50 mM trehalose solution. B) V2a interneurons were
derived from a mESC line that expresses puromycin resistance under the control of the Chx10 promoter and has
constitutively active TdTomato expression. Following selection, interneurons were seeded onto aggrewell plates
for 2 days to allow neuroaggregates to form prior to embedding them into HA hydrogels.

epithelial growth factor (EGF) (Peprotech, Rocky Hill, NJ), 10 ng/mL fibroblast growth factor 1
(FGF-1) (Peprotech) and 1 µg/mL laminin (Fisher Scientific) for 5 days. On day 11, the cultures
were switched into lineage-specific media for 10 additional days. Fibrous media: DMEM/F12
plus 1x G5 supplement (Invitrogen), 10 µg/mL ciliary neurotrophic factor (CNTF) (Peprotech);
Protoplasmic media: DFK5 plus 10 µg/mL FGF-1, 10 µg/mL bone morphogenetic protein 4
(BMP4) (Peprotech).
At D21, astrocytes were seeded onto gelatin-coated TC treated 10 cm dishes
(ThermoFisher) at a density of 20,000 cells/cm2 and culture in appropriate lineage media for 6
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days to allow for matrix deposition. After matrix deposition, cells were removed from the culture
plates using a modified Hudson decellularization protocol (Hudson, Liu, and Schmidt 2004).
Following decellularization, 1 mL of 50 mM trehalose was added to each plate and the proteins
on the plate were scraped from the plate surface with a cell scraper. The resulting suspension of
ECM proteins was then lyophilized overnight and stored at -20 °C until use in hydrogels.

4.3.3 Preparation of V2a Interneuron Neuroaggregates
V2a INs were generated from Chx10-PAC bact-TdTomato mESCs as previously
described (Iyer et al. 2016). After induction, EBs were dissociated with 0.25% trypsin and
2.5x107 cells were seeded onto a poly-L-ornithine/laminin coated T25 flask. Chx10+ cells were
then selected in half neural basal (Life Technologies)-half DFK5 media with 1x GlutaMAX (Life
Tech), 1x B27, 2 µg/mL puromycin and 10 ng/mL of the following growth factors for 24 hr:
glial-derived neurotrophic factor (GDNF) (Peprotech), NT-3 (Peprotech), and BDNF
(Peprotech). After selection, neurons were lifted from the flasks using Accutase® (Sigma)
treatment for 30 min and then 500,000 cells/well were placed into an AggreWell 400 plate with
1,200 small aggregation wells (Stemcell Technologies, Vancouver, BC). V2a INs were
maintained in V2a neuronal media (half neurobasal–half DFK5 media plus 1x GlutaMAX, 1x
B27, and 10 ng/mL of the following growth factors: BDNF, GDNF, NT-3) on the AggreWell™
plate for 2 days to allow for neuroaggregate (NA) formation (Figure 4.1B). After aggregate
formation, NAs were washed from the AggreWell plates with 100 µL of V2a neuronal media.

4.3.4 Preparation of HA Hydrogels
30% conjugated HA-furan and 39% conjugated HA-methylfuran were synthesized as
previously described from 250 MDa MW HA (Creative PEGWorks, Chapel Hill, NC) (Nimmo,
Owen, and Shoichet 2011). Percent conjugation signifies the percentage of carboxylic acid
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groups within the HA macromolecules that have been reacted to add the furan functional group.
For ECM incorporation, lyophilized ECMs were dissolved in 50 µL water and the protein
concentration determined using a Pierce 660 nm assay (ThermoFisher) according to
manufacturer instructions. All hydrogels had a final HA concentration of 1 mg/mL and a 3.5:3.0
molar ratio of the PEG-dimaleimide (Creative PEGWorks) crosslinking molecule to furan groups
added. For in vitro motoneuron assays, ECM was added to 2 mg/mL HA-furan at different
weight ratios prior to PEG addition, and then sterile phosphate-buffered saline, pH 7.4 (PBS)
was added until HA concentration was 1 mg/mL. To form thin HA gels, 50 µL of gel was added
to each well of a 48 well plate, and the plates were incubated overnight at 37 °C prior to
motoneuron seeding.
For acellular implantation studies: 2 mg/mL HA-furan was dissolved in water, or 50 mM
trehalose for HA alone implantation, followed by addition of the reconstituted astrocyte ECM at
a 1:100 weight ratio of ECM to HA, and finally the solution was diluted with sterile PBS. PEGdimaleimide was then added and 50 µL of gel solution was loaded into a Hamilton syringe and
the syringe placed at 37 °C overnight to allow gelation to occur prior to implantation. For V2a
IN transplantation: HA-methylfuran was dissolved in V2a neuronal media at a concentration of 4
mg/mL, and then astrocyte ECM was added at a 1:100 weight ratio of ECM to HA followed by
addition of sufficient NA suspension to obtain a final concentration of approximately 6 NAs/µL.
The final solution was then diluted with V2a neuronal media to 1 mg/mL HA. The NA number
used results in roughly 60 NAs, or 25,000 cells, being transplanted per animal. Once the gel
solution was prepared, 50 µL of gel was loaded into a Hamilton syringe, and the syringe placed
at 37 C for 2 hours to allow gelation to occur prior to transplantation.
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4.3.5 Motoneuron Culture on Thin HA Hydrogels
Motoneurons were derived from Hb9-Puro CAG-TdTomato mESCs that constitutively
express TdTomato under the control of the synthetic CAG promoter, as previously described (D.
A. McCreedy et al. 2014). To obtain pure motoneuron cultures, EBs were selected with 4 µg/mL
puromycin from day 5 to 6 prior to dissociation and seeding onto the prepared HA hydrogels at a
density of 20,000 cells/cm2. Motoneurons were then cultured in half DFK5 and half Neurobasal
media plus 1x B27 and imaged daily over the next 2 days.

4.3.6 Dorsal Hemisection Surgery
All animal procedures used in this work were approved by the Institutional Animal Care
and Use Committee at the University of Texas at Austin, followed the NIH Guide for the Care
and Use of Laboratory Animals, and were supported by the Animal Resources Center at the
University of Texas at Austin. Animals (female Long-Evans rats, 225-275 g, Envigo,
Indianapolis, IN) were anesthetized with 1.5-5% isoflurane and subcutaneous (SQ) injection of 5
mg/kg xylazine, surgery was performed on a heated pad. A single incision was made through the
skin on the back from approximately T4 to T12, then blunt dissection was used to expose the
muscular layer. Parallel cuts were made on either side of the spinal cord from T7 to T10 and the
muscles along the spinal cord were retracted. To expose the spinal cord, a T8 dorsal
laminectomy was performed using fine tipped rongeurs and the dura mater was removed with
fine-tipped tweezers and microscissors.
To ensure a consistent injury, the spinal column was stabilized with spinal clamps
attached to a stereotactic frame (Narishige, Tokyo, JP) and vitrectomy scissors, attached a
micromanipulator, were lowered 1.5 mm into the spinal cord. To ensure a consistent dorsal
hemisection, three cuts were administered at three separate locations moving from left to right
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across the entire spinal cord. Following hemisection, the muscular layer was closed with
degradable suture and the skin stapled closed. Post-op animals were given cefazolin (25 mg/kg
SQ) to limit infection and cefazolin injections were continued 2x/day for 5 days. For pain
management, animals were given buprenorphine (0.04 mg/kg SQ) 2x/day for the first 2 days
post-op followed by 0.01 mg/kg SQ buprenorphine injections 2x/day for an additional 3 days.
Bladders were expressed manually 2x/day until spontaneous bladder emptying resumed.

4.3.7 Hydrogel Transplantation Surgery
Two weeks after the dorsal hemisection procedure was performed, injured spinal cords
were re-exposed via the same approach used in the injury surgery. Once the spinal cord was
exposed, a small hole was made in the scar tissue to allow access into the SCI lesion cavity for a
blunt-tipped Hamilton syringe. HA hydrogels were prepared as described above and 10 µL of gel
was injected into each lesion cavity, which is sufficient gel to slightly overfill the cavities. For
sham implants, the lesion cavity was exposed as in the HA implantation animals and 10 µL
sterile 50 mM trehalose was injected. For the acellular implantation study animals were divided
into 4 groups: sham implant, HA alone, HA + Fibrous ECM (F-ECM), HA + Protoplasmic ECM
(P-ECM) (Table 4.1). In the V2a IN transplantation study animals were divided into 5 groups:
sham implant, HA-mF alone, HA + P-ECM, HA + Cells (V2a IN NAs), HA + P-ECM + Cells
Table 4.1: Study design of acellular implantation study to compare astrocyte ECM effects on SCI
recovery.

T8 Dorsal
hemisection Injury
Surgery

2 weeks

Implantation
(Treatment) Surgery

Treatment Group
Sham Implant (Injury Only)
HA alone Implant
HA + Fibrous Astrocyte ECM (F-ECM)
HA + Protoplasmic Astrocyte ECM (P-ECM)

2 weeks

Immunohistochemistry

N
8
8
7
8
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(V2a IN NAs) (Table 4.2). Post-op care was performed as in the injury surgeries, all animals in
the V2a IN transplantation study were immune suppressed with daily SQ injections of
cyclosporine-A (10 mg/kg, Novartis, Basel, CH) starting on the day of transplantation and
continuing for the duration of the study.
Two weeks after the transplantation surgery animals were euthanized via overdose of
FatalPlus (pentobarbital) and transcardial perfusion was performed with 4% paraformaldehyde
(PFA) (Fisher Scientific) in phosphate buffered saline (PBS). After dissection, spinal cords were
post-fixed in 4% PFA for 4 hours at 4 °C and washed overnight with phosphate buffer at 4 °C
prior to being cryoprotected in 30% sucrose in water for 3 days at 4 °C. Cryoprotected cords
were embedded in Tissue-Tek OCT compound, frozen and cut into 20 µm sagittal sections on a
Leica CM1950 cryostat.
Table 4.2: Study design of V2a IN transplantation study to confirm benefits of P-ECM incorporation
in a different HA hydrogel and explore the ability of HA hydrogels to support cell transplantation.

T8 Dorsal
hemisection Injury
Surgery

2 weeks

Implantation
(Treatment) Surgery

Treatment Group
Sham Implant (Injury Only)
HA alone Implant
HA + Protoplasmic Astrocyte ECM (P-ECM)
HA + V2a Interneuron Aggregates (Cells)
HA + P-ECM + Cells

2 weeks

Immunohistochemistry

N
7
7
7
8
8

4.3.8 Immunohistochemistry
After sectioning, immunohistochemistry (IHC) was performed on 7 spinal cord sections,
spaced 200 µm apart, for each animal in the study. For cord staining, OCT was washed from the
slides with PBS and the sections were permeabilized with 0.1% Triton X-100 for 15 minutes.
Following permeabilization, cord sections were washed 3x with PBS and blocked with 5%
normal goat serum in PBS (NGS) for 1 hour. Primary antibodies were then applied overnight at 4
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°C at the following dilutions in 2% NGS: Tuj-1 (BioLegend, San Diego, CA, Clone AA-10,
1:1000), GFAP (ImmunoStar, Hudson, WI, 1:100), chondroitin sulfate (CS56, Sigma, 1:250),
CD68 (ED1, Bio-Rad Antibodies, Oxford, UK, 1:200), CD8α (Bio-Rad Antibodies, 1:1000),
CD11b (Bio-Rad Antibodies, 1:1000), NeuN (EMD Millipore, Billerica, MA, 1:500), VGlut-2
(Millipore, 1:1000), NeuN (Millipore, 1:500). Following primary incubation, cords were washed
3x with PBS and were then incubated for 2 hours at room temperature in a 1:500 dilution of the
appropriate AlexaFluor secondary antibody (Life Technologies) in 2% NGS. Finally, cords were
washed 3 times with PBS and the sections mounted using ProLong Gold anti-fade reagent with
DAPI (Life Technologies).

4.3.9 Immunohistochemistry Image Analysis
To quantify IHC staining, tile scan images were taken using a CMOS camera attached to
a Leica DMi8 inverted fluorescent microscope with a 10x objective. Lesion areas were then
traced using ImageJ and the traced lesion expanded by 500 µm to assess the host response to the
implant. The resulting lesion area and lesion area + 500 µm images were quantified using a
custom Matlab (Mathworks, Natick, MA) script as previously described (Wilems and SakiyamaElbert 2015). This script determines the intensity of each pixel and then determines whether the
pixel is positive or negative for a given stain based on a user defined threshold. To facilitate
comparison between animals and groups, all sections for a given group were stained, imaged,
and analyzed at the same time. Additionally, data reported represents percent positive area for
each stain which is defined as (positive pixels/all non-black pixels)*100. Using this approach
helps to control for sectioning artifacts that result holes in the section. Quantification for the 500
µm surrounding the lesion alone was achieved by subtracting the positive and total pixel count in
the lesion only image from the equivalent pixel counts in the lesion + 500 µm images. For
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colocalization analysis, images were processed using CellProfiler (Broad Institute, Cambridge,
MA) and the number of pixels positive for both the stain of interest (Tuj-1 or VGlut-2) and
TdTomato was quantified.

4.3.10 Statistics
In vitro data was analyzed by two-way ANOVA with a Bonferroni post-hoc correction
using a 95% confidence threshold. For in vivo studies, significance was determined using the
non-parametric Kruskal-Wallis analysis of variance followed by Dunn’s test to determine
significance with 95% confidence. Power analysis was performed prior to starting the in vivo
studies. Both studies were powered to show a 30% difference with 80% confidence.

4.4 Results
4.4.1 Protoplasmic ECM Incorporation Improves Motoneuron Growth on
HA Hydrogels
Previous work has demonstrated that motoneurons exhibited longer neurite extension on
decellularized mESC-derived protoplasmic astrocyte substrates than decellularized mESCderived fibrous astrocytes substrates (R. E. Thompson et al. 2017). Since decellularization leaves
only the ECM on the plate (Hudson, Liu, and Schmidt 2004), the ability of ECMs harvested from
decellularized mESC-derived astrocyte substrates to improve motoneuron growth was explored.
To allow these ECMs to form a growth substrate, ECM was combined with a previously
described HA-furan PEG-dimaleimide hydrogel system. This HA system was chosen because of
the gentle crosslinking reaction and its ability to be used in vivo (Nimmo, Owen, and Shoichet
2011). To preserve bioactivity, ECM was scraped from decellularized plates into 50 mM
trehalose and then lyophilized. The resulting ECM powder was then dissolved in water with HAfuran in three different weight to weight ratios of ECM to HA (1:500, 1:100, 1:25 ECM:HA)
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prior to the addition of the PEGdimaleimide crosslinker. A thin
layer of gel was then allowed to
form overnight in the culture plate
prior to motoneuron seeding.
Motoneuron growth on
ECM:HA hydrogels was assessed
after 48 hours, and it was found that
1:25 Fibrous ECM (F-ECM) to HA,
and 1:100 and 1:25 Protoplasmic
Figure 4.2: Protoplasmic ECM incorporation improves
motoneuron growth after 48 hours in culture on HA
hydrogels. Ratios given are weight of ECM to weight of HA. AG) Representative images of motoneurons grown on different HA
hydrogel substrate after 48 hours. A-C: HA hydrogels containing
protoplasmic ECM; D-E: HA hydrogels containing fibrous ECM.
Scale bars: 100 µm. H) Quantification of neurite area/nucleus of
motoneurons after 48 hours in culture. Error bars = std error,
n=25-45, *: p<0.05, **: p<0.01, ***: p<0.001.

ECM (P-ECM) to HA gels
significantly improved motoneuron
neurite extension when compared to
HA gels with no added ECM
(Figure 4.2B, C, F, H). There was

also a trend demonstrating some dose dependency of the ECM with increasing ECM
concentration improving neurite growth as evidenced by 1:100 P-ECM:HA showing
significantly improved growth compared to 1:500 P-ECM:HA (Figure 4.2E). Finally, P-ECM
demonstrated greater potency than F-ECM as illustrated by motoneurons extending significantly
longer neurites on 1:100 P-ECM:HA gels than 1:100 F-ECM:HA gels (Figure 4.2B, E, H). These
data indicate that ECM can be harvested from mESC-derived astrocyte cultures, and that the
ECM maintains its ability to support neuronal growth. Based on these in vitro results, 1:100
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ECM:HA ratio gels were used to determine the effect of astrocyte-derived ECM on SCI recovery
in vivo.

4.4.2 Protoplasmic ECM can be Detected in HA Hydrogels in vitro and in
vivo
Next, the ability of the HA hydrogels to retain ECM in vivo and in vitro was investigated
using antibodies against collagen XIIα1. Collagen XIIα1 staining was used because previous
proteomic data showed that collagen XIIα1 was the most prevalent protein within P-ECM that
was significantly enriched in P-ECM over F-ECM, and it is too large to readily diffuse away (R.
E. Thompson et al. 2017). Immunohistochemistry revealed that the collagen XIIα1 within the PECM could be detected in P-ECM:HA gels, but not in HA alone gels after 1 week in vitro, and
that the incorporated collagen XIIα1 forms aggregates that are over 100 µm across within the gel
(Figure 4.3A, B). Beyond 1 week in vitro the gels began to lose integrity.
Collagen XIIα1 staining was also used to determine if the P-ECM was present two weeks
after implantation into a SCI lesion. Staining revealed collagen XIIα1 aggregates within the SCI
lesion of animals implanted with P-ECM:HA gels that were similar in size to those observed in
the in vitro staining (Figure 4.3B, D). These aggregates were not present in animals transplanted
with HA alone gels, but more diffuse collagen XIIα1 staining was detected in the HA alone and
P-ECM:HA gels suggesting that some native cells within the SCI lesion produce collagen XIIα1
(Figure 4.3C).
With collagen XIIα1 staining indicating the continued presence of implanted ECM for up
to 2 weeks in vivo, the effect of F-ECM and P-ECM on histological recovery from SCI was
explored to determine whether the observed in vitro effects of astrocyte ECMs translated into
any in vivo effects. To address this question, a subacute implantation model in rats was used
101

where a T8 dorsal hemisection SCI was performed, followed two weeks later by an implantation
(treatment) surgery. The two-week delay between injury and treatment allows the glial scar and
lesion cavity to fully develop and
stabilize in size. This limits the
continued expansion of the lesion
following implantation, which can
impede the ability of native cells to
penetrate the implant (Taylor and
Sakiyama-Elbert 2006). Two weeks
after implantation, recovery was
Figure 4.3: A-B) Collagen XIIα1 staining in HA hydrogels either
without ECM (A) or with P-ECM (B) after 1 week in vitro. C-D)
Collagen XIIα1 (green) staining in animals transplanted with HA
alone (C) or HA + P-ECM (D). Notice that native astrocytes do
produce Collagen XIIα1 (C), but not in the same aggregate
morphology seen in P-ECM gels (B, D). Scale bar: 100 µm.
Arrowheads: Collagen XIIα1 aggregates from incorporated PECM.

assessed by measuring the response
of immune cells, astrocytes, and
neurons to the HA implants using
immunohistochemistry.

4.4.3 Protoplasmic ECM Modulates Host Immune Response in Acellular
Implants
The ECMs used for this study were harvested from mouse cells and transplanted into a
rat host, so it was important to ensure that there were no signs of implant rejection by the
immunocompetent host. The immune response to HA hydrogel implantation was assessed with
staining for CD11b (general myeloid cell marker), CD8a (cytotoxic T-cell marker), and ED-1
(marker of activated macrophages and microglia). Immune staining revealed no signs of
rejection of the xenogenic ECM based on the lack of any increase in immune cell staining in the
presence of ECM (Figure 4.4). In fact, the implantation of P-ECM:HA gels was found to
significantly reduce infiltration of myeloid cells (CD11b+ area) into the lesion compared to all
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Figure 4.4: Protoplasmic ECM decreases immune cell infiltration into a SCI lesion. A-D) Representative
images of CD8a (Cytotoxic T-cells, red) staining and the CD11b (myeloid lineage cells, green) staining 2 weeks
after implantation (4 weeks after injury). Scale bars: 500 µm, dashed line denotes lesion boundary. E,F)
Quantification of CD11b+ area both within the SCI lesion (E) and in the 500 µm surrounding the SCI lesion (F).
G,H) Quantification of CD8a+ area both within the SCI lesion (G) and in the 500 µm surrounding the SCI lesion
(H). J,K) Quantification of ED1+ area (macrophages) both within the SCI lesion (J) and in the 500 µm
surrounding the SCI lesion (K). *: p<0.05, **:p<0.01. n=7 HA + Fibro ECM, 8 for all other groups.
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other groups (Figure 4.4A-E), and decrease CD11b staining around the lesion compared to the
sham implant group (Figure 4.4A, D, F). Staining for microglia and macrophages (ED-1+ area)
was found to mirror the pattern observed in the CD11b staining with P-ECM incorporation
causing a significant decrease in the percent ED-1+ area surrounding the lesion compared to both
the sham implant group and the HA hydrogel group (Figure 4.4J-K).

4.4.4 Protoplasmic ECM Incorporation Decreases the Presence of Inhibitory
CSPGs and Size of the Glial Scar Following Acellular Implantation
The glial scar forms around the lesion core following SCI and is known to represent both
a physical and biochemical barrier to axonal regeneration following SCI. In addition, astrocyte
reactivity is known to be upregulated in the presence of some foreign materials (Y.-T. Kim et al.
2004). Thus, it is important to assess the astrocytic response to a material implant. To determine
the level of astrocyte reactivity, GFAP (a pan-reactive astrocyte marker) was used. The
production of inhibitory molecules within the cords was also determined with an antibody
against CS56, which detects CSPGs. GFAP staining revealed that P-ECM:HA gel implantation
decreased the size of the glial scar (based on percent GFAP+ area in the 500 µm surrounding the
lesion) compared to both the sham implant group and the F-ECM:HA implant group (Figure
4.5A, C-D, F). CS56 staining also showed that P-ECM:HA gels decreased the presence of
inhibitory CSPGs within the lesion (Figure 4.5A, D, G). The presence of the HA itself was
sufficient to cause a decrease in the presence of inhibitory CSPGs in the glial scar (500 µm
surrounding the lesion); interestingly, this effect was lost in the F-ECM:HA gel group, but
maintained in the P-ECM:HA gel group (Figure 4.5A-D, H). Taken together these data show that
the type of astrocyte ECM within the implant affects the response of the host astrocytes to the
HA hydrogels with P-ECM decreasing the GFAP+ area surrounding the lesion and F-ECM
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potentially negating the reduction in CSPG staining surrounding the lesion seen in the HA alone
group.

Figure 4.5: HA reduces CSPG staining and protoplasmic ECM incorporation decreases GFAP area. A-D)
Representative images of CS56 (inhibitory CSPGs, green) staining and the GFAP (reactive astrocytes, red)
staining 2 weeks after implantation (4 weeks after injury). Scale bars: 500 µm, dashed line denotes lesion
boundary. E,F) Quantification of GFAP+ area both within the SCI lesion (E) and in the 500 µm surrounding the
SCI lesion (F). G,H) Quantification of CS56+ area both within the SCI lesion (G) and in the 500 µm surrounding
the SCI lesion (H). *: p<0.05, **:p<0.01. n=7 HA + Fibro ECM, 8 for all other groups.
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4.4.5 Protoplasmic ECM Incorporation Increases Neurite Growth into a SCI
Lesion Following Acellular Implantation
With encouraging results in terms of the immune and astrocyte reaction to P-ECM:HA
gels, the next important question was whether these scaffolds had any impact on growth of axons
into the SCI lesion. This is important to measure since the penetration of native axons into the
transplanted material could aid in future reconnection of the signaling pathways within the spinal
cord. Staining for β-tubulin III (Tuj-1) was used to assess the presence of neuronal processes
within and around the SCI lesions. Based on percentage of the lesion/border area staining
positive for β-tubulin III, it was found that P-ECM:HA gels increased axonal growth into the
lesion compared to both the sham implant control and the F-ECM:HA gel group (Figure 4.6AE). This increase in β-tubulin III indicates that the presence of P-ECM improves the ability of
native neurons to extend into the SCI lesion and glial scar environment, consistent with the
improvement seen in in vitro neuron growth in the presence of P-ECM (Figure 4.2) (R. E.
Thompson et al. 2017).
Overall, P-ECM:HA hydrogel implantation appeared to improve histological outcomes
following SCI injury, so the ability of these hydrogels to support the transplantation of a
neuronal population was explored. For cellular transplantation within the HA gels to be possible,
the HA crosslinking had to be modified to accelerate the gelation kinetics to enhance cell
viability. Changing from HA-furan to HA-methylfuran (HA-mF) was recently described as a
method that utilizes the same crosslinking chemistry and material properties, but allows for faster
gelation (L. J. Smith et al., n.d.). By maintaining as much of the same material properties and
similar chemistry, it seemed likely that the P-ECM:HA-mF gel implants would exhibit the same
benefits that were observed in P-ECM:HA implants.
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Figure 4.6: Protoplasmic ECM incorporation increases neural fiber staining within an SCI lesion. A-D)
Representative images of β-tubulin III (neurons, green) staining and the GFAP (reactive astrocytes, red) staining
2 weeks after implantation (4 weeks after injury). Scale bars: 500 µm, dashed line denotes lesion boundary. E,F)
Quantification of Tuj1+ area both within the SCI lesion (E) and in the 500 µm surrounding the SCI lesion (F). *:
p<0.05, **:p<0.01. n=7 HA + Fibro ECM, 8 for all other groups.

4.4.6 Protoplasmic ECM Maintains Immunomodulatory Effects in the
Presence of Systemic Immune Suppression
Recently there has been increased interest in the ability of INs to support local rewiring
and hence facilitate spontaneous recovery following SCI. Thus far IN transplantation has largely
focused on inhibitory, GABAergic IN precursors that are isolated from the forebrain. These INs
have been successfully transplanted into the spinal cord, and they have been shown to integrate
and improve post-SCI pain and bladder function (Etlin et al. 2016; Fandel et al. 2016). Recently,
a Chx10-PAC mESC line has been developed that allows for derivation of highly enriched V2a
INs (Iyer et al. 2016). Since V2a INs have been suggested as an important type of neurons for
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local rewiring and represent an excitatory population, mESC-derived V2a INs with constitutively
active TdTomato were used in this study. To facilitate survival thru transplantation, V2a INs
were aggregated with approximately 420 cells/NAs using an AggreWell™ plate before addition
to the HA solution prior to gelation. Roughly 60 NAs were transplanted into each animal
resulting in a total of ~25,000 cells per transplant. This cell transplantation study had 5 groups:
sham implant (to allow for comparison to the acellular study), HA-mF alone, HA-mF + P-ECM,
HA-mF + Cells and HA-mF + P-ECM + Cells (Table 4.2).

Figure 4.7: Protoplasmic ECM decreases macrophage staining, even in the presence of
immunosuppression. A-E) Representative images of ED-1 staining (macrophages/microglia, green) 2 weeks
after implantation (4 weeks after injury). Scale bars: 500 µm, dashed line denotes lesion boundary. F,G)
Quantification of ED-1+ area both within the SCI lesion (F) and in the 500 µm surrounding the SCI lesion (G). *:
p<0.05. n=7 for Sham, HA, and HA + Proto ECM, 8 for HA + Cells and HA + Proto ECM + Cells.
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To confirm that immune suppression was sufficient and to compare to the
macrophage/microglia findings of the acellular study, ED-1 staining was performed on sections
from the second in vivo study. Quantification of ED-1 staining revealed that, similar to what was
observed in the acellular implantation study, P-ECM significantly decreased the percentage of
the lesion area stained positive for ED1compared to sham and HA-mF alone (Figure 4.7F). The
percent ED1+ area was also found to be significantly lower in the 500 µm surrounding the lesion
in P-ECM transplantation than the sham implant group (Figure 4.7F-G). Importantly there was
no indication of a significant increase in ED-1 staining when the NAs were transplanted,
indicating sufficient immune suppression (Figure 4.7A, D-E, F-G).

4.4.7 Incorporation of V2a INs Decreases GFAP Staining while HA-mF
Decreases Inhibitory CSPG Staining
Staining for GFAP and CS56 in the cellular transplantation study revealed similar effects
on the glial scar to those observed in the acellular implantation study. In particular, the presence
of HA-mF hydrogels seemed to be sufficient to significantly decrease inhibitory CSPG staining
within the 500 µm surrounding the lesion (Figure 4.8A-C, G). Similar to the acellular study, the
percent GFAP+ area was found to be significantly decreased in the presence of P-ECM compared
to both sham and HA alone groups. (Figure 4.8J). The GFAP staining was also found to be
altered in the presence of the V2a NAs with both cellular groups showing significantly less
GFAP staining within and around the lesion than the HA alone group (Figure 4.8B, D-E, H-J).
These observations indicate that HA-mF has the same effect on the scar astrocytes as observed in
the HA furan and that P-ECM incorporation causes GFAP downregulation regardless of the HA
used.
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Figure 4.8: Hydrogel implantation modulates the response of the host astrocytes. A-E) Representative
images of CS56 staining (inhibitory CSPGs, green) 2 weeks after implantation (4 weeks after injury). Scale bars:
500 µm, dashed line denotes lesion boundary. F,G) Quantification of CS56+ area both within the SCI lesion (F)
and in the 500 µm surrounding the SCI lesion (G). H,J) Quantification of GFAP+ area both within the SCI lesion
(H) and in the 500 µm surrounding the SCI lesion (J). *: p<0.05. n=7 for Sham, HA, and HA + Proto ECM, 8 for
HA + Cells and HA + Proto ECM + Cells.

4.4.8 V2a IN Aggregates Survive Within HA-mF Hydrogels and P-ECM:HA
Hydrogels and Increase Neuronal Process Staining Within and Surrounding
the SCI Lesion
Since there was no sign of immune rejection of transplants, the presence of V2a INs
within the lesion was assessed by quantifying TdTomato fluorescence. The percentage of the
area within the SCI lesion found to be TdTomato+ was significantly higher in the HA + Cells and
the HA + P-ECM + Cells group than the associated acellular hydrogel groups (Figure 4.9B-F).
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Figure 4.9: A-E) Representative images of β-tubulin III staining (neurons, green) and tdTomato (transplanted
cells, red) 2 weeks after implantation (4 weeks after injury). Scale bars: 500 µm. F,G) Quantification of the
percent TdTomato+ area both within the SCI lesion (F) and in the 500 µm surrounding the SCI lesion (G). H,J)
Quantification of percent Tuj1+ area both within the SCI lesion (H) and in the 500 µm surrounding the SCI
lesion (J). *: p<0.05. n=7 for Sham, HA, and HA + Proto ECM, 8 for HA + Cells and HA + Proto ECM + Cells.

However, this difference did not extend to the 500 µm surrounding the lesion (Figure 4.9G).
Together these observations suggest that the V2a NAs are surviving with the gel for up to 2
a

weeks following transplantation.
Based on the continued presence of V2a NAs within the SCI lesion, staining for β-tubulin
III was performed to see if the presence of V2a NAs resulted in an increase of area staining
positive for neuronal processes within and around the lesion. β-tubulin III staining revealed a
similar pattern among the acellular groups as observed in the first in vivo study with HA + P111

ECM demonstrating significantly more neural fibers than either HA or sham within the SCI
lesion (Figure 4.9H). The presence of cells also resulted in a significant increase of β-tubulin III
within the lesion compared to both the sham implant and the HA alone implant groups (Figure
4.9H). β-tubulin III staining surrounding the lesion was also found to be significantly increased
in HA + P-ECM, HA + Cells, and HA + P-ECM + Cells when compared to HA alone (Figure
4.9J). Furthermore, animals with HA + P-ECM + Cells transplants were found to have a
significantly higher percentage of β-tubulin III+ area around the lesion than sham transplant
animals (Figure 4.9J).

4.4.9 Transplanted Cells Maintain V2a Identity, Extend Neural Processes
within and around Lesion, and Migrate into Host Spinal Cord
To determine whether transplanted V2a interneurons maintained a glutamatergic,
neuronal identity, colocalization between TdTomato fluorescence and staining for β-tubulin III,
vesicular glutamate transporter 2 (VGlut-2), or neuronal nuclei (NeuN) was assessed. Visual
inspection of cord sections revealed locations both within and around the lesion where these
stains colocalized with TdTomato (Figure 4.10A-C). The presence this colocalization around the
lesion suggests that the transplanted interneurons are able to migrate into the host spinal cord.
The percent of area within and around the lesion that was positive for both β-tubulin III and
TdTomato was quantified to determine the level of neuronal process extension from the
transplanted cells both within the lesion and in the host. This analysis found that the cellular
groups exhibited significantly more colocalization than the acellular groups, indicating that the
transplanted V2a NAs extended neuronal processes (Figure 4.10D-E).
Similar quantification was performed on VGlut-2 staining and it was found that the HA +
P-ECM + Cells group had significantly more colocalization of VGlut-2+ and TdTomato+ both
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Figure 4.10: Transplanted V2a Interneurons maintain identity and enter the host spinal cord A-C) 20x
magnification of the lesion boundary in animal transplanted with HA + P-ECM + Cells showing locations where
β-tubulin III (A), VGLUT2 (B), or NeuN (C) staining colocalizes with TdTomato (arrowheads) both within the
lesion (L) and in the glial scar (S). Scale bar: 100 µm. D-E) Percent of area within the lesion (D) and in the 500
µm surrounding the lesion (E) staining positive for both TdTomato and β-tubulin III. F-G) Percent of area
within the lesion (F) and in the 500 µm surrounding the lesion (G) staining positive for both TdTomato and
VGLUT-2. *: p<0.05, **:p<0.01. n=7 for Sham, HA, and HA + Proto ECM, 8 for HA + Cells and HA + Proto
ECM + Cells.

within the lesion and in the 500 µm surrounding the lesion than any of the acellular groups
(Figure 4.10F-G). Together these observations suggest that the V2a NAs are surviving within the
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HA hydrogels and that they continue to be glutamatergic. These data also suggest that some
combination of the NAs extending neuronal processes and the host increasing axonal growth
(perhaps due to the presence of the NAs) accounts for the observed increase in β-tubulin III+ area
both within and around the SCI lesion in the HA + Cells group compared to the HA alone group.

4.5 Discussion
4.5.1 HA Hydrogel Implantation Decreases Inhibitory CSPG Staining Within
the Glial Scar and Protoplasmic Astrocyte ECM Incorporation Decreases
Astrocyte Reactivity
Glial scar formation assessment with CS56 and GFAP staining revealed that the presence
of either HA-furan or HA-mF hydrogels within the lesion area resulted in decreased staining of
inhibitory proteoglycans in the 500 µm surrounding the lesion (Figures 4.5,4.8). Downregulation
of CSPGs staining has been previous described in response to acute implantation of either a
photo-crosslinked high molecular weight HA hydrogel or a poly-L-lysine (PLL) modified HA
hydrogel (Khaing et al. 2011; Wen et al. 2016). This effect has been found the be dependent on
the molecular weight of the HA with lower molecular HA (40 to 400 kDa) observed to cause an
upregulation of CSPG expression and an increase in the size of glial scar (Pandey et al. 2013). In
the present studies, HA hydrogel implantation is found to cause a similar downregulation of
CSPG expression when delivered two weeks after injury, unlike the acute treatment used in
previous studies. This effect of HA on CSPG expression has not been observed in implantation
studies of fibrin (Wilems and Sakiyama-Elbert 2015), fetal spinal cord ECM (Lemons, Howland,
and Anderson 1999), or methylcellulose hydrogels (Pakulska, Tator, and Shoichet 2017)
following SCI. This suggests that the observed decrease in CSPG expression might be a specific
benefit of HA hydrogels.

114

Despite the decrease in CSPG area, there was no observed downregulation of GFAP in
the presence of HA hydrogels compared the sham implant animals (Figure 4.5, 4.8). GFAP
immunoreactivity in response to material implantation has been found to be highly variable
across with some materials, such as fibrin, leading to decreased GFAP+ area (Johnson, Parker,
and Sakiyama-Elbert 2009; Johnson et al. 2010), while others, such as poly(lactic-co-glycolic
acid) (PLGA) and gelatin sponges, increased GFAP immunoreactivity (Du et al. 2014).
Incorporation of P-ECM was found to reduce the percent GFAP+ area in the 500 µm surrounding
the lesion with both HA hydrogel formulations tested compared to sham implantation. The HA +
P-ECM hydrogels were also found to demonstrate a similar decrease in CSPG staining as
observed in the HA alone hydrogels (Figure 4.5, 4.8). This finding suggests that P-ECM
presence may help to reduce the reactivity and/or hypertrophy of native astrocytes surrounding
the lesion, while maintaining the benefits of HA on CSPG expression.
Interestingly, the beneficial effects of HA implantation on the glial scar was largely lost
when a F-ECM:HA hydrogel was implanted. This change is evidenced by the significant
increase in GFAP staining in the 500 µm surrounding the lesion in F-ECM:HA implanted
animals compared to P-ECM:HA implanted groups, and the loss of the HA-associated CSPG
reduction in the F-ECM:HA group (Figure 4.5). This suggests that F-ECM incorporation may
result in some phenotype switch of native astrocytes toward a more inhibitory phenotype, which
results in the observed increase in astrocyte reactivity and CSPG production. The concept of
ECM components affecting astrocyte phenotype is not new, with astrocytes known to upregulate
a “scar” phenotype in response the integrin binding to certain ECM components, such as
collagen I (Hara et al. 2017; Tysseling-Mattiace et al. 2008). Studies of some of the major
proteins found to be upregulated in P-ECM compared to F-ECM, namely fibronectin and
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aggrecan (R. E. Thompson et al. 2017), have also been found to decrease GFAP and CSPG
expression by astrocytes in vitro (Hsiao, Tresco, and Hlady 2015). These studies provide a
potential basis for further experiments to identify the specific components within F-ECM and PECM that cause these apparent changes in native astrocyte phenotype.

4.5.2 P-ECM Decreases Immune Cell Infiltration both in and around the SCI
Lesion
Since the ECM transplants were xenogenic, it was important to ensure that they were not
being rejected by the host. Consistent with previous decellularized ECM implantation studies
(Hudson et al.), no increase in immune cell infiltration was observed in any of the ECM implant
groups despite an immunocompetent host in the acellular implant study (Figure 4.4). In fact, the
data indicated that P-ECM, but not F-ECM, resulted in a decrease in myeloid cell and
macrophage/microglia infiltration in the 500 µm surrounding the lesion compared to sham
implantation (Figure 4.4). Furthermore, HA:P-ECM implantation was found to significantly
reduce myeloid cell staining within the lesion compared to all other groups (Figure 4.4). This
observation suggests that P-ECM may exhibit an immunomodulatory role within the spinal cord.
ECM-dependent immune modulation has been previously described in the transplantation
of other ECM materials (Dziki et al. 2017), and has been observed in transplantation of either
decellularized urinary bladder or decellularized whole spinal cord ECM following SCI
(Tukmachev et al. 2016). One potential explanation for P-ECM, but not F-ECM, displaying
evidence of immunomodulation is the presence of significantly more fibronectin and laminin in
P-ECM. Fibronectin and laminin together have been found to cause tumor necrosis factor alpha
(TNF-α), a known pro-inflammatory cytokine, to bind to fibronectin and adopt a pro-adhesive
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function (Hershkoviz, Goldkorn, and Lider 1995). This binding of TNF-α limits its diffusion and
could help to control and localize the inflammatory response.
Another possible explanation is that P-ECM may alter the ratio of classically activated
M1 macrophages, that cause tissue destruction, to “alternatively” activated M2 macrophages,
which have been shown to be important to normal tissue repair throughout the body and CNS
(Kigerl et al. 2009). In support of this idea, decreased macrophage infiltration and increased M2
macrophage presence has been described in response to implantation of increasing
concentrations of decellularized urinary bladder ECM into a stroke cavity (Ghuman et al.
2016b). Based on these studies, it would be potentially enlightening to explore the macrophage
activation state following P-ECM implantation to determine if P-ECM implantation is causing an
increase in the presence of M2 macrophages. Overall, the immunomodulation effects observed in
this study are a relatively unique advantage of ECM-based treatments, since many materials used
for implantation are immunologically inert.

4.5.3 Protoplasmic, but not Fibrous, Astrocyte ECM Improves Neuron
Growth on Acellular HA hydrogels both in vivo and in vitro
In vitro motoneuron growth assays on thin HA hydrogels found that both F-ECM and PECM increased average neurite extension. P-ECM exhibited more potency demonstrating an
effect at a 1:100 weight ratio of ECM to HA, while no significant effect was observed with FECM until a 1:25 weight ratio (Figure 4.2). These in vitro findings were somewhat replicated in
the in vivo implantation studies with 1:100 P-ECM:HA hydrogel implantation resulting in
significantly more axon growth into the SCI lesion than when a 1:100 F-ECM:HA hydrogel or
nothing was implanted (Figure 4.6). Both ECMs were used at 1:100 ratios for the in vivo studies
to better facilitate comparison between them. P-ECM incorporation was also found to increase
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axon growth in the HA-mF hydrogel system with acellular P-ECM:HA-mF hydrogels
demonstrating significantly more axon growth into the lesion compared to HA-mF alone
hydrogels and sham implant animals. Previous studies have shown implantation of either
decellularized fetal spinal cord or urinary bladder ECM following dorsal hemisection SCI
increases neuronal growth, supporting the idea that the naïve spinal cord ECM could have proregenerative properties (Tukmachev et al. 2016).
In both in vivo studies, there is an observable inverse correlation in the acellular treatment
groups between the percent GFAP+ area in the 500 µm surrounding the lesion and the percent βtubulin III+ area within the lesion (Figures 4.5, 4.6, 4.8, 4.9). This suggests that the axonal
growth benefits observed in the presence of P-ECM may be related to a phenotypic switch of the
native astrocytes to a less reactive state. Further experimentation is required to determine the
precise nature of any astrocyte phenotype change and what specific factors within the implanted
ECMs might be responsible for these changes.

4.5.4 V2a INs Survive within HA Hydrogels, Migrate/Extend Processes into
the Host, and Increase Neuronal Process Area both within and around the
SCI Lesion regardless of P-ECM Presence
Quantification of the continued presence of the V2a IN NAs, using TdTomato
fluorescence, revealed that both HA-mF hydrogels and P-ECM:HA-mF supported cellular
transplantation (Figure 4.9). Staining for β-tubulin III revealed that the presence of V2a NAs led
to a significant increase in neuronal processes within and around the lesion area. This V2a INassociated increase in neuronal process staining could be the result of two different sources:
growth from the transplanted INs, and/or increased axon ingrowth from the host promoted by the
INs within the lesion. Quantification of the colocalization TdTomato and β-tubulin III suggests
that a combination of these two effects is occurring, since the TdTomato+ neuronal processes
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only explain some of the observed increase in neuronal processes (Figure 4.10D-E).
Colocalization analysis also revealed that some TdTomato+ processes entered the host spinal
cord, indicating that these transplanted cells might be able to integrate with the host or at least
are able to move out the lesion site itself (Figure 4.10E). The ability of the transplanted cells to
migrate into the host is further supported by the presence of NeuN+ TdTomato+ nuclei in the
region surrounding the lesion (Figure 4.10C). Analysis of VGlut-2 staining showed that
VGLUT-2+ TdTomato+ pixels represented a significantly larger percent of the area within and
around the lesion in the HA + P-ECM + Cells group than observed in any acellular group (Figure
4.10F-G). This finding indicates that the transplanted V2as are maintaining their glutamatergic
identity following transplantation.
Overall, neuronal staining data demonstrated that either V2a IN NA transplantation or PECM incorporation conferred a significant benefit on neuronal growth compared to HA alone,
but the combination of these factors did not significantly increase the area staining positive for
neuronal processes (Figure 4.9). Importantly, TdTomato colocalization with NeuN, VGlut-2, and
β-tubulin III indicates that the transplanted V2a interneurons maintain their identity as
glutamatergic neurons, migrate into the host, and extending neuronal processes both within the
lesion and into the surrounding cord (Figure 4.10). Future long-term recovery studies will be
required to determine if these transplanted V2a INs are able to functionally integrate into the host
spinal cord, and if the presence V2a INs and/or the increased neuronal area caused by P-ECM
incorporation translates into any behavioral improvements.
This work, as a whole, demonstrates that mESC-derived P-ECM, but not F-ECM,
incorporation into HA hydrogels results in significant improvements in histological markers of
recovery following SCI. Furthermore, ECM implantation was found to alter the behavior of
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immune cells, astrocytes, and neurons within the context of the injured spinal cord, showing the
multifactorial functionality of the HA:P-ECM material. The HA hydrogels were also found to
support the transplantation of V2a INs into the SCI lesion and the presence of these cells was
found to cause similar increases in neuronal process staining to those observed with P-ECM
implantation. HA is the primary component of the native CNS ECM and HA alone implantation
was found to decrease CSPG staining around the lesion, and support cellular transplantation.
These observations indicate that HA may be preferable to other materials for CNS injury
treatment. This work also shows that mESCs can be used as a scalable source of bioactive ECM
as well as a source of V2a INs. The use of mESCs increases the potential clinical impact of this
work, since the materials used do not require donor tissue to be generated. (R. E. Thompson et al.
2018)
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Chapter 5: Summary of Findings and Future
Directions
5.1 Summary of Findings
This work has strived to develop strategies to improve treatment for SCI by better
defining the ability of different astrocyte populations to support neuron growth either in vitro and
in vivo following SCI. We chose to focus on astrocytes in this project because recent studies
have found that some astrocyte populations are required for recovery, and so it seems likely that
not all astrocytes are primarily inhibitory as previously believed. With the goal of eventually
translation of this project in mind, we focused on deriving the materials used in this work from
mouse embryonic stem cells (mESCs). mESCs were chosen for this work because they can be
more readily scaled up and involve fewer ethical concerns than primary cells. In addition,
techniques that are developed in mESCs can, and have, been modified to allow similar cell
populations to be derived from human induced pluripotent stem cells (iPSCs). This means that
this work could eventually to be used to generate astrocyte population from human iPSCs, which
would be an appropriate cell source for human transplantation.
The first aim of this project was to develop methodologies that could be used to
differentiate specifically fibrous-like (white matter) astrocytes or protoplasmic-like (grey matter)
astrocytes from mESCs. This protocol was developed based on previous work on mESCderivation by Benveniste et al., iPSCs-derivation by Roybon et al., and deriving specific
astrocyte subtypes from primary glial progenitors by Davies et al. (R. J. Benveniste, Keller, and
Germano 2005; Roybon et al. 2013; J. E. Davies et al. 2008). In Chapter 2, we showed that by
combining aspects of these previously published works we could obtain cultures that contained
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astrocytes that were predominantly fibrous or predominantly protoplasmic. Importantly, we
found that these protocols resulted in protoplasmic populations that did not contain many
astrocytes that exhibited fibrous hallmarks and vice versa. We then tested the abilities of these
astrocytes to support the growth of motoneurons and interneurons. These experiments
demonstrated that protoplasmic astrocytes were able to support significantly longer neurite
extension than fibrous astrocytes from both neuron populations used.
Neuronal growth effect was particularly marked when the neurons were grown on
decellularized astrocyte extracellular matrices (ECMs). Since ECM-based treatments have shown
significant promise in other injuries with poor native regeneration, we focused on further
characterization of the mESC-derived astrocytes ECMs. First, we identified all of the proteins
found within our protoplasmic ECM (P-ECM) and fibrous ECM (F-ECM) using label-free
proteomics. Then, with the help of Dr. Dougherty’s lab, we compared the proteomics data to a
dataset of the mRNA expression profile of astrocytes in vivo. This comparison revealed that our
astrocyte ECMs were consistent with what an in vivo astrocyte produces. Finally, analysis of the
ECM proteins revealed that P-ECM in general contained higher levels proteins known to be axon
growth permissive than F-ECM, while F-ECM was found to be relatively enriched for proteins
known to be inhibitory to axon growth. Knockdown of some of these proteins, with the highest
levels of expression, revealed that the neuron growth benefits of protoplasmic ECM were
somewhat reduced in laminin α5 or laminin β1 knockdown while F-ECM was able to support
longer neurite extensions when spondin-1 was knocked down.
In Chapter 3 we discussed our efforts to develop a puromycin selectable astrocyte mESC
line. A selectable cell line was important to develop since our astrocyte differentiation protocol
does not result in pure astrocyte cultures, which could impede future experiments, and the
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transplantation of unpurified ESC-derived cultures has been found to lead to teratoma formation,
thus limiting to ability to transplant astrocytes using these techniques. This aspect of the project
was based on previous work done in the lab by Dr. McCreedy and Dr. Iyer who developed the
puromycin selectable motoneuron and V2a interneuron lines used in this work. We demonstrated
that the puromycin-resistance gene (PAC) was inserted into the mESC genome within one of the
aqp4 loci. Furthermore, we found that the modified cell lines did exhibit an increase in PAC
expression, coinciding with Aqp-4, over the course of astrocyte differentiation, but only in the
protoplasmic cultures. This indicates that the developed aqp4-PAC cell line cannot be used for
fibrous selection. Preliminary data does indicate that selection of aqp4-PAC-derived
protoplasmic cultures does result in a significant increase in cells staining Aqp-4+. Future work
will be required to further confirm the purity of the selected protoplasmic cultures and develop a
different selection strategy for fibrous astrocytes.
Due to the observed benefits of mESC-derived astrocyte ECM in vitro, in Chapter 4 of
this work we explored the ability of these ECMs to affect recovery following SCI in rats. To
develop the harvested mESC-derived astrocyte ECMS into a useable therapeutic, we combined
the lyophilized ECM with a hyaluronic acid (HA) hydrogel system previously developed by Dr.
Shoichet’s group (Nimmo, Owen, and Shoichet 2011). Using a thin layer of hydrogel, we tested
the effects of different ECM concentrations on the growth of motoneurons in vitro. This work
revealed that a 1:100 weight ratio of ECM to HA was sufficient for the protoplasmic ECM to
significantly improve neurite extension from the motoneurons in vitro. This observation led us to
use this ratio for animal implant studies.
The initial animal study was performed with 4 groups: sham implant, HA alone, HA + FECM, and HA + P-ECM. This study revealed that the HA hydrogel reduced the presence of
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inhibitory proteoglycans around the lesion and that addition of P-ECM reduced staining for
reactive astrocyte as well. The observed beneficial effects on the glial scar environment were lost
in the presence of F-ECM, indicating that F-ECM may cause an upregulation of a more
inhibitory phenotype of the native astrocytes. HA + P-ECM implantation was also found to
decrease immune cell infiltration into and around the SCI lesion and to significantly increase the
penetration of axons into the SCI lesion. Based on these histological improvements, we
performed a cellular transplantation study to explore the ability of these HA hydrogels to support
transplantation of V2a interneurons as a pilot transplant population.
The V2a transplantation studies used a slightly modified HA hydrogel system, using HAmethylfuran (HA-mF), that was recently developed by Dr. Shoichet’s group to have faster
gelation kinetics and so allow for cellular encapsulation. Our V2a study had 5 groups: sham
implant, HA alone, HA + P-ECM, HA + Cells, HA + P-ECM + Cells. This study found largely
similar effects as observed in the first, acellular study with P-ECM incorporation demonstrating
distinct benefits in histological markers of recovery compared to HA alone or sham implant. In
addition, we found that either HA or HA + P-ECM supported the transplantation of V2a
interneurons and that the presence of interneurons was found to significantly increase the
staining for neuronal processes within the SCI lesion.
Overall, this work demonstrates that mESCs can be used to generate specific subtypes of
astrocytes and that these astrocytes had differential capacities to support neuronal growth. We
also found that these effects translated into an in vivo setting with P-ECM containing HA
hydrogels improving histological outcomes in rats following a T8 dorsal hemisection SCI.
Finally, HA hydrogels were shown to support transplantation of V2a interneurons. This work
represents a novel approach to generating an ECM-based material and shows that the effect of
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astrocyte ECM on histological outcomes SCI depends on astrocyte phenotype. Further work
should focus on determining if the improved histological outcomes results in functional
improves, and what proteins within the ECMs result in these observed histological changes.

5.2 Future Directions
5.2.1 Live Astrocyte Transplantation
Based on the results from our ECM transplantation, it would be interesting to explore the
potential of live mESC-derived astrocyte transplantation to improve SCI outcomes. Toward this
end, we are working toward the generation of a selectable astrocyte cell line uses an astrocyte
specific gene, aqp4, to drive puromycin resistance expression. This cell line still needs to be
further characterized to demonstrate that selection the residual stem cells from the culture so
there is no risk of teratomas formation (Johnson et al. 2010), and that the astrocytes functionally
mature based on calcium imaging. In addition, calcium imaging can be used to further validate
that the mESC-derived astrocyte populations have functional properties consistent with in vivo
populations. In particular, protoplasmic astrocytes should exhibit gap junction-dependent
calcium waves (B. Haas et al. 2005), while fibrous astrocyte exhibit purinergic receptordependent calcium waves (Hamilton et al. 2008). Blocking these signaling pathways and
performing calcium imaging in the cultures should elicit different responses in our mESCderived astrocyte populations. Since calcium imaging is important for normal astrocyte-neuron
interactions, this type of functional assay would be important to show to indicate that we have
functionally mature astrocytes. Once selection has been accomplished, and validated, it would be
interesting to transplant purified protoplasmic astrocytes in HA hydrogels and compare to results
to the HA + P-ECM data reported in this work to see how much of the live cell transplant effect
is captured by implanting the ECM alone.
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5.2.2 Engineered ECMs
The proteomics data collected in this work shows the composition of both P-ECM and FECM. We did perform some validation experiments in this work that showed the importance of
spondin-1 as an inhibitory component of the fibrous ECMs, and laminin α5 and laminin β1 as a
permissive component of the protoplasmic ECM; however, further work is required to better
define what elements in these ECMs cause the observed differences in neuronal growth and in
vivo effects. Based on these future studies, and the data presented here, it would be potentially
interesting to explore adding a small number of specific proteins to the HA hydrogels and
determining if these hydrogels can replicate the effect of the full ECM implant. In addition to
adding specific proteins, it could be also productive to add small peptides that contain the
binding sequencing of the ECM proteins and cell surface proteins. This type of peptide
implantation has been done in SCI treatment using integrin binding peptides with some success
(Tysseling-Mattiace et al. 2008; Pan et al. 2014). I think that one particularly interesting peptide
sequence to explore is the binding sequence of the neural cell adhesion molecule (NCAM)
(Neiiendam et al. 2004). By incorporating this peptide sequence, it may be possible to capture
some of the benefits observed when the neurons were grown on frozen astrocyte substrates
because NCAM is a major astrocyte membrane component. In this way, the NCAM peptide
could be used to increase the benefits of P-ECM implantation without adding any elements that
require immunosuppression of the host. Overall the combination of pure proteins and binding
peptide offers an exciting and controlled method to generate materials for the treatment of SCI.

5.2.3 Functional Recovery from SCI following P-ECM and/or V2a
Interneuron Transplantation
We collected some encouraging data showing histological recovery in rats in response to
transplant of either P-ECM or V2a Interneurons in a HA hydrogel. While the 2 week study
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showing these results suggests that the materials developed in this work are worth pursuing
further, it is important to test if any functional recovery occurs in the 8 weeks post
transplantation of, in particular, the HA + Cells + P-ECM and HA + P-ECM gels. For the T8
dorsal hemisection model used in this work, functional recovery measurement is most
appropriately accomplished with the Basso, Beattie and Bresnahan (BBB) open-field locomotor
scale (Basso, Beattie, and Bresnahan 1995), horizontal ladder test, von Frey hair sensory test,
and an incline plane test. This set of functional assays will allow for assessment of locomotor
recovery, sensory recovery in the hind limbs, stability, and coordination. It would also be
interesting to perform some tract tracing experiments following a longer recovery period to
determine if the transplanted V2a interneurons are integrating into the host spinal cord. Overall, I
believe that P-ECM represents an exciting, multifactorial treatment for SCI and I look forward to
seeing what else can be done with these P-ECM:HA hydrogels.
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